Literatur zu Buchteil VII
Literatur zu Kap. 30
1.
2.
3.
Allemann Y, Hutter D, Aeschbacher BC et al. (2001) Increased central
body fat deposition precedes a significant rise in resting blood pressure in
male offspring of essential hypertensive parents: a five year follow-up
study. J Hypertens 19: 2143–2148
Ambrosioni E, Leonetti G, Pessina AC et al. (2000) Patterns of
hypertension managementin Italy: results of a pharmacoepidemiological
survey on antihypertensive therapy. J Hypertens 18: 1691–1699
Blood Pressure Lowering Treatment Trialists' Collaboration (2000) Effects
of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering
drugs: results of prospectively designed overviews randomised trials.
Lancet 355: 1955–1964
4.
5.
6.
7.
8.
Bulpitt C J, Fletcher AE, Amery A et al. (1994) The Hypertension in the
Very Elderly Trial (HYVET) Rationale, methodology and comparison
with previous trials. Drugs Aging 5: 171–183
Deutsche Hochdruckliga (2002) Empfehlungen zur
Hochdruckbehandlung. Merkblätter Eigenverlag Heidelberg 17. Aufl
Deutsche Hochdruckliga (2001) Leitlinien für die Prävention, Erkennung,
Diagnostik und Therapie der arteriellen Hypertonie. DMW 126: Suppl 4
Florette F, Seux ML, Staessen JA et al. (1998) Prevention of dementia in
randomised double-blind placebo-controlled Systolic Hypertension in
Europe (Syst-Eur) trial. Lancet 352: 1347–1351
Gueyffier F, Boissel J P, Boutite F et al. (1997) Effect of antihypertensive
treatment in patients having already suffered from stroke. Gathering the
evidence. The INDANA (INdividual Data ANalyses of Antihypertensive
intervention trials) Project Collaboration. Stroke 28: 2557–2562
9.
10.
11.
12.
Hagemeister J, Schneider CA, Barabas S et al. (2001) Hypertension
Guidelines and their limitations – the impact of physicans'' compliance
evaluated by guideline awareness. J Hypertens 19: 2079–2086
Hansson L, Zanchetti A, Carruthers SG et al. (1998) Effects of intensive
blood-pressure lowering and low-dose aspirin in patients with
hypertension: principal results of the Hypertension Optimal Treatment
(HOT) randomised trial. Lancet 351: 1755–1762
Hansson L, Lindholm LH, Ekbom T et al. (1999) Effect of angiotensinconverting enzyme inhibition compared with conventional therapy on
cardiovascular morbidity and mortality in hypertension: the Captopril
Prevention Project (CAPPP) randomised trial. Lancet 353: 611–616
Lithell H, Hansson L, Skoog I et al. (2003) The study on cognition and
prognosis in the elderly (SCOPE) Principal results of a randomised
double-blind intervention trial. J Hypertens 21: 875–886
13.
14.
15.
16.
17.
Hansson L, Hedner T, Lund-Johanson P et al. (2000) Randomised trial of
effects of calcium antagonists compared with diuretics and ß-blockers on
cardiovascular morbidity and mortality in hypertension: the Nordic
Diltiazem (NORDIL) Study. Lancet 356: 359–365
Hostetter, TH (2001) Prevention of End-Stage Renal Disease Due to Type
2 Diabetes. N Engl J Med 345: 910–911
Hyman DJ Pavlik VN (2000) Self-reported hypertension treatment
practices among primary care physicans: blood pressure thresholds, drug
choices and the role of guidelines and evidence-based medicine. Arch
Intern Med. 160: 2281–2286
Hyman DJ, Pavlik VN (2001) Charakteristics of patients with uncontrolled
hypertension in the United States. N Engl J Med 345: 479–486
Joint National Committee on Prevention, Detection, Evaluation and
Treatment of High Blood Pressure (1997) Sixth Report. Arch Intern Med.
157: 2413–2446
18.
19.
20.
21.
22.
23.
Julius S, Valentini M, Palatini P (2000) Overweight and Hypertension. A
2-Way Street ? Hypertens 35: 807–813
Kannel WB, Sorlie P: (1975) Hypertension in Framingham. In: Paul O
(Hrsg) Epidemiology and Control of Hypertension. Stratton, New York,
553–592
Kannel WB, Garrison RJ, Dannenberg AL (1993) Secular blood pressure
trends in normotensive persons: the Framingham Study. Am Heart J 125:
1154–1158
Kaplan, N (1998) J-curve not burned off by HOT. Lancet 351: 1748–1749
Keil U (1990) Prävention der klassischen Risikofaktoren. Drug Res 40: 2–
7
Kilander L, Nyman H, Boberg M et al. : Hypertension is related to
cognitive impairment. A 20-Year Follow-up of 999 Men (1998) Hypertens
31: 780–786
24.
25.
26.
27.
28.
29.
Kjeldsen SE, Farsang C, Sleight P, Mancia G (2001) 1999 WHO/ISH
hypertension guidelines-highlights & esh update. J Hypertens 19: 2285–
2288
Kjeldsen SE, Julius S, Hedner T, Hansson L (2001) Stroke is more
common than Myocardial Infarction in Hypertension: Analysis based on
11 Major Randomised Intervention Trials. Blood Press 10: 190–192
Mallion JM, Schmitt D (2001) Patient compliance in the treatment of
hypertension. J Hypertens 19: 2281–2283
Masno K, Mikami H, Ogihara T, Tuck ML (2000) Weight Gain-Induced
Blood-Pressure Elevation. Hypertens 35: 1135–1140
Middeke M (2001) "Furberg-Bias"- oder: Vom beliebigen Umgang mit
Evidence-Based- Medicine. DMW 126: 151–152
Muiesan ML, Salvetti M, Rizzoni D et al. (1995) Association of change in
left ventricular mass with prognosis during long-term antihypertensive
treatment.J Hypertens 13: 1091–1097
30.
31.
32.
33.
34.
Pahor M, Psaty BM, Alderman MH et al. (2000) Health outcomes
associated with calcium antagonists compared with other first-line
antihypertensive therapies: a meta- analysis of randomised controlled
trials. Lancet 356: 1949–1954
Progress Collaboration Group (2001) Randomised trial of a perindoprilbased blood- pressure-lowering regimen among 6105 individuals with
previous stroke or transient ischaemic attack. Lancet 358: 1033–1041
Reisin E, Abel R, Modan M et al. (1978) Effect of weight loss without salt
restriction on blood pressure in overweight hypertensive patients. N Engl J
Med 298: 1–6
Sharma AM, Pischon T, Hardt S et al. (2001) Beta-adrenergic receptor
blockers and weight gain: A systematic analysis. Hypertens 37: 250–254
Shekelle PG, Ortiz E, Rhodes S et al. (2001) Validity of the Agency for
Healthcare Research and Qualitiy Clinical Practice Guidelines. JAMA
286: 1461–1467
35.
36.
37.
38.
39.
40.
SHEP Cooperative Research Group (1991) Prevention of stroke by
antihypertensive drug treatment in older persons with isolated systolic
hypertension. Final result of the Systolic Hypertension in the Elderly
Program (SHEP) JAMA 265: 3255–3264
Skoog I, Lernfelt B, Laudahl S et al. (1996) 15-year lomgitudinal study of
blood pressure and dementia. Lancet 347: 1141–1145
Society of Actuaries (1959) Build and Blood Pressure Study. Chicago
Sowers JR, Reed J (2000) Clinical advisory treatment of hypertension in
diabetes. J Clin Hypertens 2: 132–133
Staessen JA, Wang JG, Thijs, L (2001) Cardiovascular protection and
blood pressure reduction: a meta-analysis. Lancet 358: 1305–1315
Turner ST, Schwartz GL, Chapman AB et al.(2001) Antihypertenisve
pharmacogenetics: getting the right drug into the right patient. J Hypertens
19: 1–11
41.
42.
43.
44.
Vasan RS, Larson MG, Leip EP et al. (2001) Assessment of frequency of
progression of hypertension in non-hypertensive participants in the
Framingham Heart Study: a cohort study. Lancet 358: 1682–1686
Verdecchia P, Schillaci G, Borgioni I et al. (1998) Prognostic significance
of serial changes in left ventricular mass in essential hypertension.
Circulation 97: 48–54
Veterans Administration Cooperative Study Group on Antihypertensive
Agents (1967) Effects of treatment on morbidity in hypertension. Results
in patients with diastolic blood pressure averaging 115 through
129 mmHg. JAMA 202: 116–121
Veterans Administration Cooperative Study Group on Antihypertensive
Agents (1970) Effects of treatment on morbidity in hypertension. II.
Results in patients with diastolic blood pressure averaging 90 through
114 mmHg. JAMA 213: 1143–1152
45.
46.
47.
48.
49.
Veterans Administration Cooperative Study Group on Antihypertensive
Agents (1972) Effects of treatment on morbidity in hypertension. III.
Influence of age, diastolic pressure, and prior cardiovascular disease;
further analysis of side effects. Circulation 45: 991–1004
Voko Z, Bots ML, Hofman A et al. (1999) J-Shaped Relation Between
Blood Pressure and Stroke in Treated Hypertensives. Hypertens 34: 1181–
1185
Wenzel U, Röben T, Schwietzer G, Stahl RAK (2001) Die Therapie der
arteriellen Hypertonie. Eine Umfrage bei niedergelassenen Ärzten. DMW
126: 1454–1459
Whelton PK, Appel LJ, Espeland MA et al. (1998) Sodium Reduction and
Weight loss in the Treatment of Hypertension in Older Persons. JAMA
279: 839–846
WHO/ISH Guidelines Subcomittee (1999) Hypertension Guidelines für
the Management of Hypertension. J Hypertens 17: 151–183
50.
51.
52.
53.
54.
Witteman JCM, D'Agostino RB, Stijen T et al. (1998) G-estimation of
Causal Effects: Isolated Systolic Hypertension and cardiovascular Death in
the Framingham Heart Study. Am J Epidemiol 148: 390–401
Wolff FW, Lindemann RD (1966) Effects of treatment in hypertension. J
Chron Disease 19: 227–240
Zanchetti A, Hansson L, Ménard J et al. (2001) Risk assessment and
treatment benefit in intensively treated hypertensive patients of the
Hypertension Optimal Treatment (HOT) study. J Hypertens 19 (819–825)
Zanchetti A, Hansson L, Dahlöf B et al. (2001) Effect of individual risk
factors on the incidence of cardiovascular events in the treated
hypertensive patients of the Hypertension Optimal Treatment Study. J
Hypertens 19: 1149–1159
Chobanian AV, Bakris GL, Black HR et al. (2003) The seventh report of
the joint national committee on prevention, detection, evaluation, and
55.
56.
treatment of high blood pressure. The JNC 7 Report. JAMA 289: 2560–
2544
Psaty BM, Lumley T, Furberg CD et al. (2003) Health outcomes
associated with various antihypertensive therapies used as first-line agents.
A network meta-analysis. JAMA 289: 2534–2544
The ALLHAT Officers and Coordinators for the ALLHAT Collaboration
Research Group (2002) Major outcomes in high-risk, hypertensive patients
randomized to angiotensin-converting enzyme inhibitor or calcium
channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288: 2981–
2997
Literatur zu Kap. 31
1.
2.
3.
4.
Agence Nationale d'Accréditation et d'Evaluation en Santé (2000)
Management of patients with essential hypertension. Clinical
recommendations and economic data. Guidelines April 2000.
Recommendations of the ANAES. J Mal Vasc 25: 366–376
ALLHAT Collaborative Research Group (2000) Major cardiovascular
events in hypertensive patients randomized to doxazosin vs chlorthalidone:
the antihypertensive and lipid-lowering treatment to prevent heart attack
trial (ALLHAT) JAMA 283: 1967–1975
Black HR (1999) Does the evidence from clinical trials justify the
treatment of hypertension? Clin Cornerstone 2: 13–26
Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, and
Rubin HR (1999) Why don't physicians follow clinical practice
guidelines? A framework for improvement. JAMA 282: 1458–1465
5.
6.
7.
8.
Campbell NR, Burgess E, Choi BC, Taylor G, Wilson E, Cleroux J, Fodor
JG, Leiter LA, and Spence D (1999) Lifestyle modifications to prevent
and control hypertension. 1. Methods and an overview of the Canadian
recommendations. Canadian Hypertension Society, Canadian Coalition for
High Blood Pressure Prevention and Control, Laboratory Centre for
Disease Control at Health Canada, Heart and Stroke Foundation of
Canada. CMAJ 160: S1–S6
Deutsche Hochdruckliga (2001) Leitlinien für die Prävention, Erkennung,
Diagnostik und Therapie der arteriellen Hypertonie. Dtsch Med
Wochenschr 126: S201–S238
Deutsche Hochdruckliga (2002) Empfehlungen zur
Hochdruckbehandlung. 17. Auflage, Heidelberg
Donner-Banzhoff N, Echterhoff HH, Hense HW, Kunz R, Sawicki P,
Thurmann P, Jonitz G, and Ollenschlager G (2000) Guidelines Clearing
House Statement "Hypertension". Summary and recommendations for a
9.
10.
11.
12.
rational hypertension guideline in Germany. Z Ärztl Fortbild Qualitätssich
94: 341–349
Elliott WJ (1999) Intensive antihypertensive treatment to the new lower
blood pressure targets. Curr Hypertens Rep 1: 313–319
Fahey TP, and Peters TJ (1996) What constitutes controlled hypertension?
Patient based comparison of hypertension guidelines. BMJ 313: 93–96
Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers
SG, Floras JS, Haynes RB, Honos G, Leenen FH, Leiter LA, Logan AG,
Myers MG, Spence JD, and Zarnke KB (1999) 1999 Canadian
recommendations for the management of hypertension. Task Force for the
Development of the 1999 Canadian Recommendations for the
Management of Hypertension. CMAJ 161 Suppl 12: S1–17
Feldman RD, Campbell N, and Larochelle P (2000) First-line
antihypertensive therapy. Task Force for the Development of the 1999
13.
14.
15.
Canadian Recommendations for the Management of Hypertension. Lancet
356: 509
Gyarfas I (1996) Lessons from worldwide experience with hypertension
control. J Hum Hypertens 10 Suppl 1: S21–S25
Hanon O, Anagnostopoulos K, Franconi G, Amah G, Safar M, and Girerd
X (2000) [Are the 1999 World Health Organization-International Society
of Hypertension recommendations applicable to clinical practice?]. Arch
Mal Coeur Vaiss 93: 953–957
Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S,
Menard J, Rahn KH, Wedel H, and Westerling S (1998) Effects of
intensive blood-pressure lowering and low-dose aspirin in patients with
hypertension: principal results of the Hypertension Optimal Treatment
(HOT) randomised trial. HOT Study Group [see comments]. Lancet 351:
1755–1762
16.
17.
18.
19.
Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A,
Luomanmaki K, Dahlöf B, de Faire U, Morlin C, Karlberg BE, Wester
PO, Bjorck JE (1999) Effect of angiotensin-converting-enzyme inhibition
compared with conventional therapy on cardiovascular morbidity and
mortality in hypertension: the Captopril Prevention Project (CAPPP)
randomised trial. Lancet 353: 611–616
Jackson R (2000) Updated New Zealand cardiovascular disease riskbenefit prediction guide [see comments]. BMJ 320: 709–710
Joint-National-Committee (1997) The sixth report of the Joint National
Committee on prevention, detection, evaluation, and treatment of high
blood pressure. Arch Intern.Med 157: 2413–2446
Knight EL, Glynn RJ, Levin R, Ganz DA, and Avorn J (2000) Failure of
evidence-based medicine in the treatment of hypertension in older patients.
J Gen Intern Med 15: 702–709
20.
21.
22.
23.
24.
McAlister FA, O'Connor AM, Wells G, Grover SA, and Laupacis A
(2000) When should hypertension be treated? The different perspectives of
Canadian family physicians and patients. CMAJ 163: 403–408
McAlister FA, Campbell NR, Zarnke K, Levine M, and Graham ID (2001)
The management of hypertension in Canada: a review of current
guidelines, their shortcomings and implications for the future. CMAJ 164:
517–522
Menotti A, Puddu PE, and Lanti M (2000) Comparison of the framingham
risk function-based coronary chart with risk function from an italian
population study [In Process Citation]. Eur Heart J 21: 365–37
Milon H, Mestre C, and Lantelme P (2000) [Hypertension. New French
recommendations]. Arch Mal Coeur Vaiss 93: 1479–148
O'Brien E, and Staessen JA (2000) Critical appraisal of the JNC VI,
WHO/ISH and BHS guidelines for essential hypertension. Expert Opin
Pharmacother 1: 675–682
25.
26.
27.
28.
Ogden LG, He J, Lydick E, and Whelton PK (2000) Long-term absolute
benefit of lowering blood pressure in hypertensive patients according to
the JNC VI risk stratification. Hypertension 35: 539–543
Ollenschläger G, Oesingmann U, Thomeczek C, Lampert U, Kolkmann F
(1998) Leitlinien und Evidence-based Medicine in Deutschland. Münchner
Med Wochenschr 140: 30–33
Peters TJ, Montgomery AA, and Fahey T (1999) How accurately do
primary health care professionals use cardiovascular risk tables in the
management of hypertension? Br J Gen Pract 49: 987–988
Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG,
King AJ, Klahr S, Massry SG, Seifter JL (1995 Blood pressure control,
proteinuria, and the progression of renal disease. The Modification of Diet
in Renal Disease Study. Ann Intern Med 123: 754–762
29.
30.
31.
32.
33.
Petrella RJ (2000) Diagnosis and treatment of high blood pressure. New
directions and new approaches: 1999 Canadian recommendations for
management of hypertension. Can Fam Physician 46: 1479–1484
Ramsay L, Williams B, Johnston G, MacGregor G, Poston L, Potter J,
Poulter N, and Russell G (1999) Guidelines for management of
hypertension: report of the third working party of the British Hypertension
Society. J Hum Hypertens 13: 569–592
Ramsay LE, Ul H, I, Yeo WW, and Jackson PR (1996) Interpretation of
prospective trials in hypertension: do treatment guidelines accurately
reflect current evidence? J Hypertens Suppl 14: S187–S194
Ramsay LE, Wallis EJ, Yeo WW, and Jackson PR (1998) The rationale
for differing national recommendations for the treatment of hypertension.
Am J Hypertens 11: 79S–88S
Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter
JF, Poulter NR, and Russell G (1999) British Hypertension Society
34.
35.
36.
37.
guidelines for hypertension management 1999: summary [see comments].
BMJ 319: 630–635
Schafers RF, Lutkes P, Ritz E, and Philipp T (1999) [Guidelines for the
treatment of arterial hypertension in diabetes mellitus. The consensus
recommendations of the German League for the Fight against High Blood
Pressure, Inc., the German Diabetes Society and the Society for
Nephrology]. Dtsch Med Wochenschr 124: 1356–1372
Shaneyfelt TM, Mayo-Smith MF, and Rothwangl J (1999) Are guidelines
following guidelines? The methodological quality of clinical practice
guidelines in the peer-reviewed medical literature. JAMA 281: 1900–1905
Siegel D (2000) The influence of national guidelines on antihypertensive
prescribing patterns. Curr Hypertens Rep 2: 247–252
Sowers JR, Epstein M, and Frohlich ED (2001) Diabetes, hypertension,
and cardiovascular disease : an update. Hypertension 37: 1053–1059
38.
39.
40.
41.
Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH,
Bulpitt CJ, de-Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G,
Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, and
Zanchetti A (1997) Randomised double-blind comparison of placebo and
active treatment for older patients with isolated systolic hypertension. The
Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet
350: 757–764
Tifft CP (2000) Joint National Committee VI: individualized vs.
indiscriminate therapy for hypertension. Curr Hypertens Rep 2: 243–246
UK Prospective Diabetes Study Group (1998) Tight blood pressure control
and risk of macrovascular and microvascular complications in type 2
diabetes: UKPDS 38. BMJ 317: 703–713
WHO/ISH-Guidelines Subcommittee (1999) 1999 World Health
Organization-International Society of Hypertension Guidelines for the
Management of Hypertension. J Hypertens 17: 151–183
42.
43.
44.
45.
46.
Wright JM (2000) Choosing a first-line drug in the management of
elevated blood pressure: what is the evidence? 3: Angiotensin-convertingenzyme inhibitors. CMAJ 163: 293–296
Wright JM (2000) Choosing a first-line drug in the management of
elevated blood pressure: what is the evidence? 2: Beta-blockers. CMAJ
163: 188–192
Wright JM (2000) Choosing a first-line drug in the management of
elevated blood pressure: what is the evidence? 1: Thiazide diuretics.
CMAJ 163: 57–60
Chobanian AV, Bakris GL, Black HR et al. (2003) The Seventh Report of
the Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289: 2560–
2572
Dahlöf B, Devereux RB, Kjeldsen SE et al. (2002) Cardiovascular
morbidity and mortality in the losartan intervention for endpoint reduction
47.
48.
in hypertension study (LIFE): a randomized trial against atenolol. Lancet
359: 995–1003
Lindholm LH, Ibsen H, Dahlöf B et al. (2002) Cardiovascular morbidity
and mortality in patients with diabetes in the losartan intervention for
endpoint reduction in hypertension study (LIFE): a randomized trial
against atenolol. Lancet 359: 1004–1010
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative
Research Group (2002) Major outcomes in high-risk hypertensive patients
randomized to angiotensin-converting enzyme inhibitor or calcium
channel blocker vs diuretic: The antihypertensive and lipid-lowering
treatment to prevent heart attack trial (ALLHAT) JAMA 288: 2981–2997
Literatur zu Kap. 32
1.
2.
3.
4.
5.
Böttcher-Bühler E (1999) Patienten wünschen mehr "Hochdruck-Infos"
vom Arzt. Ergebnisse einer Umfrage zum Thema Blutdruck. Fortschritte
der Medizin 117: 31
Gleichmann S, Klaus D, Lohmann FW (1991) Bluthochdruck – Wege und
Ziele der Patienteninformation. Springer, Berlin Heidelberg New York
Tokio
Grüsser M, Lohmann FW und Jörgens V (1995) Hypertonie-Behandlungsund Schulungsprogramm für die Arztpraxis. Allgemeinarzt 17: 2040
Grüsser M, Lohmann FW und Jörgens V (1996) Erfolgreiche
Implementierung des Hypertonieprogrammes für die Arztpraxis.
Allgemeinarzt 18: 2010
Lohmann FW (1999) Therapie der arteriellen Hypertonie. In: Platt D,
Mutschler E (Hrsg) Pharmakotherapie im Alter. Wiss Verlagsges,
Stuttgart, S 118–137
6.
Lohmann FW, Bars C, Ehbrecht HJ, Wörz K (1997) Was wissen Sie über
Bluthochdruck? Allgemeinarzt 19: 589
Literatur zu Kap. 33
Literatur zu Kap. 33.1
1.
Aldermann, M.H., Cohan, H., Madhavan, S. (1998) Dietary sodium intake
and mortality: The England Health and Nutrition on Examination Survey
(NHANES I) Lancet 351: 781–789
2.
Appel, L.J., Miller, E.R., Seidler, A.J., Whelton, P. K. (1993) Does
supplementation of diet with 'fish and oil' reduce blood pressure? A metaanalysis of controlled clinical trials. Arch Intern Med 153: 1429–1438
3.
Ascherio, A., Rimm, E.B., Hernan, M. A., Giovannucci, E. L., Kawachi,
I., Stampfer, M.J., Willet, W.C. (1998) Intake of potassium, magnesium,
calcium and fiber and risk of stroke among US-men. Circulation 98: 1198–
1204
4.
Bao, D.Q., Mori, T.A., Burke, V. et al. (1998) Effects of dietary fish and
weight reduction on ambulatory blood pressure in overweight
hypertensives. Hypertension 32: 710–717
5.
6.
7.
8.
9.
Clarkson, P., Montgomery, HE., Mullen, MJ., Donald, AE., Powe, AJ.,
Bull, T., Jubb, M., World, M., Deanfield, JE. (1999) Exercise training
enhances endothelial function in young men. JACC 33: 1379–1385
Cutler, JA., Britain, E. (1990) Calcium and blood pressure. An
epidemiologic perspective. Am J Hypertens 3: 137–139
Cutler, JA., Follmann, D., Elliott; P. et al. (1991) An overview of
randomized trials of sodium reduction and blood pressure. Hypertension
17 (Suppl I): 1–11
Engström, G., Hedblad, B., Janzon, C. (1999) Hypertensive men who
exercise regularly have lower rate of cardiovascular mortality. J Hypertens
17: 737–742
Everson, SA., Kaplan, GA., Goldberg, DE., Salonen, JT. (2000)
Hypertension incidence is predicted by high levels of hopelessness in
finish man. Hypertension 35: 561–567
10.
11.
12.
13.
14.
15.
Fagard, R. (1985) Habitual physical activity, training and blood pressure
in normotension and hypertension. Int J Sports Med 6: 57–61
Ferrara, L.A., Raimondi, S., d'Episcopa, L. et al. (2000) Olive oil and
reduced need for antihypertensive medications. Arch Intern Med 160:
837–842
Franz, I.-W. (1987): Der Einfluss von Betarezeptorenblockern auf die
körperliche Belastbarkeit. Dtsch Z f. Sportmed 88: 512–521
Franz, I.-W. Sportliche Aktivität: Beitrag eines regelmäßigen körperlichen
Trainings zur nichtmedikamentösen Therapie. Münch med Wochenschr
1987; 129: 60–68
Franz, I.-W. Hypertonie und Herz. Springer-Verlag, Berlin, Heidelberg,
New York, 1993
Franz, I.-W. Belastungsblutdruck bei Hochdruckkranken, Springer-Verlag,
Heidelberg New York, 1993
16.
17.
18.
19.
20.
Franz, I.-W. (1994) Alternativen zur medikamentösen Hypertonietherapie.
Der Bayr Int 14: 32–38
Grimsgaaard, S., Bonaa, K.H., Jacobsen, B.K., Bjerve, K.S. (1999) Plasma
saturated and linoleic fatty acids are independently associated with blood
pressure. Hypertension 34: 478–483
Hayashi, T., Tsumura, K., Suematsu, C., Okada, K., Fuyii, S., Endo, G.
(1999) Walking to work and the risk for hypertension in men: The Osaka
Health Study. Am Intern Med 130: 21–26
He, J., Whelton, P.K., Appel, L.J., Charleston, J., Klag, M.J. (2000) Longterm effects of weight loss and dietary sodium reduction on incidence of
hypertension. Hypertension 35: 544–549
Hu, F.B., Stamper, M.J., Coditz, G.A., Ascherio, A., Rexrode, K.M.
Willert, W.C., Manson, J.E. (2000) Physical activity and risk of stroke in
women. JAMA 283: 2961–2967
21.
22.
23.
24.
Huber, H: , Feinleib, M., McNamara, P.M. et al. (1983) Obesity as an
independent risk factor for cardiovascular disease: A 26-year follow-up of
participants in the Framingham Heart Study. Circulation 67: 969–974
Intersalt cooperative Research group (1988) Intersalt: An international
study of electrolyte excretion and blood pressure: Results for 24 hour
urinary sodium and potassium excretion. B M J 297: 319–326
Joint National Committee on Detection, Evaluation and Treatment of High
Blood Pressure (1997) The sixth report of the Joint National Committee on
Prevention, Detection and Treatment of High Blood Pressure. (JNC
VI).Arch Intern Med 157: 2413–2446
Jorde, R., Sundsfjord, J., Fitzgerald, P., Bonaak, H. (1999): Serum calcium
and cardiovascular risk factors and diseases. The Tromsö Study.
Hypertension 34: 484–490
25.
26.
27.
28.
29.
30.
Kant, A.K., Schatzkin, A., Granbadr, B.I., Schairer, C. (2000): A
prospective study of diet qualitiy and mortality in women. JAMA 283:
2109–2115
Kaplan, N.M. (1985) Non-drug treatment of hypertension. Ann Intern Med
3: 359–373
Ketelhut, R.G., Franz, I.-W., Scholze, J. (1997) Efficacy and position of
endurance training as a non-drug therapy in the treatment of arterial
hypertension. J Human Hypertens 11: 651–655
Ketelhut, R.G., Behr, U., Franz, I.-W. (2000) Long-term weight reduction
on arterial pressure at rest and during exercise in obese hypertensives. J
Amer Coll Cardiol 35: 250 A
Laufs, U.M., Bohm, M. (2000) Kardiovaskulärer Risikofaktor Adipositas.
Dtsch med Wochenschr 125: 262–268
Löllgen, H., Dickhuth, H.H., Dirschedl, P. (1998) Vorbeugung durch
körperliche Bewegung. Dtsch Ärztebl 95: 1120–1127
31.
32.
33.
34.
35.
Luft, F.C., Geiger, H., Schmieder, R., Mann, J. (1992)
Nichtpharmakologische Faktoren in der Behandlung der arteriellen
Hypertonie. Dtsch med Wochenschr 117: 145–149
Manson, J.,Tosteson, H., Ridker, P. et al. (1992) The primary prevention
of myocardial infarction. N Engl J Med 326: 14o6–1411
McCarron, D.A., Oparis, S., Chart, E. et al. (1997) Nutritional
management of cardiovascular risk factors. Arch Intern Med 157: 169–177
Moore, I.J., Vollmer, W.M., Appel, L.J., Sacks, F.M., Svetkey, L.P., Vogt,
T.M., Conlin, P.R., Simons-Mortz, D.G., Carter-Edwards, L., Harsha,
D.W. (1999) Effect of dietary patterns on ambulatory blood pressure.
Results from the Dietary Approaches to Stop Hypertension (DASH) Trial.
Hypertension 34: 472–477
Morimoto, A., Uzu, T., Fujii, T. Nishimura, M., Kuroda, S., Nakamura, S.
(1997) Sodium sensitivy and cardiovascular events in patients with
essential hypertension. Lancet 350: 1734–1737
36.
37.
38.
39.
Müller, J.F.M., Franz, I.-W. (1999) ABPM and Ergometry in the
assessment of blood pressure in normotensive and hypertensive patients. J
Amer Coll Cardiol 33: 288 A
National High Blood Pressure Education Program. National High Blood
Pressure Education Program. Working Group Report on Primary
Prevention of Hypertension. Bethesda, MD: U.S. Department of Health
and Human Services, National Heart, Lung. and Blood Institute; NIH
publication 1993; 93: 2669
Neaton. J.D., Grimm jr., R.H., Prineas, R.J. et al. (1993) Treatment of mild
Hypertension Study (TOHMS): Final results. J Amer med Ass 27o: 713–
719
Nelson, L., Esler, M D., Jennings G L. (1986) Effect of changing levels of
physical activity on blood pressure and haemodynamics in essential
hypertension. Lancet I 473–481
40.
41.
42.
43.
44.
Patel, C., Marmot, M.G. Terry, D.J. (1981) Controlled trial of
biofeedback-aided behavioural methods in reducing mild hypertension. Br
Med J (Clin.Res) 282: 2005–2008
Pavan, L., Lasiglia, E., Braga, L.M., Winnicki, M., Puato, M. Panletto, P.,
Passina, A.C. (1999): Effects of a traditional lifestyle on the
cardiovascular risk profile: the Amondata population of the Brazilian
Amazon comparison with matched African, Italian and Polish population.
J Hypertens 17: 749–756
Ross, R., Dagnone, D., Jones, P.J. et al. (2000) Reduction in Obesity and
related comorbid conditions after diet-induced weight loss or exerciseinduced weight loss in men. Ann Intern Med 133: 92–103
Saunders, J.B., Beeveers, D.G., Paton, A. (1981) Alcohol-induced
hypertension. Lancet II: 653–657
Schotte, D.E., Stunkard, A.J. (1990) The effects of weight reduction on
blood pressure in 301 obese patients. Arch intern Med 15o: 17o1–1705
45.
46.
47.
48.
Stampfer, J., Hu, F.B., Manson, J. B., Runin, E.B., Willelt, W.C. (2000)
Primary prevention of coronary heart disease in women through diet and
life style. N Engl J Med 343: 16–22
Thun, M.J., Peto, R., Lopez, A.D., Monaco, J.H., Henly, J., Heath, C.W.,
Doll, R. (1997) Alcohol consumption and mortality among middle-aged
and elderly US adults. N Engl J Med 337: 1705–1709
Trials of Hypertension Prevention Collaborative Research Group (1997)
Effects of weight loss and sodium reduction intervention on blood pressure
and hypertension incidence in overweight people with high normal blood
pressure: the Trials of Hypertension Prevention, phase II. Arch Intern Med
157: 657–667
Weinsier, R.L., Norris, D.J., Birch. R. (1985) The relative contribution of
body fat and fat pattern to blood pressure level. Hypertens 7: 578–585
49.
50.
Whelton, P.K. He, J., Cutler, J.A. et al. (1997) Effects of oral potassium on
blood pressure: meta-analysis of randomized controlled clinical trials.
JAMA 277: 1624–1632
Whelton, P.K., Appel, L.J. Espeland, M.A. et al. (1998) Efficacy of
sodium reduction and weight loss in the treatment of hypertension in older
persons: main results of the randomized controlled trial of
nonpharmacologic interventions in the elderly (TONE) 2799 (11): 839–
846
Literatur zu Kap. 33.2
1.
Bellissant E, Sebille V, Vaintaud G. Methodological issues in
pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 1998,
35: 151–166
2.
Bonnabry P, Sievering J, Leemann T, Dayer P. Quantitative drug
interactions prediction system (Q-DIPS) A dynamic computer-based
method to assist in the choice of clinically relevant in vivo studies. Clin
Pharmacokinet 2001, 40 (9): 631–640
3.
Brown JJ, Davies DL, Lever AF, Peart WS, Robertson JI. Plasma
concentration of renin in a patient with Conn's syndrome with fibrinoid
lesions of the renal arterioles: the effect of treatment with spironolactone. J
Endocrinol 1965 Oct; 33 (2): 279–293
4.
Celis H, Thijs L, Staessen JA, Birkenhager WH, Bulpitt CJ, de Leeuw
PW, Leonetti G, Nachev C, Tuomilehto J, Fagard RH. Interaction between
nonsteroidal anti-inflammatory drug intake and calcium-channel blocker-
5.
6.
7.
8.
based antihypertensive treatment in the Syst-Eurtrial. J Hum Hypertens
2001 Sep; 15 (9): 613–618
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations
between dose regimens and medication compliance. Clin Ther 2001 Aug;
23 (8): 1296–1310
Cusi D, Barlassina C, Azzani T et al. Polymorphisms of a-adducin and salt
sensitivity in patients with essential hypertension. Lancet 1997; 349,
1353–1357
Dettli L. Translation of pharmacokinetics to clinical medicine. J
Pharmacokinet Biopharm 1973 Oct; 1 (5): 403–418
Glorioso N, Manunta P, Filigheddu F et al. The role of a-adducin
polymorphism in blood pressure and sodium handling regulation may not
be excluded by a negative association study. Hypertension 1999; 34, 649–
654
9.
10.
11.
Goldberg MR, Sciberras D, De Smet M, Lowry R, Tomasko L, Lee Y,
Olah TV, Zhao J, Vyas KP, Halpin R, Kari PH, James I. Influence of betaadrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5HT1B/1D agonist: differential effects of propranolol, nadolol and
metoprolol. Br J Clin Pharmacol 2001 Jul; 52 (1): 69–76
Hansson JH, Schild L, Lu Y, Wilson TA, Gautschi I, Shimkets R, NelsonWilliams C, Rossier BC, Lifton RP. A de novo missense mutation of the
beta subunit of the epithelial sodium channel causes hypertension and
Liddle syndrome, identifying a proline-rich segment critical for regulation
of channel activity. Proc Natl Acad Sci USA 1995 Dec 5; 92 (25): 11495–
11499
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoeller J, Johne
A, Cascorbi I, Gerolff T, Roots I, Eichelbaum M, Brinkmann U.
Functional polymorphisms of the human multidrug-resistance gene;
multiple sequence variations and correlation of one allele with p-
12.
13.
14.
15.
16.
glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA
2000, 97: 3473–3478
Holford NH. Target concentration intervention: beyond Y2 K. Br J Clin
Pharmacol 1999 Jul; 48 (1): 9–13
Jaffe R, Livshits T, Bursztyn M. Adverse interaction between clonidine
and verapamil. Ann Pharmacother 1994 Jul-Aug; 28 (7–8): 881–883
Johnson TR, Tobias JD. Hypotension following the initiation of tizanidine
in a patient treated with an angiotensin converting enzyme inhibitor for
chronic hypertension. J Child Neurol 2000 Dec; 15 (12): 818–819
Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM. Simvastatindiltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn
Med 2001 Sep; 94 (9): 339–341
Keller F, Zellner D, Giehl M, Czock D. Explicit function for dependence
of effect-duration time on elimination half-life. Pharmacol Toxicol 2001,
89 Suppl I: 86 (Abstract)
17.
18.
19.
20.
21.
22.
Keller F, Griesshammer M, Haeussler U, Paulus W, Schwarz A.
Pregnancy and renal failure; the case for application of dosage guidelines.
Drugs 2001, 61: 1901–1920
Kunin CM. A guide to use of antibiotics in patients with renal disease. A
table of recommended doses and factors governing serum levels. Ann
Intern Med 1967 Jul; 67 (1): 151–158
Kunin CM. Dosage schedules of antimicrobial agents: a historical review.
Rev Infect Dis 1981 Jan-Feb; 3 (1): 4–11
Leff P, Scaramellini C, Law C, McKechnie K. A three-state receptor
model of agonist action. Trends Pharmacol Sci 1997 Oct; 18 (10): 355–62.
Review
Marino MR, Vachharajani NN. Drug interactions with irbesartan. Clin
Pharmacokinet 2001; 40 (8): 605–614
Midtvedt K, Hartmann A, Bentdal O, Brekke IB, Fauchald P. Bilateral
nephrectomy simultaneously with renal allografting does not alleviate
23.
24.
25.
26.
27.
hypertension 3 months following living-donor transplantation. Nephrol
Dial Transplant 1996 Oct; 11 (10): 2045–2049
Nuutinen M, Lautala P, Remes M, Uhari M. Nephrectomy in severe
hypertension. Clin Nephrol 2000 Oct; 54 (4): 342–346
Meibohm B, Derendorf H. Pharmacokinetic/pharmacodynamic studies in
drug product development. J Pharm Sci 2002 Jan; 91 (1): 18–31
Pelegri A, Romero R, Reguant M, Aisa L. Non-resectable
phaeochromocytoma: long term follow-up. J Hum Hypertens 1989 Apr; 3
(2): 145–147
Rescigno A. Clearance, turnover time, and volume of distribution.
Pharmacol Res 1997, 35: 189–193
Rosenkranz S, Erdmann E. Interaction between sildenafil and
antihypertensive drugs: what is evidence-based? Dtsch Med Wochenschr
2001 Oct 12; 126 (41): 1144–1149
28.
29.
30.
31.
Rosenthal J, Bahrmann H, Benkert K, Baumgart P, Bonner G, Klein G,
Neiss A, Schnelle K, Frohlich ED. Analysis of adverse effects among
patients with essential hypertension receiving an ACE inhibitor or a betablocker. Cardiology 1996 Sep-Oct; 87 (5): 409–414
Ruzicka M, Leenen FH. Monotherapy vs. combination therapy as first line
treatment of uncomplicated arterial hypertension. Drugs 2001; 61 (7):
943–954
Schwarz ER, Heintz B, Stefanidis L, vom Dahl J, Sieberth HG. The
heterogeneous and delayed course of blood pressure normalization in
hypertensive patients after bilateral nephrectomy with and without
subsequent renal transplantation. Ren Fail 2000; 22 (5): 591–604
Staessen JA, Bieniaszewski L, Buntinx F, Celis H, O'Brien ET, VanHoof
R, Fagard R. The trough-to-peak ratio as an instrument to evaluate
antihypertensive drugs. Hypertension 1995, 26: 942–949
32.
33.
34.
35.
36.
37.
Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal
crisis. Ann Intern Med 2000 Oct 17; 133 (8): 600–603
Swanson DJ, Reitberg DO, Smith H, Wels PB, Schentag JP. Steady-state
moxalactam pharmacokinetics in patients: noncompartmental vs. twocompartmental analysis. J Pharmacokinet Biopharm 1983, 11: 337–353
Textor SC, Wilcox CS. Renal artery stenosis: a common, treatable cause
of renal failure? Annu Rev Med 2001; 52: 421–442. Review
van Zwieten PA. Renewed interest in centrally acting antihypertensive
drugs. Cardiovasc J S Afr 2000 Aug; 11 (4): 225–229
Wesnes K, Simpson PM, Jansson B, Grahnen A, Weimann HJ, Kuppers
H. Moxonidine and cognitive function: interactions with moclobemide and
lorazepam. Eur J Clin Pharmacol 1997; 52 (5): 351–358
Wilson JF, Weale ME, Smith AC, Gratrix F, Fletcher B, Thomas MG,
Bradman N, Goldstein DB. Population genetic structure of variable drug
response. Nature Genetics 2001, 29: 265–269
38.
39.
Wright JG, Boddy AV. All half-lives are wrong, but some half-lives are
useful. Clin Pharmacokinet 2001, 40: 237–244
Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M,
Dahl ML, Eliasson E. Role of CYP2C9 polymorphism in losartan
oxidation. Drug Metab Dispos 2001 Jul; 29 (7): 1051–1056
Literatur zu Kap. 33.3
1.
Achhammer I, Metz P (1991) Low dose diuretics in essential hypertension.
Experience with torasemide. Drugs 41 (Suppl 3): 80–91
2.
ALLHAT Collaborative Research Group (2002) Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme
inhibitor or calcium channel blocker vs diuretic. JAMA 288: 2981–2997
3.
Amery A, Birkenhäger W, Brixko P et al. (1985) Mortality and morbidity
results from the European Working Party on high blood pressure in the
elderly trial. Lancet 1: 1349–1354
4.
Ames RP (1983) Negative effects of diuretic drugs on metabolic risk
factors for coronary heart disease: possible alternative therapies. Am J
Cardiol 51: 632–638
5.
Ames RP (1995) Indapamide vs thiazides: a meta-analysis comparing
antihypertensive response and lipid effects. Am J Hypertens 8: 45
6.
7.
8.
9.
10.
Ames RP, Hill P (1976) Elevation of serum lipid levels during diuretic
therapy of hypertension. Am J Med 61: 748–757
Bengtsson C et al. (1984) Do antihypertensive drugs precipitate diabetes?
BMJ 289: 1495–1497
Bennett WM, McDonald WJ, Kuehnel E, Hartnett MN, Porter GA (1977)
Do diuretics have antihypertensive properties independent of natriuresis?
Clin Pharmacol Ther 22: 499–504
Blaustein MP, Hamlyn JM (1991) Pathogenesis of essential hypertension.
A link between dietary salt and high blood pressure. Hypertension 18
(Suppl III) 184–195
Bolte HD, v. Armin T, Erdmann E (1981) Myokardiale Natrium-KaliumATPase und Wirkungen von Diuretika am Myokard. In: Krück F, Schrey
A (Hrsg): Diuretika. Wolf, München, S80
11.
12.
13.
14.
Brilla CG (1994) The cardiac structure-function relationship and the reninangiotensin-aldosterone system in hypertension and heart failure. Curr
Opin Cardiol 9 (Suppl 1): 2–11
Brown M, Palmer C, Castaigne A et al. (2000) Morbidity and mortality in
patients randomised to double-blind treatment with a long-acting calcium
channel blocker or diuretic in the International Nifedipine GITS study:
Intervention as a Goal in Hypertension Treatment (INSIGHT) Lancet 356:
366–372
Calder JA, Schachter M, Sever PS (1992) Direct vascular actions of
hydrochlorothiazide and indapamide in isolated small vessels. Eur J
Pharmacol 220: 19–26
Collins R, Peto R, MacMahon S, Hebert P et al. (1990) Blood pressure,
stroke, and coronary heart disease. Part 2. Lancet 336: 827–838
15.
16.
17.
18.
19.
Cruickshank J, Lewis J, Moore V, Dodd C (1992) Reversibility of left
ventricular hypertrophy by differing types of antihypertensive therapy. J
Hum Hypertens 6: 85–90
Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO
(1991) Morbidity and mortality in the Swedish Trial in Old Patients with
Hypertension (STOP-Hypertension) Lancet 338: 1281–1285
Dahlöf B, Pennert K, Hansson L (1992) Reversal of left ventricular
hypertrophy in hypertensive patients: a metaanalysis of 109 treatment
studies. Am J Hypertens 5: 95–110
Fajans SS, Floyd JC, Knopf RF, Rull J, Guntsche EM, Conn JW (1966)
Benzothiadiazine suppression of insulin release from normal and abnormal
islet tissue in man. J Clin Invest 45: 481–502
Felson DT, Sloutkis D, Anderson JJ, Anthony JM, Kiel DP (1991)
Thiazide diuretics and the risk of hip fracture. JAMA 265: 370–373
20.
21.
22.
23.
24.
Finnerty FA, Davidov M, Kakaviatios (1969) Relation of sodium balance
to arterial pressure during drug-induced saluresis. Circulation 37: 175–185
Fuh M, Shieh SM, Wu DA, Chen YD, Reaven GM (1987) Abnormalities
of carbohydrate and lipid metabolism in patients with hypertension. Arch
Intern Med 147: 1035–1038
Grantham JJ, Chonko AM (1978) The physiological basis and clinical use
of diuretics. In: Brenner BM, Stein JH (Hrsg): Sodium and water
homeostasis. Churchill Livingstone, New York, S178–211
Grees TW, Tieto FJ, Shahar R, Wofford MR, Brancati FL (2000)
Hypertension and antihypertensive therapy as risk factors for type 2
diabetes mellitus N Engl J Med 342: 905–912
Greger R, Knauf H, Mutschler E (1995) Diuretics, Handbook of Experim.
Pharmcol, vol 117. Springer, Berlin Heidelberg New York
25.
26.
27.
28.
Haddy FJ, Pamnani MB, Swindall BT, Johnston J, Cragie EJ (1985)
Sodium channel blockers are vasodilators as well as natriuretic and
diuretic agents. Hypertension 7 (Suppl I): I121–I126
Hansson L, Zanchetti A, Carruthers SG et al. for the HOT Study Group
(1998) Effects of intensive blood pressure lowering and low-dose aspirin
in patients with hypertension: principal results of the Hypertension
Optimal Treatment (HOT) randomised trial. Lancet 351: 1755–1762
Hansson L, Lindholm LH, Ekbom T et al. for the STOP-Hypertension-2
Study Group (1999) Randomised trial of old and new antihypertensive
drugs in elderly patients: cardiovascular mortality and morbidity. The
Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 354:
1751–1756
Hansson L, Lindholm LH, Niskanen L et al, for the Captopril Prevention
Project (CAPPP) Study Group (1999) Effect of angiotensin-convertingenzyme inhibition compared with conventional therapy on cardiovascular
29.
30.
31.
morbidity and mortality in hypertension: the Captopril Prevention Project
(CAPPP) randomised trial. Lancet 353: 611–616
Hansson L, Hedner T, Lund-Johansen P et al. (2000) Randomised trial of
effects of calcium antagonists compared with diuretics and β-blockers on
cardiovascular morbidity and mortality in hypertension: the Nordic
Diltiazem (NORDIL) study. Lancet 356: 359–365
Hasenfuß G, Holubarsch C, Herzog C, Knauf H, Spahn H, Mutschler E,
Just H (1987) Influence of cardiac function on the diuretic and
hemodynamic effects of the loop diuretic piretanide. Clin Cardiol 10: 83–
88
Helderman JH, Elahi D, Andersen DK, Raizes GS, Tobin JD, Shocken D,
Andres R (1983) Prevention of glucose intolerance of thiazide diuretics by
maintenance of body potassium. Diabetes 32: 106–111
32.
33.
34.
35.
36.
Hoes AW, Grobbee DE, Lubsen J, Man in t'Veld AJ, van der Does E,
Hofman A (1995) Diuretics, β-blockers and the risk for sudden cardiac
death in hypertensive patients. Ann Intern Med 123: 481–487
Holzgreve H (1996) Der Stellenwert von Diuretika als Antihypertensiva.
Nieren- und Hochdruckkrankheiten 25 (6): 239–244
Hypertension Detection and Follow-up Program Cooperative Group
(1979) Five year findings of the Hypertension Detection and Follow-up
Program. Reduction in mortality of persons with high blood pressure,
including mild hypertension. JAMA 242: 2562–2571
Hypertension Detection and Follow-up Program Cooperative Group
(1982) Five year findings of the Hypertension Detection and Follow-up
Program. Reduction in stroke incidence among persons with high blood
pressure. JAMA 247: 633–638
Hypertension Detection and Follow-up Program Cooperative Group
(1984) Effect of stepped care treatment on the incidence of myocardial
37.
38.
39.
40.
infarction and angina pectoris. Five-year findings. Hypertension 6
(Suppl 1): 198–206
IPPPSH Collaborative Group (1985) Cardiovascular risk and risk factors
in a randomized trial of treatment based on the beta-blocker oxprenolol:
the international prospective primary prevention study in hypertension
(IPPPSH) J Hypertens 3: 379–392
Johnston GD, Nicholls DP, Leahey WJ, Finch MB (1983) The effects of
captopril on the acute vascular effects of furosemide in man. Clin Sci 65:
359
Knauf H, Mutschler E (1995) Diuretic effectiveness of
hydrochlorothiazide and furosemide alone and in combination in chronic
renal failure. J Cardiovasc Pharmacol 26: 394–400
Lardinois CK, Neuman SL (1988) The effect of antihypertensive agents on
serum lipids and lipoproteins. Arch Intern Med 148: 1280–1288
41.
42.
43.
44.
45.
46.
Lever AF, Ramsay LRE (1995) Treatment of hypertension in the elderly. J
Hypertens 13: 571–579
McMahon FG (1990) Management of essential hypertension. The once-aday era. Futura, New York S297–378
Medical Research Council Working Party (1985) MRC trial of treatment
of mild hypertension: principal results. BMJ 291: 97–104
Messerli FH, Frohlich ED, Dreslinski G et al. (1980) Serum uric acid in
essential hypertension: an indicator of renal vascular involvement. Ann
Intern Med 93: 817–821
Mironneau J, Savineau JP, Mironneau C (1981) Compared effects of
indapamide, hydrochlorothiazide and chlorthalidone in electrical and
mechanical activities in vascular smooth muscle. Eur J Pharmacol 75:
109–113
MRC Working Party (1992) Medical research council trial of treatment of
hypertension in older adults: principal results. BMJ 304: 405–412
47.
48.
49.
50.
51.
Moser M (1994) Effect of diuretics on morbidity and mortality in the
treatment of hypertension. Cardiology 84 (Suppl 2): 27–35
Multiple Risk Factor Intervention Trial Research Group (1982) Multiple
risk factor intervention trial. Risk factor changes and mortality results.
JAMA 248: 1465–1477
Nauman d'Alnoncourt C, Hornberger M, Lüderitz B (1976) Interaktionen
von Triamteren und Herzglykosiden am Erregungsleitungssystem des
Herzens. Verh Dtsch Ges Inn Med 82: 1236
Neal B et al., Blood Bressure Lowering Treatment Trialists Collaboration
(2000) Effects of ACE inhibitors, calcium antagonists, and other blood
pressure-lowering drugs: results of prospectively disigned overviews of
randomised trials. Lancet 356: 1955–1964
Neaton JD, Grimm RH, Prineas RJ et al. (1993) Treatment of mild
hypertension study. JAMA 270: 713–724
52.
53.
54.
55.
56.
57.
Papademetriou V, Burris JF, Notargiacoma A, Fletcher RD, Freis ED
(1988) Thiazide therapy is not a cause of arrhythmia in patients with
systemic hypertension. Arch Intern Med 148: 1272–1276
Pecker MS (1990) Pathophysiologic effects and strategies for long-term
diuretic treatment of hypertension. In: Laragh JH, Brenner BM (eds)
Hypertension, vol 2. Raven, New York, pp 2143–2167
Pitt B, Zannad F, Remme WJ et al. (1999) The effect of spironolactone on
morbidity and mortality in patients with severe heart failure. N Engl J Med
341: 709–717
Ramsay LRE, Yeo WW, Jackson PR (1994) Metabolic effects of diuretics.
Cardiology 84 (Suppl 2): 48–56
Report by the Management Committee (1980) The Australien Therapeutic
Trial in Mild Hypertension. Lancet I: 1261–1267
Ruppert M, Diehl J, Kolloch R, Overlack A, Kraft K, Göbel B, Hittel N,
Stumpe KO (1991) Short-term dietary sodium restriction increases serum
58.
59.
60.
61.
lipids and insulin salt-sensitivity in salt-resistant normotensive adults. Klin
Wochenschr 69 (Suppl XXV): 51–57
Schlaich MP, Schmieder RE (1998) Left ventricular hypertrophy and its
regression: Pathophysiology and therapeutical approach. Am J Hypertens
11: 1394–1404
Schoenfield MF, Goldberger E (1964) Hypercholesterinemia induced by
thiazides: a pilot study. Br Ther Res 6: 180–184
SHEP Cooperative Research Group (1991) Prevention of stroke by
antihypertensive drug treatment in older persons with isolated systolic
hypertension. JAMA 265: 3255–3264
Singh BN, Hollenberg NJK, Poole-Wilson PA, Robertson JIS (1992)
Diuretic-induced potassium and magnesium deficiency: relation to druginduced QT prolongation, cardiac arrhythmias and sudden death. J
Hypertens 10: 301–316
62.
63.
64.
65.
66.
67.
Siscovick D, Raghunathan TE, Psaty BM et al. (1994) Diuretic therapy for
hypertension and the risk of primary cardiac arrest. N Engl J Med 330:
1852–1857
Strauer BE (1972) Evidence for a positive inotropic effect of aldadiene (K, -Na) on the isolated ventricular myocardium. Klin Wochenschr 50: 387
Thijs L, Fagard R, Lijnen P, Staessen J, van Hoof R, Amery A (1993) A
meta-analysis of outcome trials in elderly hypertensives. J Hypertens 10:
1103–1109
Tobian L (1967) Why do diuretics lower blood pressure in essential
hypertension? Annu Rev Pharmacol 7: 399–408
Unwin RJ, Capasso G (1997) Hypertension and its treatment: The place of
diuretics In: Seldin D, Giebisch G (eds) Diuretic Agents: Clinical
Physiology and Pharmacology, Academie Press New York, pp 437–459
Unwin RJ, Ligueros M, Shakelton C, Wilcox CS (1995) Diuretics in the
management of hypertension. In "Hypertension: Pathophysiology,
68.
69.
70.
Diagnosis, and Management" Laragh JH, Brenner BM, Eds., pp. 2785–
2799. Raven Press, New York
Valette H, Hebert JL, Apoi IE (1983) Acute hemodynamic effects of a
single intravenous dose of piretanide in congestive heart failure. Eur J Clin
Pharmacol 24: 163–167
Veterans Administration Cooperative Study Group on Antihypertensive
Agents (1967) Effects of treatment on morbidity in hypertension. Results
in patients with diastolic blood pressure averaging 115 through
129 mmHg. JAMA 202, 116–121
Veterans Administration Cooperative Study Group on Antihypertensive
Agents (1970) Effects of treatment on morbidity in hypertension. Results
in patients with diastolic blood pressure averaging 90 through 114 mmHg.
JAMA 213, 1143–1152
71.
72.
73.
74.
75.
76.
Warram JH, Laffel LMB, Valsania P, Christlieb AR, Krolewski AS (1991)
Excess mortality associated with diuretic therapy in diabetes mellitus.
Arch Intern Med 151: 1350–1356
Weber JJ (1972) Intravenous triamterene in the treatment of acute digitalis
intoxication. Clin Pharmacol Ther 13: 868
Weidmann P (1980) Recent pathogenic aspects in essential hypertension
and hypertension associated with diabetes mellitus. Klin Wochenschr 58:
1971
Weidmann P, Gerber A, Mordasini R (1983) Effects of antihypertensive
therapy on serum lipoproteins. Hypertension 5 (Suppl III): III120-III131
Weinberger MH (1982) Comparison of captopril and hydrochlorothiazide
alone and in combination in mild-to-moderate essential hypertension. Br J
Clin Pharmacol 14: 127S–131S
Weinberger MH (1986) Antihypertensive therapy and lipids: paradoxical
influences on cardiovascular risk. Am J Med 80 (Suppl 2A): 64–70
77.
Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H,
Hosie J, Hörnkvist PE, Pennert K, Tuomilehto J, Wedel H (1987) Betablockers vs. diuretics in hypertensive men: Main results from the
HAPPHY trial. J Hypertension 5: 561–572
Literatur zu Kap. 33.4
1.
Belch JJ, Bridges AB, Scott N, Chopra M (1991) Oxygen free radicals and
congestive heart failure. Br Heart J 65: 245–248
2.
Benovic JL, Staniszewski C, Mayor FJ, Caron MG, Lefkowitz RJ (1988)
Beta-adrenergic receptor kinase. Activity of partial agonists for
stimulation of adenylate cyclase correlates with ability to promote receptor
phosphorylation. J Biol Chem 263: 3893–3897
3.
Blumenfeld JD, Sealey JE, Mann SJ et al. (1999) Beta-adrenergic receptor
blockade as a therapeutic approach for suppressing the renin-angiotensinaldosterone system in normotensive and hypertensive subjects. Am J
Hypertens 12: 451–419
4.
Bolli R (1990) Mechanism of myocardial "stunning". Circulation 82: 723–
738
5.
Bristow MR (1997) Mechanism of action of beta-blocking agents in heart
failure. Am J Cardiol 80: 26L–40L
6.
7.
8.
9.
10.
Bristow MR, Larrabee P, Minobe W et al. (1992) Receptor pharmacology
of carvedilol in the human heart. J Cardiovasc Pharmacol 19 (Suppl 1):
S68–S80
Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ (1998) The
role of third-generation beta-blocking agents in chronic heart failure. Clin
Cardiol 21: I3–I13
Brixius K, Bundkirchen A, Bolck B, Mehlhorn U, Schwinger RH (2001)
Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic
sympathomimetic activity in human myocardium. Br J Pharmacol 133:
1330–1338
CIBIS II Investigators (1999) The Cardiac Insufficiency Bisoprolol Study
II (CIBIS-II): a randomised trial. Lancet 353: 9–13
Cruickshank JM (2000) Beta-blockers continue to surprise us. Eur Heart J
21: 354–364
11.
12.
13.
14.
15.
Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO
(1991) Morbidity and mortality in the Swedish Trial in Old Patients with
Hypertension (STOP-Hypertension). Lancet 338: 1281–5
Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, HernandezLopez E (1996) Increased malondialdehyde in peripheral blood of patients
with congestive heart failure. Am Heart J 131: 146–152
Dorrow P (1986) Effects of single oral doses of bisoprolol and atenolol on
airways function in non-asthmatic chronic obstructive lung disease and
angina pectoris. Eur J Clin Pharmacol 31: 143
EIS Group. European infarction study (EIS) A secondary prevention study
with slow release oxprenolol after myocardial infarction. Eur Heart J 3:
583–586
Eriksson H, Svärdsudd K, Larsson B et al. (1989): Risk factors for heart
failure in the general population: The study of men born in 1913. Eur.
Heart J. 10: 647–656
16.
17.
18.
19.
20.
Gilbert EM, Olsen SL, Renlund DG, Bristow MR (1993) Beta-adrenergic
receptor regulation and left ventricular function in idiopathic dilated
cardiomyopathy. Am J Cardiol 71: 23C–29C
Gillman MW, Kannel WB, Belanger A, D'Agostino RB (1993) Influence
of heart rate on mortality among persons with hypertension: the
Framingham Study. Am Heart J 125: 1148–1154
Gold MR, Dec GW, Cocca-Spofford D, Thompson BT (1991) Esmolol
and ventilatory function in cardiac patients with COPD. Chest 100: 1215–
1218
Gottlieb SS, McCarter RJ, Vogel RA (1998) Effect of beta-blockade on
mortality among high-risk and low-risk patients after myocardial
infarction. N Engl J Med 339: 489–497
Gray A, Clarke P, Raikou M et al. (2001) An economic evaluation of
atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54) Diabet
Med 18: 438–444
21.
22.
23.
24.
25.
Gurwitz JH, Goldberg RJ, Chen Z, Gore JM, Alpert JS (1992) Betablocker therapy in acute myocardial infarction: evidence for
underutilization in the elderly. Am J Med 93: 605–610
Hash TW, Prisant LM (1997) Beta-blocker use in systolic heart failure and
dilated cardiomyopathy. J Clin Pharmacol 37: 7–19
Hausdorff WP, Caron MG, Lefkowitz RJ (1990) Turning off the signal:
desensitization of beta-adrenergic receptor function. FASEB J 4: 2881–
2889
Hill MF, Singal PK (1996) Antioxidant and oxidative stress changes
during heart failure subsequent to myocardial infarction in rats. Am J
Pathol 148: 291–300
HINT Research Group: Report of The Holland Interuniversity
Nifedipine/Metoprolol Trial (HINT) Research Group (1986) Early
treatment of unstable angina in the coronary care unit: a randomised,
double blind, placebo controlled comparison of recurrent ischaemia in
26.
27.
28.
29.
patients treated with nifedipine or metoprolol or both. Br Heart J 56: 400–
413
Hjalmarson A, Elmfeldt D, Herlitz J et al. (1981) Effect on mortality of
metoprolol in acute myocardial infarction. A double-blind randomised
trial. Lancet 2: 823–827
Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D (1993):
Survival after the onset of congestive heart failure in Framingham Heart
Study subjects. Circulation 88: 107–115
Holmer SR, Hengstenberg C, Mayer B et al.(2001) Marked suppression of
renin levels by beta-receptor blocker in patients treated with standard heart
failure therapy: a potential mechanism of benefit from beta-blockade. J
Intern Med 249: 167–172
ISIS–1 (First International Study of Infarct Survival) Collaborative Group
(1988) Mechanisms for the early mortality reduction produced by beta-
30.
31.
32.
33.
blockade started early in acute myocardial infarction: ISIS–1. Lancet 23:
921–923
Kannel WB, Cupples A (1988): Epidemiology and risk profile of cardiac
failure. Cardiovasc Drugs Ther 2: 387–395
Kannel WB, Levy D, Cupples LA (1987): Left ventricular hypertrophy
and risk of cardiac failure: Insights from the Framingham study. J.
Cardiovasc. Pharmacol. 10 (Suppl.6): S135–S140
Kannel WB, Wolf PA, Garrison RJ (1987) Section34: Some risk factors
related to the annual incidence of cardiovascular disease and death using
pooled repeated biennial measurements: Framingham Heart Study, 30-year
follow-up. Springfield, Va: National Technichal Information Service
Karlson BW, Herlitz J, Hjalmarson A (1993) Prognosis of acute
myocardial infarction in diabetic and non-diabetic patients. Diabet Med
10: 449–454
34.
35.
36.
37.
Kjekshus JK (1986) Importance of heart rate in determining beta-blocker
efficacy in acute and long-term acute myocardial infarction intervention
trials. Am J Cardiol 57: 43F–49F
Lacy F, O'Connor DT, Schmid-Schonbein GW (1998) Plasma hydrogen
peroxide production in hypertensives and normotensive subjects at genetic
risk of hypertension. J Hypertens 16: 291–303
Lauridsen UB, Christensen NJ, Lyngsoe J (1983) Effects of nonselective
and beta–1-selective blockade on glucose metabolism and hormone
responses during insulin-induced hypoglycemia in normal man. J Clin
Endocrinol Metab 56: 876–882
Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ (1990) BetaArrestin: a protein that regulates beta-adrenergic receptor function.
Science 248: 1547–1550
38.
39.
40.
41.
42.
Maack C, Flesch M, Südkamp M, Böhm M (2000): Different intrinsic
activities of bucindolol, carvedilol and metoprolol in human ventricular
myocardium. Br J Pharmacol 130: 1131–1139
Maack C, Tyroller S, Schnabel P et al. (2001): Characterization of β1selectivity, adrenoceptor GS-protein interaction and inverse agonism of
nebivolol and bisoprolol in human myocardium. Br J Pharmacol 132:
1817–1826
Malmberg K, Herlitz J, Hjalmarson A, Ryden L (1989) Effects of
metoprolol on mortality and late infarction in diabetics with suspected
acute myocardial infarction: retrospective data from two large studies. Eur
Heart J 10: 423–428
Mancia G (1989): Treatment of hypertension and ischemic heart disease. J
Cardiovasc Pharmacol 14: S9–12
Mangano DT, Layug EL, Wallace A, Tateo I (1996) Effect of atenolol on
mortality and cardiovascular morbidity after noncardiac surgery.
43.
44.
45.
46.
47.
Multicenter Study of Perioperative Ischemia Research Group. N Engl J
Med 335: 1713–1720
Mangrella M, Rossi F, Fici F, Rossi F (1998) Pharmacology of nebivolol.
Pharmacol Res 38: 419–431
MERIT-HF Investigators (1999) Effect of metoprolol CR/XL in chronic
heart failure: Metoprolol CR/XL Randomised Intervention Trial in
Congestive Heart Failure (MERIT-HF). Lancet 353: 2001–2007
Mosterd A, D´Agostino RB, Silbershatz H et al. (1999): Trends in the
prevalence of hypertension, antihypertensive therapy, and left ventricular
hypertrophy from 1950 to 1989. N Engl J Med 340: 1221–1227
MRC trial of treatment of mild hypertension: principal results (1985)
Medical Research Council Working Party. Br Med J 291: 97–104
MRC Working Party (1992) Medical Research Council trial of treatment
of hypertension in older adults: principal results. BMJ 304: 405–412
48.
49.
50.
51.
52.
Nicholas G, Oakley C, Pouleur H, Rousseau MF, Rydén LE, Wellens H
for The Xamoterol In Heart Failure Study Group (1990) Xamoterol in
severe heart failure. Lancet 336: 1–6
Ohlstein EH, Douglas SA, Sung C-P et al. (1993) Carvedilol, a
cardiovascular drug, prevents vascular smooth muscle cell proliferation,
migration and neointimal formation following vascular injury. Proc Natl
Acad Sci USA 90: 6189–1693
Packer M, Bristow MR, Cohn JN et al. for the US Carvedilol Heart Failure
Study Group (1996) The effect of carvedilol on morbidity and mortality in
patients with chronic heart failure. N Engl J Med 334: 1349–1355
Packer M, Coats AJ, Fowler MB et al. (2001) Effect of carvedilol on
survival in severe chronic heart failure. N Engl J Med 344: 1651–1658
Pauwels PJ, Gommeren W, van Lommen G, Janssen PAJ, Leysen JE
(1989) The receptor binding profile of the new antihypertensive agent
53.
54.
55.
nebivolol and its stereoisomers compared with various β-adrenergic
blockers. Mol Pharmacol 34: 843–851
Pauwels PJ, van Gompel P, Leysen JE (1991) Human β1- and β2adrenergic receptor binding and mediated accumulation of cAMP in
transfected Chinese hamster ovary cells. Biochem Pharmacol 42: 1683–
1689
Poldermans D, Boersma E, Bax JJ et al. (1999) The effect of bisoprolol on
perioperative mortality and myocardial infarction in high-risk patients
undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk
Evaluation Applying Stress Echocardiography Study Group. N Engl J Med
341: 1789–1794
Reaven GM (1988) Role of insulin resistance in human disease. Diabetes
37: 1595–607
56.
57.
58.
59.
60.
Remes J, Reunanen A, Aromaa A, Pyörälä K (1992): Incidence of heart
failure in eastern Finland: a population-based surveillance study. Eur Heart
J 13: 588–593
Roberts R, Rogers WJ, Mueller HS et al. (1991) Immediate vs. deferred
beta-blockade following thrombolytic therapy in patients with acute
myocardial infarction. Results of the Thrombolysis in Myocardial
Infarction (TIMI) II-B Study. Circulation 83: 422–437
Sawicki PT, Siebenhofer A (2001) Betablocker treatment in diabetes
mellitus. J Intern Med 250: 11–7
Schunkert H, Hense HW, Brockel U et al. (1998) Differential effects of
antihypertensive drugs on neurohormonal activation: insights from a
population-based sample. J Intern Med 244: 109–119
SHEP Cooperative Research Group (1991) Prevention of stroke by
antihypertensive drug treatment in older persons with isolated systolic
61.
62.
63.
64.
hypertension. Final results of the Systolic Hypertension in the Elderly
Program (SHEP). JAMA 265: 3255–3264
Soriano JB, Hoes AW, Meems L, Grobbee DE (1997) Increased survival
with beta-blockers: importance of ancillary properties. Prog Cardiovasc
Dis 39: 445–456
Sung C-P, Arleth AJ, Ohlstein EH (1993) Carvedilol inhibits vascular
smooth muscle cell proliferation. J Cardiovasc Pharmacol 21: 221–227
Teerlink JR, Goldhaber SZ, Pfeffer MA (1991): An overview of
contemporary etiologies of congestive heart failure. Am Heart J 121:
1852–1853
The Australian and Swedish Pindolol Study Group (1983) The effect of
pindolol on the two years mortality after complicated myocardial
infarction. Eur Heart J 4: 367–375
65.
66.
67.
68.
The Beta-Blocker Evaluation of Survival Trial Investigators (2001) A trial
of the beta-blocker bucindolol in patients with advanced chronic heart
failure. N Engl J Med 344: 1659–1667
The BHAT Research Group (1983) A randomized trial of propranolol in
patients with acute myocardial infarction. II. Morbidity results. JAMA
250: 2814–2819
The IPPPSH Collaborative Group (1985) Cardiovascular risk and risk
factors in a randomized trial of treatment based on the beta-blocker
oxprenolol: the International Prospective Primary Prevention Study in
Hypertension (IPPPSH). J Hypertens 3: 379–392
The MIAMI Trial Research Group (1985) Metoprolol in acute myocardial
infarction (MIAMI): A randomised placebo-controlled international trial.
Eur Heart J 6: 199–226
69.
70.
71.
72.
The Norwegian Multicenter Study Group (1981) Timolol-induced
reduction in mortality and reinfarction in patients surviving acute
myocardial infarction. N Engl J Med 304: 801–807
Tuininga YS, Crijns HJ, Brouwer J, van den Berg MP, Man in't Veld AJ,
Mulder G, Lie KI (1995) Evaluation of importance of central effects of
atenolol and metoprolol measured by heart rate variability during mental
performance tasks, physical exercise, and daily life in stable postinfarct
patients. Circulation 92: 3415–23
Tzemos N, Lim PO, MacDonald TM (2001) Nebivolol reverses
endothelial dysfunction in essential hypertension: a randomized, doubleblind, crossover study. Circulation 104: 511–514
UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and
captopril in reducing risk of macrovascular and microvascular
complications in type 2 diabetes: UKPDS 39. BMJ 317: 713–720
73.
74.
75.
76.
van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ et al. (1992)
Partial escape of angiotensin converting enzyme (ACE) inhibition during
prolonged ACE inhibitor treatment: does it exist and does it affect the
antihypertensive response? J Hypertens 10: 803–812
Wallace A, Layug B, Tateo I et al. (1998) Prophylactic atenolol reduces
postoperative myocardial ischemia. McSPI Research Group.
Anesthesiology 88: 7–17
White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ
(1987) Left ventricular end-systolic volume as the major determinant of
survival after recovery from myocardial infarction. Circulation 76: 44–51
Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G
(1988) Primary prevention with metoprolol in patients with hypertension.
Mortality results from the MAPHY study. JAMA 259: 1976–1982
77.
78.
79.
80.
81.
Wilhelmsen L, Berglund G, Elmfeldt D et al. (1987) Beta-blockers vs.
diuretics in hypertensive men: main results from the HAPPHY trial. J
Hypertens 5: 561–572
Wilhelmsen L, Berglund G, Elmfeldt D, Tibblin G, Wedel H, Pennert K,
Vedin A, Wilhelmsson C, Werko L (1986) The multifactor primary
prevention trial in Goteborg, Sweden. Eur Heart J 7: 279–288
Woolcock AJ, Anderson SD, Peat JK et al. (1991) Characteristics of
bronchial hyperresponsiveness in chronic obstructive pulmonary disease
and in asthma. Am Rev Respir Dis 143: 1438–1443
Yue TL, Cheng H-J, Lysko PG, McKenna PJ, Feuerstein R, Gu J-L, Lysko
KA, Davis LL, Feuerstein G (1992a) Carvedilol, a new vasodilator and
beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger.
J Pharmacol Exp Ther 263: 92–98
Yue T-L, Liu T, Feuerstein G (1992b) Carvedilol, a new vasodilator and
beta-adrenoceptor antagonist, inhibits oxygen radical mediated lipid
peroxidation in swine ventricular membranes. Pharmacol Communications
1: 27–35
Literatur zu Kap. 33.5
Zitierte Literatur
1.
ALLHAT Collaborative Research Group. Major cardiovascular events in
hypertensive patients randomized to doxazosin vs chlorthalidone: the
antihypertensive and lipid-lowering treatment to prevent heart attack trial
(ALLHAT) JAMA 2000 Apr 19; 283 (15): 1967–1975
2.
Andersen P, Seljeflot I, Herzog A, Arnesen H, Hjermann I, Holme I.
Effects of doxazosin and atenolol on atherothrombogenic risk profile in
hypertensive middle-aged men. J Cardiovasc Pharmacol 1998 May; 31 (5):
677–683
3.
Calo L, Davis PA, Cantaro S, Bonfante L, Castrignano R, Carraro G,
D'Angelo A. Effect of doxazosin in mild to moderate hypertensive patients
with insulin-dependent diabetes mellitus. Acta Diabetol 1998 Jul; 35 (2):
96–100
4.
5.
6.
7.
Clifford GM, Farmer RD. Medical therapy for benign prostatic
hyperplasia: a review of the literature. Eur Urol 2000 Jul; 38 (1): 2–19.
Review
Daae LN, Westlie L. A 5-year comparison of doxazosin and atenolol in
patients with mild-to-moderate hypertension: effects on blood pressure,
serum lipids, and coronary heart disease risk. Blood Press 1998 Jan; 7 (1):
39–45
Fawzy A, Hendry A, Cook E, Gonzalez F. Long-term (4 year) efficacy and
tolerability of doxazosin for the treatment of concurrent benign prostatic
hyperplasia and hypertension. Int J Urol 1999 Jul; 6 (7): 346–354
Feldman RD, Campbell N, Larochelle P. First-line antihypertensive
therapy. Task Force for the Development of the 1999 Canadian
Recommendations for the Management of Hypertension. Lancet 2000 Aug
5; 356 (9228): 509
8.
9.
10.
11.
Frohlich ED. Treatment guideline in the USA: hypertension in the elderly.
Br J Urol 1998 Mar; 81 Suppl 1: 26–28
Grimm RH, Margolis KL, Papademetriou V, Cushman WC, Ford CE,
Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro V,
Eckfeldt J, Hawkins CM, Perry HM, Proschan M. Baseline Characteristics
of Participants in the Antihypertensive and Lipid Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT) Hypertension 2001 Jan; 37 (1): 19–
27
Hall DR, Odendaal HJ, Steyn DW, Smith M. Nifedipine or prazosin as a
second agent to control early severe hypertension in pregnancy: a
randomised controlled trial. BJOG 2000 Jun; 107 (6): 759–765
Harris SI, Alvarez C. Alpha 2-agonist versus alpha 1-antagonist in mildto-moderate hypertension: comparison of transdermal clonidine and
terazosin monotherapies. Am J Ther 1997 Jan; 4 (1): 9–15
12.
13.
14.
15.
Kaplan SA, D'Alisera PM. Tolerability of alpha-blockade with doxazosin
as a therapeutic option for symptomatic benign prostatic hyperplasia in the
elderly patient: a pooled analysis of seven double-blind, placebocontrolled studies. J Gerontol A Biol Sci Med Sci 1998 May; 53 (3):
M201–6
Karter Y, Aran S, Seyahi N, Tunckale A, Yaldiran A, Sipahioglu F,
Ozturk E. The antihypertensive effects of doxazosin on the arterial system:
changes in peripheral vascular resistance and wall tension. Eur. J. Intern.
Med. 2000 Jun; 11 (3): 140–144
Levy D, Walmsley P, Levenstein M. Principal results of the Hypertension
and Lipid Trial (HALT): a multicenter study of doxazosin in patients with
hypertension. Am Heart J 1996 May; 131 (5): 966–973
Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyo JM.
Treatment of hypertension after renal transplantation: long-term efficacy
16.
17.
18.
19.
of verapamil, enalapril, and doxazosin. Kidney Int Suppl 1998 Dec; 68:
S130–134
Maruenda J, Bhatnagar V, Lowenthal DT. Hypertension in the elderly
with coexisting benign prostatic hyperplasia. Urology 1999 Mar; 53 (3
Suppl 3a): 7–12; discussion 12–13, 41–42
Nalbantgil S, Nalbantgil I, Onder R. Clinically additive effect between
doxazosin and amlodipine in the treatment of essential hypertension. Am J
Hypertens 2000 Aug; 13 (8): 921–926
Narayan P, Tewari A. A second phase III multicenter placebo controlled
study of 2 dosages of modified release tamsulosin in patients with
symptoms of benign prostatic hyperplasia. United States 93–01 Study
Group. J Urol 1998 Nov; 160 (5): 1701–1706
Oliver RM, Upward JW, Dewhurst AG, Honeywell R, Renwick AG,
Waller DG. The pharmacokinetics of doxazosin in patients with
20.
21.
22.
23.
hypertension and renal impairment. Br J Clin Pharmacol 1990 Apr; 29 (4):
417–422
Os I, Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic
system formulation versus doxazosin standard and placebo in mild-tomoderate hypertension. Doxazosin Investigators' Study Group. J
Cardiovasc Pharmacol 1999 May; 33 (5): 791–797
Pasanisi F, Imperatore G, Vaccaro O, Iovine C, Ferrara LA. Effects of a 3month treatment with terazosin on fasting and postprandial glucose and
lipid metabolism in type 2 diabetic patients with hypertension. Nutr Metab
Cardiovasc Dis 1999 Apr; 9 (2): 73–77
Penenberg D, Chung M, Walmsley P, Vashi V. The effects of hepatic
impairment on the pharmacokinetics of doxazosin. J Clin Pharmacol 2000
Jan; 40 (1): 67–73
Rosenthal J. Lipid metabolism: implications of alpha 1-blockade. J Clin
Pharmacol 1993 Sep; 33 (9): 883–887. Review
24.
25.
26.
27.
Schwenger V, Zeier M, Ritz E. Antihypertensive therapy in renal patients
– benefits and difficulties. Nephron 1999; 83 (3): 202–213
Tamasawa N, Matsui J, Ogawa Y, Gotoh T, Hinata T, Murakami H, Zhi
GJ, Suda T. Effect of doxazosin on the size of LDL particle in the type 2
diabetic patients with hypertension. J Diabetes Complications 2000 MayJun; 14 (3): 135–139
Toth K, Kesmarky G, Vekasi J, Nemes J, Czopf L, Kapronczay P,
Halmosi R, Papp E, Juricskay I (1999) Hemorheological and
hemodynamic parameters in patients with essential hypertension and their
modification by alpha–1 inhibitor drug treatment. Clin Hemorheol
Microcirc 1999; 21 (3–4): 209–216
Tsujii T. Comparison of prazosin, terazosin and tamsulosin in the
treatment of symptomatic benign prostatic hyperplasia: a short-term open,
randomized multicenter study. BPH Medical Therapy Study Group.
Benign prostatic hyperplasia. Int J Urol 2000 Jun; 7 (6): 199–205
28.
29.
30.
Vashi V, Chung M, Hilbert J, Lawrence V, Phillips K. Pharmacokinetic
interaction between finasteride and terazosin, but not finasteride and
doxazosin. J Clin Pharmacol 1998 Nov; 38 (11): 1072–1076
Weinberger MH, Fawzy A. Doxazosin in elderly patients with
hypertension. Int J Clin Pract 2000 Apr; 54 (3): 181–189
Zusman RM. The role of alpha 1-blockers in combination therapy for
hypertension. Int J Clin Pract 2000 Jan-Feb; 54 (1): 36–40
Weiterführende Literatur
•
Ajayi AA, Sofowora GG, Balogun MO. Concurrent alpha 1-adrenergic
blockade and angiotensin converting enzyme inhibition in the treatment of
congestive heart failure. Int J Cardiol 1996 Dec 6; 57 (2): 173–176
•
Alabaster VA, Davey MJ. The alpha 1-adrenoceptor antagonist profile of
doxazosin: preclinical pharmacology. Br J Clin Pharmacol 1986; 21
Suppl 1: 9S–17S
•
•
•
•
ALLHAT Collaborative Research Group. Major cardiovascular events in
hypertensive patients randomized to doxazosin vs chlorthalidone: the
antihypertensive and lipid-lowering treatment to prevent heart attack trial
(ALLHAT) JAMA 2000 Apr 19; 283 (15): 1967–1975
Andersen P, Seljeflot I, Herzog A, Arnesen H, Hjermann I, Holme I.
Effects of doxazosin and atenolol on atherothrombogenic risk profile in
hypertensive middle-aged men. J Cardiovasc Pharmacol 1998 May; 31 (5):
677–683
Anderton JL, Notghi A. An evaluation of the efficacy and safety of
doxazosin in the treatment of hypertension associated with renal
insufficiency. J Hum Hypertens 1990 Oct; 4 Suppl 3: 52–57
Awan NA, Lee G, DeMaria AN, Mason DT. Ambulatory prazosin
treatment of chronic congestive heart failure: development of late
tolerance reversible by higher dosage and interrupted substitution therapy.
Am Heart J 1981 May; 101 (5): 541–547
•
•
•
•
•
Baez MA, Garg DC, Jallad NS, Weidler DJ. Antihypertensive effect of
doxazosin in hypertensive patients: comparison with atenolol. Br J Clin
Pharmacol 1986; 21 Suppl 1: 63S–67S
Bailey RR, Nairn PL, Walker RJ. Effect of doxazosin on blood pressure
and renal haemodynamics of hypertensive patients with renal failure. N Z
Med J 1986 Dec 10; 99 (815): 942–945
Bauer JH, Jones LB, Gaddy P. Effects of prazosin therapy on BP, renal
function, and body fluid composition. Arch Intern Med 1984 Jun; 144 (6):
1196–1200
Black HR, Chrysant SG, Curry CL, Frishman WH, Grimm RH, Lasseter
KC, Okun R, Pool JL, Raizada V, Vlachakis ND et al. Antihypertensive
and metabolic effects of concomitant administration of terazosin and
methyclothiazide for the treatment of essential hypertension. J Clin
Pharmacol 1992 Apr; 32 (4): 351–359
Blaschke TF, Rubin PC. Hepatic first-pass metabolism in liver disease.
•
•
•
•
•
Clin Pharmacokinet 1979 Nov-Dec; 4 (6): 423–432
Bloom DS, Rosendorff C, Kramer R. Clinical evaluation of prazosin as the
sole agent for the treatment of hypertension: a double-blind cross-over
study with methyldopa. Curr Ther Res Clin Exp 1975 Jul; 18 (1 pt 2):
144–150
Bolli P, Wood AJ, Simpson FO. Effects of prazosin in patients with
hypertension. Clin Pharmacol Ther 1976 Aug; 20 (2): 138–141
Bradley WF. A long-term clinical trial of prazosin. Postgrad Med 1975
Nov; Spec No: 95–99
Bradley WF, Hoffman FG, Hutchison JC, Kalams Z, Waldron SL.
Comparison of prazosin and methyldopa in mild to moderate hypertension,
a multicenter cooperative study. Curr Ther Res Clin Exp 1977 Jan; 21 (1):
28–35
Brogden RN, Heel RC, Speight TM, Avery GS. Prazosin: a review of its
pharmacological properties and therapeutic efficacy in hypertension.
•
•
•
•
•
Drugs 1977 Sep; 14 (3): 163–97
Brown MJ. Efficacy and tolerance of doxazosin: a review. J Hum
Hypertens 1990 Oct; 4 Suppl 3: 34–8. Review
Brown MJ, Dickerson JE. Alpha-blockade and calcium antagonism: an
effective and well-tolerated combination for the treatment of resistant
hypertension. J Hypertens 1995 Jun; 13 (6): 701–707
Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC.
Efficacy and safety of sustained-release alfuzosin 5 mg in patients with
benign prostatic hyperplasia. ALGEBI Study Group. Eur Urol 1997; 31
(2): 190–198
Calo L, Davis PA, Cantaro S, Bonfante L, Castrignano R, Carraro G,
D'Angelo A. Effect of doxazosin in mild to moderate hypertensive patients
with insulin-dependent diabetes mellitus. Acta Diabetol 1998 Jul; 35 (2):
96–100
Cambridge D, Davey MJ, Massingham R. Prazosin, a selective antagonist
•
•
•
•
•
of post-synaptic alpha-adrenoceptors [proceedings]. Br J Pharmacol 1977
Mar; 59 (3): 514P–515P
Carlson RV, Bailey RR, Begg EJ, Cowlishaw MG, Sharman JR.
Pharmacokinetics and effect on blood pressure of doxazosin in normal
subjects and patients with renal failure. Clin Pharmacol Ther 1986 Nov; 40
(5): 561–566
Carruthers G, Dessain P, Fodor G, Newman C, Palmer W, Sim D.
Comparative trial of doxazosin and atenolol on cardiovascular risk
reduction in systemic hypertension. The Alpha Beta Canada Trial Group.
Am J Cardiol 1993 Mar 1; 71 (7): 575–581
Carruthers SG. Adverse effects of alpha 1-adrenergic blocking drugs.
Drug Saf 1994 Jul; 11 (1): 12–20
Carruthers SG. The place of alpha blockers in the antihypertensive
armamentarium. J Clin Pharmacol 1993 Mar; 33 (3): 260–263
Catalano M, Libretti A. A multicenter study of doxazosin in the treatment
•
•
•
•
•
of patients with mild or moderate essential hypertension and concomitant
intermittent claudication. Am Heart J 1991 Jan; 121 (1 Pt 2): 367–371
Chaignon M, Le Roux E, Aubert P, Lucsko M, Safar M, Flouvat B,
Guedon J. Clinical pharmacology of prazosin in hypertensive patients with
chronic renal failure. J Cardiovasc Pharmacol 1981 Jan-Feb; 3 (1): 151–
160
Cheung DG, Hoffman CA, Ricci ST, Weber MA. Mild hypertension in the
elderly. A comparison of prazosin and enalapril. Am J Med 1989 Jan 23;
86 (1B): 87–90
Chrysant SG. Experience with terazosin administered in combination with
other antihypertensive agents. Am J Med 1986 May 23; 80 (5B): 55–61
Clifford GM, Farmer RD. Medical therapy for benign prostatic
hyperplasia: a review of the literature. Eur Urol 2000 Jul; 38 (1): 2–19.
Review
Cohen A. Efficacy and safety of intravenous terazosin in hypertensive
•
•
•
•
•
patients. A preliminary report. Am J Med 1986 May 23; 80 (5B): 86–93
Cohen BM. Prazosin hydrochloride (CP–12,299–1), an oral antihypertensive agent: preliminary clinical observations in ambulatory
patients. J Clin Pharmacol J New Drugs 1970 Nov-Dec; 10 (6): 408–417
Cohen JD. Long-term efficacy and safety of terazosin alone and in
combination with other antihypertensive agents. Am Heart J 1991 Sep;
122 (3 Pt 2): 919–925
Cox DA, Leader JP, Milson JA, Singleton W. The antihypertensive effects
of doxazosin: a clinical overview. Br J Clin Pharmacol 1986; 21 Suppl 1:
83S–90S
Cubeddu LX, Fuenmayor N, Caplan N, Ferry D. Clinical pharmacology of
doxazosin in patients with essential hypertension. Clin Pharmacol Ther
1987 Apr; 41 (4): 439–449
Cubeddu LX, Pool JL, Bloomfield R, Klotman PE, Pickering BI, Wombolt
DG, Nelson EB, Halperin A. Effect of doxazosin monotherapy on blood
•
•
•
•
•
pressure and plasma lipids in patients with essential hypertension. Am J
Hypertens 1988 Apr; 1 (2): 158–167
Curtis JR, Bateman FJ. Use of prazosin in management of hypertension in
patients with chronic renal failure and in renal transplant recipients. Br
Med J 1975 Nov 22; 4 (5994): 432–434
Cushman WC. Optimising diuretic therapy in elderly patients with
hypertension. Drugs Aging 1995 Aug; 7 (2): 88–96
Daae LN, Westlie L. A 5-year comparison of doxazosin and atenolol in
patients with mild-to-moderate hypertension: effects on blood pressure,
serum lipids, and coronary heart disease risk. Blood Press 1998 Jan; 7 (1):
39–45
Dauer AD. Terazosin: an effective once-daily monotherapy for the
treatment of hypertension. Am J Med 1986 May 23; 80 (5B): 29–34
Deger G. Comparison of the safety and efficacy of once-daily terazosin
versus twice-daily prazosin for the treatment of mild to moderate
•
•
•
•
hypertension. Am J Med 1986 May 23; 80 (5B): 62–67
De la Paz AG, Reyes AL, de Guia R, Saldivar c, Aquino a, Saniel EG,
Durante M, Unson L. A new quinazoline derivative in the treatment of
hypertension. A cooperative study in four medical centres in the
Philippines.Philippine J Cardiol 1976, 4: 47
Desch CE, Magorien RD, Triffon DW, Blanford MF, Unverferth DV,
Leier CV. Development of pharmacodynamic tolerance to prozosin in
congestive heart failure. Am J Cardiol 1979 Nov; 44 (6): 1178–1182
DiBianco R, Parker JO, Chakko S, Tanser PH, Emmanuel G, Singh JB,
Marlon A. Doxazosin for the treatment of chronic congestive heart failure:
results of a randomized double-blind and placebo-controlled study. Am
Heart J 1991 Jan; 121 (1 Pt 2): 372–380
Donnelly R, Elliott HL, Meredith PA, Reid JL. Concentration-effect
relationships and individual responses to doxazosin in essential
hypertension. Br J Clin Pharmacol 1989 Nov; 28 (5): 517–526
•
•
•
•
•
Drayer JI, Weber MA, DeYoung JL, Brewer DD. Long-term BP
monitoring in the evaluation of antihypertensive therapy. Arch Intern Med
1983 May; 143 (5): 898–901
Elliott HL, Donnelly R, Meredith PA, Reid JL. Predictability of
antihypertensive responsiveness and alpha-adrenoceptor antagonism
during prazosin treatment. Clin Pharmacol Ther 1989 Nov; 46 (5): 576–
583
Estler C-J. Pharmakologie und Toxikologie. Schattauer Verlag Stuttgart
New York, 2000
Falase AO, Salako LA, Aminu JM. Lack of effect of low doses of prazosin
in hypertensive Nigerians. Curr Ther Res Clin Exp 1976 Jun; 19 (6): 603–
611
Farry JP, Fischl SJ, Tighe MJ, Krell MJ. Effects of prazosin and labetalol
on blood pressure control and blood lipid levels in patients with mild-tomoderate essential hypertension. Am J Med 1989 Jan 23; 86 (1B): 41–44
•
•
•
•
Faulkner JK, Himanen P, Karjalainen U, Saraste M. The pharmacokinetics
and pharmacodynamics of doxazosin compared with atenolol during longterm double-blind treatment. Eur J Clin Pharmacol 1987; 31 (6): 685–693
Fawzy A, Hendry A, Cook E, Gonzalez F. Long-term (4 year) efficacy and
tolerability of doxazosin for the treatment of concurrent benign prostatic
hyperplasia and hypertension. Int J Urol 1999 Jul; 6 (7): 346–354
Feher MD, Henderson AD, Wadsworth J, Poulter C, Gelding S, Richmond
W, Sever PS, Elkeles RS. Alpha-blocker therapy; a possible advance in the
treatment of diabetic hypertension–results of a cross-over study of
doxazosin and atenolol monotherapy in hypertensive non-insulin
dependent diabetic subjects. J Hum Hypertens 1990 Oct; 4 (5): 571–577
Feldman RD, Campbell N, Larochelle P. First-line antihypertensive
therapy. Task Force for the Development of the 1999 Canadian
Recommendations for the Management of Hypertension. Lancet 2000 Aug
5; 356 (9228): 509
•
•
•
•
•
Fernandes M, Smith IS, Weder A, Kim KE, Gould AB, Busby P, Swartz
C, Onesti G. Prazosin in the treatment of hypertension. Clin Sci Mol Med
Suppl 1975 Jun; 2: 181s–184 s
Ferrara LA, Marotta T, Rubba P, De Simone B, Leccia G, Soro S, Mancini
M. Effects of alpha-adrenergic and beta-adrenergic receptor blockade on
lipid metabolism. Am J Med 1986 Feb 14; 80 (2A): 104–108
Franz IW. Effect of the alpha 1-receptor blocker prazosin and the beta 1receptor blocker acebutolol and their combination on blood pressure and
pressure rate product. Ergometric studies of hypertensive patients. Z
Kardiol 1984 Jan; 73 (1): 21–28
Frei U, Schindler R, Koch KM. Influence of antihypertensive therapy on
renal function. Clin Investig 1992; 70 Suppl 1: S120–S126
Frick MH, Halttunen P, Himanen P, Huttunen M, Porsti P, Pitkajarvi T,
Poyhonen L, Pyykonen ML, Reinikainen P, Salmela P et al. A long-term
double-blind comparison of doxazosin and atenolol in patients with mild
•
•
•
•
to moderate essential hypertension. Br J Clin Pharmacol 1986; 21 Suppl 1:
55S–62S
Frick MH, Cox DA, Himanen P, Huttunen M, Pitkajarvi T, Porsti P,
Poyhonen L, Pyykonen ML, Reinikainen P, Salmela P et al. Serum lipid
changes in a one-year, multicenter, double-blind comparison of doxazosin
and atenolol for mild to moderate essential hypertension. Am J Cardiol
1987 May 29; 59 (14): 61G–67G
Frohlich ED. Treatment guideline in the USA: hypertension in the elderly.
Br J Urol 1998 Mar; 81 Suppl 1: 26–28
Gillin AG, Fletcher PJ, Horvath JS, Hutton BF, Bautovich GJ, Tiller DJ.
Comparison of doxazosin and atenolol in mild hypertension, and effects
on exercise capacity, hemodynamics and left ventricular function. Am J
Cardiol 1989 Apr 15; 63 (13): 950–954
Giorda C, Appendino M, Mason MG, Imperiale E, Pagano G. Alpha 1blocker doxazosin improves peripheral insulin sensitivity in diabetic
•
•
•
•
•
hypertensive patients. Metabolism 1995 May; 44 (5): 673–676
Goto Y. Effects of alpha- and beta-blocker antihypertensive therapy on
blood lipids: a multicenter trial. Am J Med 1984 Feb 27; 76 (2A): 72–78
Grant PK, Reuben SR, Jones R, Hillis WS, Bayliss J et al.
Pharmacodynamics of terazosin in heart failure. European Heart Journal
1983; 4 (Suppl E): 111
Grimm RH, Margolis KL, Papademetriou V, Cushman WC, Ford CE,
Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro V,
Eckfeldt J, Hawkins CM, Perry HM, Proschan M. Baseline Characteristics
of Participants in the Antihypertensive and Lipid Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT) Hypertension 2001 Jan; 37 (1): 19–
27
Guevara-Viales L. Prazosin: New antihypertensive drug. Comparative
study with α-methyldopa. Revista Medica de Costa Rica 1976; 43: 11
Guthrie R. Terazosin in the treatment of hypertension and symptomatic
•
•
•
•
•
benign prostatic hyperplasia: a primary care trial. J Fam Pract 1994 Aug;
39 (2): 129–133
Hall DR, Odendaal HJ, Steyn DW, Smith M. Nifedipine or prazosin as a
second agent to control early severe hypertension in pregnancy: a
randomised controlled trial. BJOG 2000 Jun; 107 (6): 759–765
Harris SI, Alvarez C. Alpha 2-agonist versus alpha 1-antagonist in mildto-moderate hypertension: comparison of transdermal clonidine and
terazosin monotherapies. Am J Ther 1997 Jan; 4 (1): 9–15
Hasford J, Bussmann WD, Delius W, Kopcke W, Lehmann K, Weber E.
Design and analysis of the HYPREN-trial: safety of enalapril and prazosin
in the initial treatment phase of patients with congestive heart failure. Z
Kardiol 1991; 80 Suppl 2: 21–27
Hayduk K. Efficacy and safety of doxazosin in hypertension therapy. Am
J Cardiol 1987 May 29; 59 (14): 35G–39G
Hayduk K, Schneider HT. Antihypertensive effects of doxazosin in
•
•
•
•
systemic hypertension and comparison with terazosin. Am J Cardiol 1987
May 29; 59 (14): 95G–98G
Hjortdahl P, von Krogh H, Daae L, Holme I, Hjermann I. A 24-week
multicenter double-blind study of doxazosin and hydrochlorothiazide in
patients with mild to moderate essential hypertension. Acta Med Scand
1987; 221 (5): 427–434
Hockings BE, Cope GD, Clarke GM, Taylor RR. Prazosin in the treatment
of severe chronic congestive cardiac failure. Aust N Z J Med 1980 Aug;
10 (4): 420–425
Holme I, Fauchald P, Rugstad HE, Stokke HP. Preliminary results of the
Norwegian doxazosin postmarketing surveillance study: a twelve-week
experience. Am Heart J 1991 Jan; 121 (1 Pt 2): 260–267
Holmes B, Sorkin EM. Indoramin. A review of its pharmacodynamic and
pharmacokinetic properties, and therapeutic efficacy in hypertension and
related vascular, cardiovascular and airway diseases. Drugs 1986 Jun; 31
•
•
•
•
•
(6): 467–499
Holtzman JL, Kaihlanen PM, Rider JA, Lewin AJ, Spindler JS, Oberlin
JA. Concomitant administration of terazosin and atenolol for the treatment
of essential hypertension. Arch Intern Med 1988 Mar; 148 (3): 539–543
Horky K. Alpha 1-blockade in the management of hypertension. J Clin
Pharmacol 1993 Sep; 33 (9): 874–478
Inoue Y, Kaku K, Kaneko T, Matsumura S, Nakayama H, Yoshizaki Y,
Ando S, Inoue M, Hatao M. Antihypertensive and metabolic effects of
doxazosin in hypertensive patients with concomitant non-insulindependent diabetes mellitus. J Int Med Res 1996 Jan-Feb; 24 (1): 138–146
Itskovitz HD, Krug K, Khoury S, Mollura JL. The long-term
antihypertensive effects of prazosin and atenolol. Am J Med 1989 Jan 23;
86 (1B): 82–86
Jaillon P, Rubin P, Yee YG, Ball R, Kates R, Harrison D, Blaschke T.
Influence of congestive heart failure on prazosin kinetics. Clin Pharmacol
•
•
•
•
•
•
Ther 1979 Jun; 25 (6): 790–794
Jansson JH, Johansson B, Boman K, Nilsson TK. Effects of doxazosin and
atenolol on the fibrinolytic system in patients with hypertension and
elevated serum cholesterol. Eur J Clin Pharmacol 1991; 40 (4): 321–326
Jounela AJ, Kanniainen E, Lilja M. Interaction between clonidine and
alpha blockers. Clin Cardiol 1985 Dec; 8 (12): 641–642
Jungers P, Ganeval D, Pertuiset N, Chauveau P. Influence of renal
insufficiency on the pharmacokinetics and pharmacodynamics of
terazosin. Am J Med 1986 May 23; 80 (5B): 94–99
Kaplan NM. Importance of coronary heart disease risk factors in the
management of hypertension. An overview. Am J Med 1989 Jan 23; 86
(1B): 1–4
Kaplan NM. Effects of antihypertensive therapy on insulin resistance.
Hypertension 1992 Jan; 19 (1 Suppl): I116–118
Kaplan SA, D'Alisera PM. Tolerability of alpha-blockade with doxazosin
•
•
•
•
as a therapeutic option for symptomatic benign prostatic hyperplasia in the
elderly patient: a pooled analysis of seven double-blind, placebocontrolled studies. J Gerontol A Biol Sci Med Sci 1998 May; 53 (3):
M201–M206
Karter Y, Aran S, Seyahi N, Tunckale A, Yaldiran A, Sipahioglu F,
Ozturk E. The antihypertensive effects of doxazosin on the arterial system:
changes in peripheral vascular resistance and wall tension. Eur. J. Intern.
Med. 2000 Jun; 11 (3): 140–144
Kellaway GS. Adverse drug reactions during treatment of hypertension.
Drugs 1976; 11 SUPPL 1: 91–99
Kersting F, Kupp M, Giesen G. Preliminary evidence for the mechanism
underlying the development of tolerance to prazosin in congestive heart
failure: the alpha-agonistic properties of dobutamine unmasked by
prazosin treatment. J Cardiovasc Pharmacol 1993 Apr; 21 (4): 537–543
Kiruluta GH, Mercer AR, Winsor GM. Prazosin as cause of urinary
•
•
•
•
•
incontinence. Urology 1981 Dec; 18 (6): 618–619
Kobrin I, Amodeo C, Ventura HO, Messerli FH, Frohlich ED. Immediate
hemodynamic effects of urapidil in patients with essential hypertension.
Am J Cardiol 1985 Mar 1; 55 (6): 722–725
Kondo K, Ohashi K, Ebihara A. The pharmacokinetics and
pharmacological effects of terazosin, a new α-blocking agent, in
normotensive volunteers. Japanese Journal of Clinical Pharmacology and
Therapeutics 1983; 14: 147
Kyncl JJ. Pharmacology of terazosin. Am J Med 1986 May 23; 80 (5B):
12–19
Lameire N, Gordts J. A pharmacokinetic study of prazosin in patients with
varying degrees of chronic renal failure. Eur J Clin Pharmacol 1986; 31
(3): 333–337
Langdon CG. Doxazosin: a study in a cohort of patients with hypertension
in general practice–an interim report. Am Heart J 1991 Jan; 121 (1 Pt 2):
•
•
•
•
268–273
Langdon CG, Packard RS. Doxazosin in hypertension: results of a general
practice study in 4809 patients. Br J Clin Pract 1994 Nov-Dec; 48 (6):
293–298
Langtry HD, Mammen GJ, Sorkin EM. Urapidil. A review of its
pharmacodynamic and pharmacokinetic properties, and therapeutic
potential in the treatment of hypertension. Drugs 1989 Dec; 38 (6): 900–
940
Lechner W, Daxenbichler G, Marth C. Inhibition of uterine contractions
by alpha adrenergic receptor blockaders. Z Geburtshilfe Perinatol 1987
May-Jun; 191 (3): 102–104
Lehtonen A, Himanen P, Saraste M, Niittymaki K, Marniemi J. Doubleblind comparison of the effects of long-term treatment with doxazosin or
atenolol on serum lipoproteins. Br J Clin Pharmacol 1986; 21 Suppl 1:
77S–81S
•
•
•
•
•
Lemke R, Trompler A, Kaltenbach M, Bussmann WD. Effect of prazosin
in therapy-resistant chronic cardiac failure. Dtsch Med Wochenschr 1979
Dec 14; 104 (50): 1769–1773
Lenz ML, Pool JL, Laddu AR, Varghese A, Johnston W, Taylor AA.
Combined terazosin and verapamil therapy in essential hypertension.
Hemodynamic and pharmacokinetic interactions. Am J Hypertens 1995
Feb; 8 (2): 133–145
Lepor H. Role of alpha-adrenergic blockers in the treatment of benign
prostatic hyperplasia. Prostate Suppl 1990; 3: 75–84
Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, Ice
K, Dias N. Doxazosin for benign prostatic hyperplasia: long-term efficacy
and safety in hypertensive and normotensive patients. The Multicenter
Study Group. J Urol 1997 Feb; 157 (2): 525–530
Leren P, Foss PO, Helgeland A, Hjermann I, Holme I, Lund-Larsen PG.
Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lancet
•
•
•
•
•
1980 Jul 5; 2 (8184): 4–6
Leren P. (1987 a) Effects of antihypertensive drugs on lipid metabolism.
Clin Ther 1987; 9 (3): 326–332
Leren P. (1987 b) Comparison of effects on lipid metabolism of
antihypertensive drugs with alpha-and beta-adrenergic antagonist
properties. Am J Med 1987 Jan 5; 82 (1A): 31–35
Levenson J, Simon AC, Bouthier JD, Benetos A, Safar ME. Post-synaptic
alpha-blockade and brachial artery compliance in essential hypertension. J
Hypertens 1984 Feb; 2 (1): 37–41
Levy D, Walmsley P, Levenstein M. Principal results of the Hypertension
and Lipid Trial (HALT): a multicenter study of doxazosin in patients with
hypertension. Am Heart J 1996 May; 131 (5): 966–973
Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH Jr,
Neaton JD, Stamler J. Comparison of five antihypertensive monotherapies
and placebo for change in left ventricular mass in patients receiving
•
•
•
•
•
nutritional-hygienic therapy in the Treatment of Mild Hypertension Study
(TOMHS) Circulation 1995 Feb 1; 91 (3): 698–706
Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid
metabolism. Diabetes Care 1991 Mar; 14 (3): 203–209
Lowe FC. Safety assessment of terazosin in the treatment of patients with
symptomatic benign prostatic hyperplasia: a combined analysis. Urology
1994 Jul; 44 (1): 46–51
Lowe SA, Rubin PC. The pharmacological management of hypertension
in pregnancy. J Hypertens 1992 Mar; 10 (3): 201–207
Lubbe WF, Hodge JV. Combined alpha- and beta-adrenoceptor
antagonism with prazosin and oxprenolol in control of severe hypertension
in pregnancy. N Z Med J 1981 Sep 9; 94 (691): 169–172
Lubbe WF, Hodge JV, Kellaway GS. Antihypertensive treatment and fetal
welfare in essential hypertension in pregnancy: a retrospective survey of
experience with various regimes at National Women's Hospital, Auckland,
•
•
•
•
•
1970–80. N Z Med J 1982 Jan 13; 95 (699): 1–5
Lubbe WF. Hypertension in pregnancy. Pathophysiology and
management. Drugs 1984 Aug; 28 (2): 170–188
Lui HK, Awan NA, Needham K, Mason DT. Comparative evaluation of
the new oral systemic vasodilator terazosin and nitroprusside in severe
chronic heart failure. Clinical Research 1985; 33: 207A
Lund-Johansen P. Hemodynamic changes at rest and during exercise in
long-term prazosin therapy for essential hypertension. Postgrad Med 1975
Nov; Spec No: 45–52
Lund-Johansen P, Omvik P. Acute and chronic hemodynamic effects of
drugs with different actions on adrenergic receptors: a comparison
between alpha blockers and different types of beta blockers with and
without vasodilating effect. Cardiovasc Drugs Ther 1991 Jun; 5 (3): 605–
615
Lytle TB, Coles SJ, Waite MA. (1991 a) A multicentre, hospital study of
•
•
•
•
the efficacy and safety of terazosin and its effects on the plasma
cholesterol levels of patients with essential hypertension. J Clin Pharm
Ther 1991 Aug; 16 (4): 263–273
Lytle T, Coles S, Waite MA. (1991 b) A multicentre, hospital study of the
efficacy and safety of terazosin and its effects on the plasma cholesterol
levels of patients with untreated essential hypertension. J Hum Hypertens
1991 Feb; 5 (1): 35–38
Magarian EO, Dietz AJ, Freeman DS, Carlson JD. Effect of prazosin and
beta-blocker monotherapy on serum lipids: a cross-over, placebocontrolled study. J Clin Pharmacol 1987 Oct; 27 (10): 756–761
Maher PH. Clinical evaluation of prazosin in 20 private practice patients.
Postgrad Med 1975 Nov; Spec No: 107–114
Manos J. A long-term study of doxazosin in the treatment of mild or
moderate essential hypertension in general medical practice. Am Heart J
1991 Jan; 121 (1 Pt 2): 346–351
•
•
•
•
•
Markham RV Jr, Corbett JR, Gilmore A, Pettinger WA, Firth BG.
Efficacy of prazosin in the management of chronic congestive heart
failure: a 6-month randomized, double-blind, placebo-controlled study.
Am J Cardiol 1983 May 1; 51 (8): 1346–1352
Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyo JM.
Treatment of hypertension after renal transplantation: long-term efficacy
of verapamil, enalapril, and doxazosin. Kidney Int Suppl 1998 Dec; 68:
S130–134
Maruenda J, Bhatnagar V, Lowenthal DT. Hypertension in the elderly
with coexisting benign prostatic hyperplasia. Urology 1999 Mar; 53 (3
Suppl 3a): 7–12; discussion 12–13, 41–42
McKenney JM, Goodman RP, Wright JT Jr. Use of antihypertensive
agents in patients with glucose intolerance. Clin Pharm 1985 Nov-Dec; 4
(6): 649–656
McLaughlin B, Daly L, Devlin JG. Doxazosin in the management of
•
•
•
•
hypertensive diabetes–a cautionary note (?) Ir J Med Sci 1992 Jan; 161
(1): 9–11
Mersey JH. Long-term experience with terazosin for treatment of mild to
moderate hypertension. Am J Med 1986 May 23; 80 (5B): 68–72
Miller K. Pharmacological management of hypertension in paediatric
patients. A comprehensive review of the efficacy, safety and dosage
guidelines of the available agents. Drugs 1994 Dec; 48 (6): 868–887
Misson R, Merkel T, Cutler RE. Comparison of blood pressure, plasma
lipid and cardiac performance responses to prazosin versus propranolol in
thiazide-treated hypertensive patients. Am J Cardiol 1984 Jan 27; 53 (3):
51A–54A
Miura Y, Watanabe M, Yoshinaga K. An evaluation of the efficacy and
safety of doxazosin in hypertension associated with renal dysfunction. The
Japanese Doxazosin Study Group. Am Heart J 1991 Jan; 121 (1 Pt 2):
381–388
•
•
•
•
•
Mroczek WJ, Finnerty FA Jr. Prazosin – a double-blind evaluation. In:
Cotton (Ed) Prazosin - Evaluation of a new antihypertensive agent.
Excerpta medica, Amsterdam 1974
Mroczek WJ, Fotiu S, Davidov ME, Finnerty FA Jr. Prazosin in
hypertension: a double-blind evaluation with methyldopa and placebo.
Curr Ther Res Clin Exp 1974 Aug; 16 (8): 769–777
Naber FB. An open, noncomparative study of doxazosin in essential
hypertension: experience in general practice in The Netherlands. Am Heart
J 1991 Jan; 121 (1 Pt 2): 273–279
Nalbantgil S, Nalbantgil I, Onder R. Clinically additive effect between
doxazosin and amlodipine in the treatment of essential hypertension. Am J
Hypertens 2000 Aug; 13 (8): 921–926
Narayan P, Tewari A. A second phase III multicenter placebo controlled
study of 2 dosages of modified release tamsulosin in patients with
symptoms of benign prostatic hyperplasia. United States 93–01 Study
•
•
•
•
Group. J Urol 1998 Nov; 160 (5): 1701–1706
Nash DT, Schonfeld G, Reeves RL, Black H, Weidler DJ. A double-blind
parallel trial to assess the efficacy of doxazosin, atenolol and placebo in
patients with mild to moderate systemic hypertension. Am J Cardiol 1987
May 29; 59 (14): 87G–90G
Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ,
Cutler JA, Flack JM, Schoenberger JA, McDonald R et al. Treatment of
Mild Hypertension Study. Final results. Treatment of Mild Hypertension
Study Research Group. JAMA 1993 Aug 11; 270 (6): 713–724
Nechwatal W, Berger J, Blumrich W, Bouzo H, Brandl K, Braun S,
Laukaitis A, Muller G, Ryba W, Schreiegg J. A double-blind comparative
study of doxazosin and nitrendipine in patients with mild-to-moderate
essential hypertension. Am Heart J 1988 Dec; 116 (6 Pt 2): 1806–1814
Oates HF. A new prazosin analogue, Abbott–45975 (A–45975) N Z Med J
1981 Jul 22; 94 (688): 67
•
•
•
•
•
O'Connor DT, Preston RA, Sasso EH. Renal perfusion changes during
treatment of essential hypertension: prazosin versus propranolol. J
Cardiovasc Pharmacol 1979 Nov-Dec; 1 (6 Suppl): S38–S42
Okun R, Kraut J. A comparison of prazosin versus nadolol in combination
with a diuretic. Am J Cardiol 1984 Jan 27; 53 (3): 37A–39A
Oliver RM, Upward JW, Dewhurst AG, Honeywell R, Renwick AG,
Waller DG. The pharmacokinetics of doxazosin in patients with
hypertension and renal impairment. Br J Clin Pharmacol 1990 Apr; 29 (4):
417–422
Os I, Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic
system formulation versus doxazosin standard and placebo in mild-tomoderate hypertension. Doxazosin Investigators' Study Group. J
Cardiovasc Pharmacol 1999 May; 33 (5): 791–797
Ott P, Storm TL, Krusell LR, Jensen H, Badskjaer J, Faergeman O.
Multicenter, double-blind comparison of doxazosin and atenolol in
•
•
•
•
patients with mild to moderate hypertension. Am J Cardiol 1987 May 29;
59 (14): 73G–77G
Overlack A, Stumpe KO. Comparison of the effect of indoramin and
prazosin on blood pressure and lipid profiles in essential hypertension. J
Cardiovasc Pharmacol 1986; 8 Suppl 2: S53–S55
Oviasu OV, Idahosa PE. Variability in effect of low doses of prozosin in
hypertensive Nigerians. Curr Ther Res Clin Exp 1976 Dec; 20 (6): 757–
762
Packer M, Medina N, Yushak M. Role of the renin-angiotensin system in
the development of hemodynamic and clinical tolerance to long-term
prazosin therapy in patients with severe chronic heart failure. J Am Coll
Cardiol 1986 Mar; 7 (3): 671–680
Pasanisi F, Imperatore G, Vaccaro O, Iovine C, Ferrara LA. Effects of a 3month treatment with terazosin on fasting and postprandial glucose and
lipid metabolism in type 2 diabetic patients with hypertension. Nutr Metab
•
•
•
•
•
Cardiovasc Dis 1999 Apr; 9 (2): 73–77
Penenberg D, Chung M, Walmsley P, Vashi V. The effects of hepatic
impairment on the pharmacokinetics of doxazosin. J Clin Pharmacol 2000
Jan; 40 (1): 67–73
Piepho RW, Fendler KJ. Antihypertensive therapy in the aged patient.
Clinical pharmacokinetic considerations. Drugs Aging 1991 May; 1 (3):
194–211
Piza Lopez A, Gutierrez Fuster E. Study on the efficacy and tolerance of a
new antihypertensive drug Prazosin hydrochloride. Comparison with αmethyldopa. Investigacion Medica International 1975, 3: 163
Pool JL, Nelson EB, Taylor AA, Mitchel JR: Alpha-1 adrenergic blockade
changes plasma lipids in man. Clinical Res 1982; 30: 213A
Pool JL. Plasma lipid lowering effects of doxazosin, a new selective
alpha1 adrenergic inhibitor for systemic hypertension. Am J Cardiol 1987
May 29; 59 (14): 46G–50G
•
•
•
•
•
Pool JL. Combination antihypertensive therapy with terazosin and other
antihypertensive agents: results of clinical trials. Am Heart J 1991 Sep;
122 (3 Pt 2): 926–931
Rab SM, Farooqui S. Prazosin in the treatment of hypertension – a
preliminary report. Br J Clin Pract 1975 Dec; 29 (12): 337–338
Rabkin SW. Mechanisms of action of adrenergic receptor blockers on
lipids during antihypertensive drug treatment. J Clin Pharmacol 1993 Mar;
33 (3): 286–291
Ram CV, Meese R, Kaplan NM, Devous MD Sr, Bonte FJ, Forland SC,
Cutler RE. Antihypertensive therapy in the elderly. Effects on blood
pressure and cerebral blood flow. Am J Med 1987 Jan 5; 82 (1A): 53–57
Ramsay LE, Yeo WW, Jackson PR. Influence of diuretics, calcium
antagonists, and alpha-blockers on insulin sensitivity and glucose
tolerance in hypertensive patients. J Cardiovasc Pharmacol 1992; 20
Suppl 11: S49–S53; discussion S53–S54
•
•
•
•
•
•
Reid JL, Vincent J. Clinical pharmacology and therapeutic role of prazosin
and related alpha-adrenoceptor antagonists. Cardiology 1986; 73 (3): 164–
174
Reid JL, Elliott HL, Vincent J, Meredith PA. Clinical pharmacology of
selective alpha blockers. Hemodynamics and effects on lipid levels. Am J
Med 1987 Jan 5; 82 (1A): 15–20
Rieckert H. Orthostatic hypotension: how to avoid it during
antihypertensive therapy. Am J Hypertens 1996 Nov; 9 (11): 155S–159S
Rosenthal J. A multicenter trial of doxazosin in West Germany. Am J
Cardiol 1987 May 29; 59 (14): 40G–45G
Rosenthal J. Lipid metabolism: implications of alpha 1-blockade. J Clin
Pharmacol 1993 Sep; 33 (9): 883–887. Review
Rouffy J, Jaillard J. Effects of two antihypertensive agents on lipids,
lipoproteins, and apoproteins A and B. Comparison of prazosin and
atenolol. Am J Med 1986 Feb 14; 80 (2A): 100–103
•
•
•
•
•
•
Rougier M, Lahon HF, Cini AR. Prazoxin – a new antihypertensive agent.
Br J Clin Pract 1974 Aug; 28 (8): 280–284
Rubin PC, Scott PJ, Reid JL. Prazosin disposition in young and elderly
subjects. Br J Clin Pharmacol 1981 Sep; 12 (3): 401–404
Rubin PC, Butters L, Low RA, Reid JL. Clinical pharmacological studies
with prazosin during pregnancy complicated by hypertension. Br J Clin
Pharmacol 1983 Nov; 16 (5): 543–547
Rudd P. Cumulative experience with terazosin administered in
combination with diuretics. Am J Med 1986 May 23; 80 (5B): 49–54
Ruoff G. Comparative trials of terazosin with other antihypertensive
agents. Am J Med 1986 May 23; 80 (5B): 42–48
Sanz Guajardo D, Espejo Martinez J. Randomized, comparative study to
evaluate efficacy and safety of doxazosin versus nitrendipine in the
treatment of mild to moderate hypertension. An Med Interna 1997 Jan; 14
(1): 15–19
•
•
•
•
•
•
Saunders E. The safety and efficacy of terazosin in the treatment of
essential hypertension in blacks. Am Heart J 1991 Sep; 122 (3 Pt 2): 936–
942
Schnaper HW, Oberman A. Double-blind studies of the clinical
effectiveness of prazosin. Postgrad Med 1975 Nov; Spec No: 81–87
Schwenger V, Zeier M, Ritz E. Antihypertensive therapy in renal patients
– benefits and difficulties. Nephron 1999; 83 (3): 202–213
Scott PJ, Hosie J, Scott MG. A double-blind and cross-over comparison of
once daily doxazosin and placebo with steady-state pharmacokinetics in
elderly hypertensive patients. Eur J Clin Pharmacol 1988; 34 (2): 119–123
Seedat YK, Seedat MA, Bhoola R. Prazosin alone and combined with a
thiazide diuretic in the treatment of hypertension. S Afr Med J 1977 Apr 2;
51 (14): 461–463
Sennello LT, Sonders RC, Glassman HN, Jordan DC, Luther RR, Tolman
KG. Effect of age on the pharmacokinetics of orally and intravenously
•
•
•
•
•
administered terazosin. Clin Ther 1988; 10 (5): 600–607
Sheu WH, Swislocki AL, Hoffman BB, Reaven GM, Chen YD. Effect of
prazosin treatment on HDL kinetics in patients with hypertension. Am J
Hypertens 1990 Oct; 3 (10): 761–768
Shionoiri H, Gotoh E, Ito T, Hata T, Iwatsubo H, Takegawa K, Ogihara T,
Mikami H, Ikegami H, Otsuka A et al. Long-term therapy with terazosin
may improve glucose and lipid metabolism in hypertensives: a multicenter
prospective study. Am J Med Sci 1994 Feb; 307 Suppl 1: S91–95
Simpson FO. Combination therapy in hypertension. Drugs 1980 Jul; 20
(1): 69–73
Singleton W, Saxton CA, Hernandez J, Prichard BN. Postjunctional
selectivity of alpha-blockade with prazosin, trimazosin, and UK–33,274 in
man. J Cardiovasc Pharmacol 1982; 4 Suppl 1: S145–S151
Smith IS, Fernandes M, Kim KE, Swartz C, Onesti G. A three-phase
clinical evaluation of prazosin. Postgrad Med 1975 Nov; Spec No: 53–60
•
•
•
•
•
•
Smyth P, Pringle S, Jackson G, Lorimer AR. 24-hour control of blood
pressure by once daily doxazosin: a multicentre double-blind comparison
with placebo. Eur J Clin Pharmacol 1988; 34 (6): 613–618
Soltero I, Guevara J, Silva H, Velasco M. A multicenter study of
doxazosin in the treatment of severe essential hypertension. Am Heart J
1988 Dec; 116 (6 Pt 2): 1767–1771
Sonders RC. Pharmacokinetics of terazosin. Am J Med 1986 May 23; 80
(5B): 20–24
Sowers JR. Hypertension in the elderly. Am J Med 1987 Jan 26; 82 (1B):
1–8
Sowers JR. Is hypertension an insulin-resistant state? Metabolic changes
associated with hypertension and antihypertensive therapy. Am Heart J
1991 Sep; 122 (3 Pt 2): 932–5. Review
Sperzel WD, Luther RR, Glassman HN (1986a) Clinical trials with
terazosin. General methods. Am J Med 1986 May 23; 80 (5B): 25–28
•
•
•
•
•
•
Sperzel WD, Glassman HN, Jordan DC, Luther RR (1986b) Overall safety
of terazosin as an antihypertensive agent. Am J Med 1986 May 23; 80
(5B): 77–81
Stokes GS, Monaghan JC, Frost GW, MacCarthy EP. Responsiveness to
prazosin in renal failure. Clin Sci (Colch) 1979 Dec; 57 Suppl 5: 383s–
385s
Stokes GS. Age-related effects of antihypertensive therapy with alphablockers. J Cardiovasc Pharmacol 1988; 12 Suppl 8: S109–S115
Stokes GS, Weber MA. Prazosin: preliminary report and comparative
studies with other antihypertensive agents. Br Med J 1974 May 11; 2
(914): 298–300
Studer JA, Piepho RW. Antihypertensive therapy in the geriatric patient:
II. A review of the alpha1-adrenergic blocking agents. J Clin Pharmacol
1993 Jan; 33 (1): 2–13
Sznajderman M. Minipress in the treatment of arterial hypertension in
•
•
•
•
light of results from a multicenter study. II. Results of long-term
monotherapy. Kardiol Pol 1989; 32 (7–9): 394–403
Talseth T, Westlie L, Daae LN. Long-term effects of doxazosin and
atenolol on serum lipids and blood pressure in hypertensive smokers. J
Hypertens Suppl 1990 Sep; 8 (5): S47–S51
Talseth T, Westlie L, Daae L. Doxazosin and atenolol as monotherapy in
mild and moderate hypertension: a randomized, parallel study with a
three-year follow-up. Am Heart J 1991 Jan; 121 (1 Pt 2): 280–285
Tamasawa N, Matsui J, Ogawa Y, Gotoh T, Hinata T, Murakami H, Zhi
GJ, Suda T. Effect of doxazosin on the size of LDL particle in the type 2
diabetic patients with hypertension. J Diabetes Complications 2000 MayJun; 14 (3): 135–139
Taylor SH, Lee PS, Sharma SK. A comparison of doxazosin and enalapril
in the treatment of mild and moderate essential hypertension. Am Heart J
1988 Dec; 116 (6 Pt 2): 1820–1825
•
•
•
•
•
Taylor SH. Efficacy and safety of doxazosin in the treatment of patients
with mild or moderate essential hypertension and elevated levels of
cholesterol. Am Heart J 1991 Jan; 121 (1 Pt 2): 362–366
Titmarsh S, Monk JP. Terazosin. A review of its pharmacodynamic and
pharmacokinetic properties, and therapeutic efficacy in essential
hypertension. Drugs 1987 May; 33 (5): 461–477
Tomoda F, Takata M, Yoshida K, Yasumoto K, Mikawa M, Sasayama S.
Hemodynamic and endocrinological effects of a new selective alpha 1blocking agent, terazosin, in patients with essential hypertension. Results
of long-term treatment. Am J Hypertens 1989 Nov; 2 (11 Pt 1): 834–839
Torvik D, Madsbu HP. Multicentre 12-week double-blind comparison of
doxazosin, prazosin and placebo in patients with mild to moderate
essential hypertension. Br J Clin Pharmacol 1986; 21 Suppl 1: 69S–75S
Torvik D, Madsbu HP. An open one-year comparison of doxazosin and
prazosin for mild to moderate essential hypertension. Am J Cardiol 1987
•
•
•
•
May 29; 59 (14): 68G–72G
Toth K, Nemes J, Czopf L, Kapronczay P, Kesmarky G, Juricskay I
(1999a) Effects of doxazosin on hemorheological, hemodynamic and lipid
parameters in patients with essential hypertension. Clin Hemorheol
Microcirc 1999; 20 (1): 57–61
Toth K, Kesmarky G, Vekasi J, Nemes J, Czopf L, Kapronczay P,
Halmosi R, Papp E, Juricskay I (1999b) Hemorheological and
hemodynamic parameters in patients with essential hypertension and their
modification by alpha–1 inhibitor drug treatment. Clin Hemorheol
Microcirc 1999; 21 (3–4): 209–216
Trost BN, Weidmann P, Riesen W, Claessens J, Streulens Y, Nelemans F.
Comparative effects of doxazosin and hydrochlorothiazide on serum lipids
and blood pressure in essential hypertension. Am J Cardiol 1987 May 29;
59 (14): 99G–104G
Tsujii T. Comparison of prazosin, terazosin and tamsulosin in the
•
•
•
•
treatment of symptomatic benign prostatic hyperplasia: a short-term open,
randomized multicenter study. BPH Medical Therapy Study Group.
Benign prostatic hyperplasia. Int J Urol 2000 Jun; 7 (6): 199–205
Valle R, Semplicini A, Serena L, Gebbin A, Fontebasso A, Gerardi G, De
Toni R, Pessina AC. Pressure and metabolic effects of terazosin in
essential hypertension. Cardiologia 1994 Jun; 39 (6): 421–424
van Brummelen P, Jie K, van Zwieten PA. Alpha-adrenergic receptors in
human blood vessels. Br J Clin Pharmacol 1986; 21 Suppl 1: 33S–39S
Vashi V, Chung M, Hilbert J, Lawrence V, Phillips K. Pharmacokinetic
interaction between finasteride and terazosin, but not finasteride and
doxazosin. J Clin Pharmacol 1998 Nov; 38 (11): 1072–1076
Velasco M, Silva H, Morillo J, Pellicer R, Urbina-Quintana A, HernandezPieretti O. Effect of prazosin on blood lipids and on thyroid function in
hypertensive patients. J Cardiovasc Pharmacol 1982; 4 Suppl 2: S225–
S227
•
•
•
•
•
Velasco M, Silva H, Feldstein E, Pellicer R, Morillo J, Urbina-Quintana
A, Hernandez-Pieretti O. Effects of prazosin and alphamethyldopa on
blood lipids and lipoproteins in hypertensive patients. Eur J Clin
Pharmacol 1985; 28 (5): 513–516
Velasco M, Hurt E, Silva H, Urbina-Quintana A, Hernandez-Pieretti O,
Feldstein E, Camejo G. Effects of prazosin and propranolol on blood lipids
and lipoproteins in hypertensive patients. Am J Med 1986 Feb 14; 80
(2A): 109–113
Venables TL, Duff RS. A comparative trial of prazosin and methyldopa.
In: Cotton (Ed) Prazosin - Evaluation of a new antihypertensive agent.
Excerpta medica, Amsterdam 1974
Verhiest W, Croonenberghs J, Devos P, Fagard R, Amery A. Double blind
cross-over study comparing prazosin and methyldopa in the treatment of
mild hypertension. Acta Cardiol 1974; 29 (3): 217–233
Vincent J, Elliott HL, Meredith PA, Reid JL. Doxazosin, an alpha 1-
•
•
•
•
adrenoceptor antagonist: pharmacokinetics and concentration-effect
relationships in man. Br J Clin Pharmacol 1983 Jun; 15 (6): 719–725
Vincent J, Meredith PA, Reid JL, Elliott HL, Rubin PC. Clinical
pharmacokinetics of prazosin–1985. Clin Pharmacokinet 1985 Mar-Apr;
10 (2): 144–154
Vincent J, Meredith PA, Elliott HL, Reid JL. The pharmacokinetics of
doxazosin in elderly normotensives. Br J Clin Pharmacol 1986 May; 21
(5): 521–524
Vyrens R, Adriaensen H. Double-blind cross-over comparative study with
low doses of prazosin and methyldopa. In: Cotton (Ed) Prazosin Evaluation of a new antihypertensive agent. Excerpta medica, Amsterdam
1974
Weidinger G. Pharmacokinetic and pharmacodynamic properties and
therapeutic use of bunazosin in hypertension. A review.
Arzneimittelforschung 1995 Nov; 45 (11): 1166–1171
•
•
•
•
•
•
Weidmann P, Boehlen LM, de Courten M, Ferrari P. Antihypertensive
therapy in diabetic patients. J Hum Hypertens 1992 Dec; 6 Suppl 2: S23–
S36
Weinberger MH, Fawzy A. Doxazosin in elderly patients with
hypertension. Int J Clin Pract 2000 Apr; 54 (3): 181–189
Wessels F. Double-blind comparison of doxazosin and enalapril in patients
with mild or moderate essential hypertension. Am Heart J 1991 Jan; 121
(1 Pt 2): 299–303
Wilson AL, Matzke GR. The treatment of hypertension in pregnancy.
Drug Intell Clin Pharm 1981 Jan; 15 (1): 21–26
Yasumoto K, Takata M, Yoshida K, Mikawa M, Tomoda F, Sasayama S.
Reversal of left ventricular hypertrophy by terazosin in hypertensive
patients. J Hum Hypertens 1990 Feb; 4 (1): 13–18
Zhu J, Wang D, Lu Z, Liu Z, Yang D. Hemodynamic effects of terazosin
in congestive heart failure. Chin Med Sci J 1993 Jun; 8 (2): 98–100
•
Zusman RM. The role of alpha 1-blockers in combination therapy for
hypertension. Int J Clin Pract 2000 Jan-Feb; 54 (1): 36–40
Literatur zu Kap. 33.6
1.
Borst E (2000) Behandlung der Herzinsuffizienz in der Praxis. In: Böhm
M, Borst UE, Schmieder RE, Wehling M (Hrsg) Therapiehandbuch
Carvedilol. Thieme, Stuttgart New York, 103–118
2.
Cleophas TJM, van der Mey N, van der Meulen J, Niemeyer MG (1996)
Quality of life during antihypertensive treatment: a comparative study of
celiprolol and atenolol. Int J Clin Pharm Ther 34, 312–317
3.
Dunn C, Spencer CM (1995) Celiprolol. An evaluation of its
pharmacological properties and clinical effects in the management of
hypertension and angina pectoris. Drugs and Aging 7, 394–411
4.
Hansson L, Himmelmann A (1998) Carvedilol in the treatment of
hypertension – a review of the clinical data base. Scand Cardiovasic J,
Suppl 47, 67–80
5.
6.
7.
8.
9.
Himmelmann A, Hedner T, Snoeck E, Lundgren R, Hedner J (1996)
Hemodynamic effects and pharmacokinetics of oral d – and l – nebivolol
in hypertensive patients. Eur J Clin Pharmacol 51, 259–263
Mc Neely W, Goa KL (1999) Nebivolol in the management of essential
hypertension. A review. Drugs 57, 633–651
Mc Tavish D, Campoli-Richards D, Sorkin EM (1993) Carvedilol – A
review of its pharmacodynamic and pharmakokinetic properties and
therapeutic efficacy. Drugs 45, 232–258
Milne RJ, Buckley MMT (1991) Celiprolol. An updated review of its
pharmakodynamic and pharmacokinetic properties and therapeutic
efficacy in cardiovascular disease. Drugs 41, 941–969
Oestergren J, Storstein L, Karlberg BE, Tiblin G (1996) Quality of life in
hypertensive patients treated either with carvedilol or enalapril. Blood
Pressure 5, 41–49
10.
11.
12.
13.
14.
Packer M, Antonopoulos GV, Berlin JA, Chittams J, Kostam MA,
Udelson JE (2001) Comparative effects of carvedilol and metoprolol on
left-ventricular ejection fraction in heart failure. Results of a metaanalysis.
Am Heart J 141, 899–907
Pauwels PJ, Gommeren W, van Lammen G, Janssen PAJ and Leysen JE
(1988) The receptor binding profile of the new antihypertensive agent
nebivolol and its stereoisomers compared with various β–adrenergic
blockers. Mol Pharmacol 34, 843–851
Ruffolo RR, Feuerstein G (1997) Pharmacology of carvedilol: Rationale
for use in hypertension, coronary artery disease and congestive heart
failure. Cardiovasc Drug Ther 11, 247–256
Sponer G,Feuerstein G (1999) The adrenergic pharmacology of carvedilol.
Heart Failure Rev. 4, 21–27
Sponer G, Bartsch W, Hooper RG (1990) Drugs acting as multiple
receptors: β–blockers with additional properties. In: Ganten D, Mulrow PJ
15.
16.
17.
(eds) Pharmacology of antihypertensive therapeutics. Handbook of
Pharmacology, vol 93. Springer, Berlin Heidelberg New York, pp 132–
226
Sponer G, Bartsch W, Strein K, Müller-Beckmann B, Böhm E (1987)
Pharmacological profile of carvedilol as a β-blocking agent with
vasodilating and hypotensive properties. J Cardiovasc Pharmacol 9, 317–
327
Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J,
Verhaegen H, Reneman RS, Janssen PAJ (1988) Pharmacological and
hemodynamic profile of nebivolol, a chemical novel, potent and selective
beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 11, 552–563
Weber K, Böhmeke T, v d Does R, Taylor SM (1996) Comparison of the
hemodynamic effects of metoprolol and carvedilol in hypertensive
patients. Cardiovasc Drug Ther 10, 113–117
18.
19.
Yue TI, Ruffolo RR, Feuerstein G (1999) Antioxidant action of carvedilol:
A potential role in treatment of heart failure. Heart Failure Rev 4, 39–51
Poole-Wilson PA, Swedberg K, Cleland JGF et al. for the COMET (2003)
Comparison of carvedilol and metoprolol on clinical outcomes in patients
with chronic heart failure in the Cavedilol Or Metoprolol European Trial
(COMET): randomised controlled trial. Lancet 362, 7–13
Literatur zu Kap. 33.7
1.
ALLHAT Collaborative Research Group (2000) Major cardiovascular
events in hypertensive patients randomized to doxazosin vs chlorthalidone:
the antihypertensive and lipid-lowering treatment to prevent heart attack
trial (ALLHAT). JAMA 283: 1967–1975
2.
Anavekar SN, Jarrott B, Toscano M, Louis WJ (1982) Pharmacokinetic
and pharmacodynamic studies of oral clonidine in normotensive subjects.
Eur J Clin Pharmacol 23: 1–5
3.
Anderson EA, Sinkey CA, Lawton WJ, Mark AJ (1989) Elevated
sympathetic nerve activity in borderline hypertensive humans.
Hypertension 14: 177–83
4.
Armah BI, Hofferber E, Stenzel W (1988): General pharmacology of the
novel centrally acting antihypertensive agent moxonidine. Arzneimittel
Forsch 38: 1435–42
5.
6.
7.
8.
9.
10.
Brannon PM, Scott D (1987) Impairment of pancreatic anion function by
reserpine in vivo and in vitro. In Vitro Cell Dev Biol 23: 429–435
Channick BJ, Kessler WB, Marks AD, Adlin EV (1981) A comparison of
chlorothalidone-reserpine and hydrochlorothiazide-methyldopa as step 2
therapy for hypertension. Clin Ther 4: 175–183
Clayden JR, Bell JW, Pollard P (1974) Monopausal slushing: double blind
trial of a non-hormonal medication. BMJ 1: 409–412
Curb JD, Hardy RJ, Labarthe DR, Borhani NO, Taylor JO (1982)
Reserpine and breast cancer in the hypertension detection and follow-up
program. Hypertension 4: 307–311
Day MD, Rand MJ (1973) A hypothesis for the mode of action of αmethyldopa in relieving hypertension. J Pharm Pharmacol 47: 217–228
Deutsche Hochdruckliga (2001) Leitlinien für die Prävention, Erkennung,
Diagnostik und Therapie der arteriellen Hypertonie. Dtsch Med
Wochenschr 126. Jahrgang, Suppl 4
11.
12.
13.
14.
15.
De Jong W, Nijkamp FP, Bohus B (1975) Role of noradrenaline and
serotinin in the central control of blood pressure in normotensive and
spontaneously hypertensive rats. Arch Int Pharmacodyn Ther 213: 272–
284
Eichstädt H, Richter W, Bäder M et al. (1989) Demonstration of
hypertrophy regression with magnetic resonance tomography under the
new adrenergic inhibitor moxonidine. Cardiovasc Drugs Ther 3 (Suppl 2)
583–587
Ernsberger P, Elliott HL, Weimann H-J et al.(1993) Moxonidine: a
second-generation antihypertensive agent. Cardiovasc Drug Res 1: 411–
431
Flacke JW (1992) Alpha 2-adrenergic agonists in cardiovascular
anesthesia. J Cardiothorac Vasc Anesth 6: 344–359
Haenni A, Lithell H (1999) Moxonidine improves insulin sensitivity in
insulin-resistant hypertensives. J Hypertens 17 (Suppl 3): 29–35
16.
17.
18.
19.
Haxhiu MA, Deshaj I, Schäfer SG, Ernsberger P (1994): Selective
antihypertensive action of moxonidine is mediated mainly by I1imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc
Pharmacol 24 (Suppl 1): 1–8
Hess HJ (1974) Biochemistry and structure activity studies with prazosin.
In: Cotton DWK (ed) Prazosin: evaluation of a new antihypertensive
agent. Excerpta Medica, Amsterdam, pp 3–15
Howes LG, Louis WJ (1990) Rauwolfia alkaloids (reserpine). In: Ganten
D, Murlow PJ (eds) Handbook of experimental pharmacology 93.
Pharmacology of antihypertensive therapeutics. Springer, Berlin
Heidelberg New York, pp 263–285
Jarrott B, Summers RJ, Culvenor AJ, Louis WJ (1980) Characterisation of
alpha adrenoceptors in rat and guinea pig tissues using radiolabelled
agonists and antagonists. Circ Res 46: 115–120
20.
21.
22.
23.
24.
Jarrott B (1984) Clonidine and related compounds. In: Doyle AE (ed)
Handbook of hypertension, 4 edn. Elsevier, Amsterdam, pp 113–168
Jirakalsomchock D, Schneyer CA (1987) Effects of saliva from
chronically reserpinized rat on Na and K transport in perfused main
excretory duct of submandibular gland of normal rat. Proc Soc Exp Biol
Med 185: 392–395
Julius S, Gudbrandsson T (1992) Early association of sympathetic
overactivity, hypertension, insulin resistance, and coronary risk. J
Cardiovasc Pharmacol, 20 (Suppl 8): 40–48
Kirch W, Hutt H-J, Plänitz V (1990) Pharmacodynamic action and
pharmacokinetics of moxonidine after single oral administration in
hypertensive patients. J Clin Pharmacol 30: 1088–1095
Küppers H, Jäger B, Hughes PR et al. (1997) Placebo-controlled
comparison of the efficacy and tolerability of once-daily moxonidine and
enalapril in mild to moderate essential hypertension. J Hypertens 15, 93–7
25.
26.
27.
28.
29.
Labarthe DR, O'Fallon WM (1980) Reserpine and breast cancer. A
community based longitudinal study of 2000 hypertensive women. JAMA
243: 2304–2310
Louis WJ, Jarrott B, Conway EL (1988) Sites of actions of alpha 2
agonists in the brain and periphery. Am J Cardiol 61: 15D–17D
Louis WJ, Doyle AE, Jerums G, Kincaid-Smith P (1967) Methyldopa and
haemolytic anaemia. Med J Aust 11: 104–106
Mancia G, Di Rienzo M, Parati G, Grassi G (1997) Sympathetic activity,
blood pressure variability and end organ damage in hypertension. J Hum
Hypertens 11 (Suppl 1): 3–8
Mitrovic V, Patnya W, Hüting J, Schlepper W (1991) Haemodynamic and
neurohormonal effects of moxonidine in patients with essential
hypertension. Cardiovasc Drugs Ther 5: 967–72
30.
31.
32.
33.
34.
Morton D, Parker A, Estrada P, Martinez JR (1980) Exocrine pancreatic
secretion in rats treated with reserpine after stimulation with pilocarpine,
dopamine and caeralein. Pediatr Res 14: 18–20
Motz W, Vogt M, Scheler S, Strauer BE (1995) Hypertensive coronary
microcirculation – effects of the imidazoline-receptor-agonist moxonidine.
Cardiovasc Risk Factors 5 (Suppl 1): 28–32
Mroczek WJ, Davidov ME (1978) A randomized clinical trial of clonidine
and propranolol in hypertensive patients receiving a diuretic and a
vasodilator. Curr Ther Res 23: 294–299
Onesti G, Schwartz AB, Kim KE, Paz-Martinez V, Swartz C (1971)
Antihypertensive effect of clonidine. Circ Res 28 (Suppl 2): II53–II69
Pickering TG (1997) The effects of environmental and lifestyle factors on
blood pressure and the intermediary role of the sympathetic nervous
system. J Hum Hypertens 11 (Suppl 1): 9–18
35.
36.
37.
38.
39.
40.
Palatini P, Julius S (1997) Association of tachycardia with morbidity:
pathophysiological considerations. J Hum Hypertens 11 (Suppl 1): 19–27
Reaven GM (Banting Lecture1988) Role of insulin resistance in human
disease. Diabetes 37: 1595–607
Reaven GM (1994) Syndrome X: 6 years later. J Intern Med 236
(Suppl 736): 13–32
Reaven GM, Lithell H, Landsberg L (1996) Hypertension and associated
metabolic abnormalities – the role of insulin resistance and the
sympathoadrenal system. N Engl J Med 334: 374–381
Ross RK, Paganini-Hill A, Krailo MD, Gerkins VR, Hendersen BE, Pike
MC (1984) Effects of reserpine on prolactin levels and incidence of breast
cancer in postmenopausal women. Cancer Res 44: 3106–3108
Rupp H, Jacob R (1995) Excess catecholamines and the metabolic
syndrome: should central imidazoline receptors be a therapeutic target?
Med Hypotheses 44: 217–225
41.
42.
43.
44.
45.
46.
Russ GR, Whitwort JA, Kincaid-Smith P (1983) Comparison of
intramuscular and intravenous clonidine in severe hypertension. Med J
Aust 2: 229–231
Schaefer HG, Toublanc N, Weimann H-J (1998) The pharmacokinetics of
moxonidine. Rev Contemp Pharmacol 9: 481–490
Scholze J, Sharma A (2001) Behandlung der Hypertonie bei Adipositas.
Herz 26: 209–221
Sen G, Boser KC (1931) Rauwolfia serpentina, a new Indian drug for
insanity and high blood pressure. Indian Med J 2: 194–201
Shafar J, Tallett ER, Knowlson PA (1972) Evaluation of clonidine in
prophylaxis of migraine. Lancet I: 403–407
Shaw JE (1984) Pharmacokinetics of nitroglycerin and clonidine delivered
by the transdermal route. Am Heart J 108: 217–223
47.
48.
49.
50.
51.
Struyker Boudier H, Smeets G, Brouwer G, Van Rossum JM (1975)
Central nervous system α-adrenergic mechanisms and cardiovascular
regulation in rats. Arch Int Pharmacodyn Ther 213: 285–293
Summers RJ, Jarrott B, Louis WJ (1980) Selectivity of a series of
clonidine-like drugs for alpha 1 and 2 adrenoceptors in rat brain. Neurosci
Lett 20: 347–350
Van Zwieten PA (1997): Centrally acting antihypertensives: a renaissance
of interest. Mechanisms and haemodynamics. J Hypertens 15 (Suppl 1): 3–
8
Vakil RJ (1949) Clinical trial of Rauwolfia serpentina in essential
hypertension. Br Heart J, 11, 350–355
Veterans Administration Study Group (1978) Evaluation of treatment in
mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary
results of tow year feasibility trial for a multicenter intervention study to
evaluate the benefits versus the disadvantages of treating mild
52.
53.
54.
55.
hypertension. Prepared for the Veterans Administration – National Heart,
Lung and Blood Institute Study Group for Evaluating Treatment in Mild
Hypertension. Ann NY Acad Sci, 304, 267–292
Waters J, Ashford J, Jäger B, Wonnacott S, Verboom CN, for the TOPIC
Investigators (1999) Use of moxonidine as initial therapy and in
combination in the treatment of essential hypertension – results of the
TOPIC (Trial Of Physiotens In Combination) Study. J Clin Cardiol 2: 219
Webster J, Koch H-F (1996) Aspects of tolerability of centrally acting
antihypertensive drugs. J Cardiovasc Pharmacol 27 (Suppl 3): 49–54
Weimann H-J, Rudolph M (1992) Clinical pharmacokinetics of
moxonidine. J Cardiovasc Pharmacol, 20 (Suppl 4), 37–41
Landsberg L (1986) Diet, obesity and hypertension: a hypothesis involving
insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J
Med 61: 1081–1090
56.
Coats AJ (1999) Heart failure 99: the MOXCON story. Int J Cardiol 71:
109–111
Literatur zu Kap. 33.8
1.
Ablad B (1963) A study of the mechanism of the hemodynamic effects of
hydralazine in man. Acta Pharmacol Toxicol (Copenh) 20: 1
2.
Abshagen U, von Mollendorff E (1986) Haemodynamic abnormalities in
hypertensive patients: a review of the influence of vasodilating drugs. J Int
Med Res 14 (6): 289
3.
Adams AP, Clarke TNS, Edmonds-Seal J et al. (1973) Effects of sodium
nitroprusside on myocardial contractility and haemodynamics. Br J
Anaesth 45: 120
4.
Alarcon-Segovia D, Wakin KG, Worthington JW, Wand LE (1967)
Clinical and experimental studies on the hydralazine syndrome and ist
relationship to systemic lupus erythematosus. Medicine 46: 1
5.
Andersson KE (1992) Clinical pharmacology and potassium channel
openers. Pharmacol Toxicol 70: 244
6.
7.
8.
9.
10.
11.
Batchelor JR, Welsh KI, Tinoco RM et al. (1980) Hydralazine-induced
systemic lupus erthematosus: influence of HLA DR and sex on
susceptibility. Lancet i: 1107
Bauer JH, Alpert MA (1980) Rapid reduction of severe hypertension with
minoxidil. J Cardiovasc Pharmacol [Suppl] 2: 189
Brazy PC, Fitzwilliam JF (1990) Progressive renal disease: role of race
and antihypertensive medications. Kidney Int 1990 37 (4): 1113
Campese V, Stein D, DeQuattro V (1979) Treatment of severe
hypertension with minoxidil: Advantages and limitations. J Clin
Pharmacol 19: 231
Charles MA, Danforth E Jr (1971) Nonketoacidotic hyperglycemia and
coma during intravenous diazoxide therapy in uremia. Diabetes 20: 501
Cohen IM, Mottet MM et al. (1976) Danger in nitroprusside therapy. Ann
Intern Med 85/2: 205
12.
13.
14.
15.
16.
17.
18.
Deutsche Hochdruckliga (Hrsg) (Juni 2001) Empfehlungen zur
Hochdruckbehandlung. 16. Auflage: 13
Dudley DK (1985) Minibolus diazoxide in the management of severe
hypertension in pregnancy. Am J Obstet Gynecol 15; 151 (2): 196
Elliott WJ (2001) Hypertensive emergencies. Crit Care Clin 17 (2): 435
Fagard RH (1995) Reversibility of left ventricular hypertrophy by
antihypertensive drugs. Neth J Med 47 (4): 173
Fenton DA, Wilkinson JD (1983) Topical minoxidil in the treatment of
alopecia areata. BMJ 287: 1015
Finnerty FA Jr (1971) Relationship of extracellular fluid volume to the
development of drug resistance in the hypertensive patient. Am Heart J 81:
563
Fivush B, Neu A, Furth S (1997) Acute hypertensive crises in children:
emergencies and urgencies. Curr Opin Pediatr 9 (3): 233
19.
20.
21.
22.
23.
24.
Gmeiner R, Reidt J, Baumgartner H (1975) Effect of sodium nitroprusside
on myocardial performance and venous tone. Eur J Pharmacol 31: 287
Goodman LS, Gilman A (eds) (1975) The Pharmacological basis of
therapeutics, 5th edn. Mac-Millan, New York, p705
Gottlieb TT, Katz FH, Chidsey CA III (1972) Combined therapy with
vasodilator drugs and beta-adrenergic blockade in hypertension: a
omparative study of minoxidil and hydralazine. Circulation 45: 571
Grim CE, Luft FC, Grim CM, Klotman PE, Van Huysse JW, Weinberger
WH (1979) Rapid blood pressure control with minoxidil: acute and
chronic effects on blood pressure, sodium excretion and the reninaldosterone system. Arch Intern Med 139: 529
Hansson L, Olander R, Aberg H et al. (1971) Treatment of hypertension
with propanolol and hydralazine. Acta Med Scand 190: 521
Höbel M, Kreye VAW, Raithelhuber A (1976) Natrium- Nitroprussid:
Toxizität, Stoffwechsel und Organverteilung. Herz 1: 130
25.
26.
27.
28.
29.
30.
31.
32.
33.
Jack RD (1974) Toxicity of sodium nitroprusside. Br J Anaesth 46: 952
Kirsten R, Nelson K, Kirsten D, Heintz B (1998) Clinical
pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet 34 (6): 457
Kloner RA, Friedewald VE Jr (2000) Case 3: A patient with systemic
hypertension and left ventricular hypertrophy. Am J Cardiol 85 (4): 522
Koch-Weser J (1974) Hypertensive emergencies. N Engl J Med 290: 211
Koch-Weser J (1974) Vasodilator drugs in the treatment of hypertension.
Arch Intern Med 133: 1017
Koch-Weser J (1975) The vasodilator antihypertensives. Drug Ther Bull
5/5: 67
Koch-Weser J (1976) Drug therapy: Diazoxide. N Engl J Med 294: 1271
Koch-Weser J (1976) Drug Therapy: Hydralazine. N Engl J Med 295: 320
Koch-Weser J, Sellers EM (1971) Drug interactions with coumarin
anticoagulants. N Engl J Med 185: 487
34.
35.
36.
37.
38.
Liebson PR (1999) Left ventricular hypertrophy. Curr Treat Options
Cardiovasc Med 1 (3): 219
Lowenthal DT, Affrime MB (1980) Pharmacology and pharmacokinetics
of minoxidil. J Cardiovasc Pharmacol [Suppl] 2: 93
Martin WB, Spodick DH, Zins GR (1980) Pericardial disorders occurring
during open-label study of 1869 severly hypertensive patients treated with
minoxidil. J Cardiovasc Pharmacol [Suppl] 2: 217
McNair A, Krogsgaard AR, Hilden T, Nielson PE (1986) Severe
hypertension with cerebral symptoms treated with furosemide, fractionated
diazoxide or dihydralazine. Danish Multicenter Study. Acta Med Scand
220 (1): 15
Michael CA (1972) Diazoxide in acute obstetrical emergencies. Aust NZ J
Obstet Gynaecol 12: 48
39.
40.
41.
42.
43.
44.
Miller WE, Gifford RW Jr, Humphrey DC et al. (1969) Management of
severe hypertension with intravenous injections of diazoxide. Am J
Cardiol 24: 870
Mitchell HC, Pettinger WA (1978) Long-term treatment of refractory
hypertensive patients with monoxidil. JAMA 239: 2131
Mitchell HC, Pettinger WA (1980) Renal function in long term
minoxidiltreated patients. J Cardiovasc Pharmacol [Suppl] 2: 163
Moore JD, Perry HN Jr (1966) Radioautographic localization of
hydralazine–1-C14 in arterial walls. Proc Soc Exp Biol Med 122: 576
Moravec CS, Ruhe T, Cifani JR, Milovanovic M, Khairallah PA (1994)
Structural and functional consequences of minoxidil-induced cardiac
hypertrophy. J Pharmacol Exp Ther 269 (1): 290
Moser M (1974) Diazoxide – an effective vasodilator in accelerated
hypertension. Am Heart J 87/6: 791
45.
46.
47.
48.
49.
50.
Mroczek WJ, Leibel BA, Davidov M et al. (1971) The importance of the
rapid administration of diazoxide in accelerated hypertension. N Engl J
Med 285: 603
Nayler WG, McInnes I, Swann JB et al (1968) Some effects of the
hypotensive drug diazoxide on the cardiovascular system. Am Heart J 75:
223
O'Malley K, Segal J, Israili Z et al. (1975) Duration of hydralazine action
in hypertension. Clin Pharmacol Ther 18: 581
Palmer RF, Lasseter KC (1975) Sodium nitroprusside. N Engl J Med 292:
294
Palmer RF, Seelman RC, Wheat MW (1965) Pharmacological approach to
the therapy of acute dissecting aneurysm of the aorta. Clin Res 13: 27
Perry HM Jr, Tan EM, Carmody S, Sakanata A (1970) Relationship of
actyl transferance activity to antinuclear antibodies and toxic symptoms in
hypertensive patients treated with hydralazine. J Lab Clin Med 76: 114
51.
52.
53.
54.
55.
56.
Pettinger WA (1980) Minoxidil in the treatment of severe hypertension. N
Engl J Med 303: 922
Pontremoli R, Robaudo C, Gaiter A, Massarino F, Deferrari G (1991)
Long-term minoxidil treatment in refractory hypertension and renal
failure. Clin Nephrol 35 (1): 39
Pruitt AW, Faraj BA, Dayton PG (1974) Metabolism of diazoxide in man
and experimental animals. J Pharmacol Exp Ther 188: 248
Ruzicka M, Leenen FH (1993) Renin-angiotensin system and minoxidilinduced cardiac hypertrophy in rats. Am J Physiol 265 (5 Pt 2): H1551
Sellers EM, Koch-Weser J (1969) Protein binding and vascular activity of
diazoxide. N Engl J Med 281: 1141
Sica DA, Gehr TW (2001) Direct vasodilators and their role in
hypertension management: minoxidil. J Clin Hypertens (Greenwich) 3 (2):
110
57.
58.
59.
60.
61.
62.
Standen NB, Quayle JM, Davies NW, Brayden JE, Huang Y, Nelson MT
(1989) Hyperpolarizing vasodilators activate ATP-sensitive K+-channels
in arterial smooth muscle. Science 14; 245 (4914): 177
Stunkard A, Wertheimer L, Redisch W (1954) Studies on hydralazine:
evidence for a peripheral site of action. J Clin Invest 33: 1047
Talseth T (1976) Studies on hydralazine. I. Serum concentrations of
hydralazine in man after a single dose and at steady-state. Eur J Clin
Pharmacol 10: 183
Talseth T (1976) Studies on hydralazine. III. Bioavailability of hydralazine
in man. Eur J Clin Pharmacol 10: 395
Taylor RM, Rubin AA (1964) Studies on the renal pharmacology of
diazoxide, an antidiuretic benzothiadiazine. J Pharmacol Exp Ther 144:
284
Tinker JH, Michenfelder JD (1976) Sodium nitroprusside: Pharmacology,
toxicology and therapeutics. Anaesthesiology 45: 340
63.
64.
65.
Tyrrell VJ, Ambler GR, Yeow WH, Cowell CT, Silink M (2001) Ten
years' experience of persistent hyperinsulinaemic hypoglycaemia of
infancy. J Paediatr Child Health 37 (5): 483
Wilburn RL, Blaufuss A, Bennett CM (1975) Long-term treatment of
severe hypertension with minoxidil, propanolol and furosemide.
Circulation 52: 706
Zacest R, Gilmore E, Koch-Weser J (1972) Treatment of essential
hypertension with combined vasodilation and beta-adrenergic blockade. N
Engl J Med 286: 617
Literatur zu Kap. 33.9
1.
Borchard U (1995) Kalziumantagonisten. 2. Auflage. Walter de Gryter,
Berlin-New York
2.
BP Trialists, Blood Pressure Lowering Treatment Trialists' Collaboration
(2000) Effects of ACE inhibitors, calcium antagonists, and other bloodpressure-lowering drugs: results of prospectively designed overviews of
randomised trials. Lancet 355: 1955–1964
3.
Brown MJ, Palmer CR, Castaigne A et al. (2000) Morbidity and mortality
in patients randomised to double-blind treatment with a long-acting
calcium-channel blocker or diuretic in the International Nifedipine GITS
study: Intervention as a Goal in Hypertension Treatment. Lancet 356:
366–372
4.
Extrablatt MMW, FDM, 5. Juli 2001
5.
6.
7.
8.
Furberg CD, Psaty BM, Meyer JV (1995) Nifedipine dose-related increase
in mortality in patients with coronary heart disease. Circulation 92: 1326–
1331
Godfraind T, Salomone S, Dessy C et al. (1992) Selectivity scale of
calcium antagonists in the human cardiovascular system based on in vitro
studies. J Cardiovasc. Pharmacol. 20 (Suppl 5): S34–S41
Hafner D, Berger F, Borchard U (1986) Simulation in electrophysiological
pharmacology: specific interactions of antiarrhythmic agents with ion
channels of the cardiac cell membrane. In: Advances in system simulation
Vol. 2. Ed. Möller DPF. Vieweg Verlag, Stuttgart, 154–164
Hanson L, Londholm LH, Ekbom T et al. (1999) Randomised trial of old
and new antihypertensive drugs in elderly patients: cardiovasclular
mortality and morbidity – the Swedish Trial in Old Patients with
Hypertension-2 Study. Lancet 354: 1751–1756
9.
10.
11.
12.
Hansson L, Hedner T, Lund-Johansen P et al. (2000) for the Nordil Study
Group: Randomised trial of effects of calcium antagonists compared with
diuretics and β-blockers on cardiovascular morbidity and mortality in
hypertension: the Nordic Diltiazem (NORDIL) Study. Lancet 356: 359–
365
Holzgreve H, Distler A, Michaelis J et al. (1989) Verapamil versus
hydrochlorothiazide in the treatment of hypertension: results of a long
term doubleblind comparative trial. Br Med J 299: 881–886
Kiowski W (1991) Klinischer Einsatz der Kalziumantagonisten in Klinik
und Praxis. In: Bönner G, Fritschka E (Hrsg) Springer, Berlin Heidelberg
New York, S 81–113
Lewis EJ, Hunsicker LG, Clarke WR et al. (2001) Renoprotective effect of
the angiotensin-receptor antagonist irbesartan in patients with nephropathy
due to type 2 diabetes. N Engl J Med 345: 851–860
13.
14.
15.
16.
Liu L, Wang JG, Gong L et al., for the Systolic Hypertension in China
(Syst-China) Collaborative Group (1998) Comparison of active treatment
and placebo in older Chinese patients with isolated systolic hypertension. J
Hypertens 16: 1823–1829
Pahor M, Psaty BM, Alderman MH et al. (2000) Health outcomes
associated with calcium antagonists compared with other first-line
antihypertensive therapies: a meta-analysis of randomised control trials.
Lancet 356: 1949–1954
Pitt B, Byington RP, Furberg CD et al. (2000) Effects of amlodipine on the
progression of atherosclerosis and the occurrence of clinical events.
Circulation 102: 1503–1510 (9)
Rafflenbeul W (2000) Prognostic benefits of antihypertensive therapy:
concern about another "solid" meta-analysis. Clinical Review 11: 703–708
17.
18.
19.
20.
21.
Schmitz G, Hankowitz J, Kovacs E.M (1991) Cellular processes in
atherogenesis: potential targets of Ca2+ channel blockers. Atherosclerosis
88: 109–132
Schrier RW, Estacio RO (1969) Additional follow-up from the ABCD trial
in patients with type 2 diabetes and hypertension. (letter) N Engl J Med
343
Sihm I et al. (1989) Long-term effects of isradipine on blood pressure and
renal function. Am. J. Med. 86 (Suppl 4A): 15–18
Staessen JA, Fagard R, Celis LT et al. (1997) Randomised double-blind
comparison of placebo and active treatment for older patients with isolated
systolic hypertension. Lancet 350: 757–764
Stanton AV, Chapman JN, Mayet J et al. (2001) Effects of blood pressure
lowering with amlodipine or lisinopril on vascular structure of the
common carotid artery. Clinical Science 101: 455–464
22.
23.
24.
25.
26.
Strauer BE (1985) Hypertrophieregression. Neue Ergebnisse zur
Pharmakotherapie des Hochdruckherzens. Therapiewoche 42: 4777–4790
Tatti P, Pahor M, Byington RP et al. (1998) Outcome results of the
fosinopril versus amlodipine cardiovascular events randomized trial in
patients with hypertension and NIDDM. Diabetes Care 21: 597–603
The Heart Outcomes Prevention Evaluation Study Investigators (2000)
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on
cardiovascular events in high-risk patients. N Engl J Med 342: 145–153
Van Harten J, Burggraaf K, Danhof M et al. (1987) Negligible sublingual
absorption of nifedipine. Lancet II: 1363–1364
Vogt M, Motz W, Strauer BE (1994) Antihypertensive Langzeittherapie
mit Isradipin. Verbesserung der koronaren Flussreserve bei Patienten mit
arterieller Hypertonie und mikrovaskulärer Angina. Arzneim.Forsch./Drug Res. 44: 1321–1328
Literatur zu Kap. 33.10
1.
Blackshear JL. Schwartz GL (2001) Step Care Therapy for Hypertension
in Diabetic Patients. Mayo Clin Proc. 76: 1266–1274
2.
Dahlöf B, Pennert K, Hansson L (1992) Reversal of left ventricular
hypertrophy in hypertensive patients. A metaanalysis of 109 treatment
studies. Am J Hypertens 5: 95–110
3.
Frishman WH (2000) Increased Vascular Compliance/Decreased
Cardiovascular Risk – What the Studies Tell Us. Heart Dis 2 (5): 380–3
4.
Gerstein H (2001) Diabetes and the HOPE study: Implications for
macrovascular and microvascular disease. IJCP Suppl 117: 8–12
5.
Giles TD, Kerut EK, Roffidal LE, Jones R, Given MB, Hutchinson H,
Tresznewky O (2001) The influence of doses of angiotensin I-converting
enzyme inhibitor on systolic blood pressure variability in heart failure: a
substudy of the Assessment of Treatment with Lisinopril and Survival in
heart failure (ATLAS) trial. Blood Press Monit 6 (2): 81–4
6.
7.
8.
9.
Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A,
Lounmanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester
PO, Björck J-E for the Captopril Prevention Project (CAPPP) study group
(1999) Effect of angiotensin-converting-enzyme inhibition compared with
conventional therapy on cardiovascular morbidity and mortality in
hypertension: the Captopril Prevention Project (CAPPP) randomised trial.
Lancet 353: 611–616
Joint National Committee (1997) The sixth report of the Joint National
Committee on Detection, Evaluation and Diagnosis of High Blood
Pressure (JNC VI). Arch Intern Med 157: 2413–2447
Kaplan NM (2001) Hypertension trials: 1990 to 2000. Curr Opin Nephrol
Hypertens 10 (4): 501–5
Lonn EM (2001) Modifying the natural history of atherosclerosis: The
SECURE trial. IJCP Suppl 117: 13–18
10.
11.
12.
13.
14.
Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J (1997)
The effects on initial drug choice and comorbidity on antihypertensive
drug compliance. Am J Hypertens 10: 697–704
Ondetti MA, Williams NJ, Sabo EF, Pluscec J, Weaver ER, Kocy O
(1971) Angiotensin-converting enzyme inhibitors from the venom of
bothrops yararaca: isolation, elucidation of structure, and synthesis.
Biochemistry 10: 4033–4039
Overlack A et al. (1994) ACE-inhibition with perindopril in essential
hypertensive patients with concomitant diseases. Am J Med 97: 126–132
Paulson OB, Jarden JO, Vorstrup S, Holm S, Godtfredsen J (1986) Effect
of captopril on the cerebral circulation in chronic heart failure. Eur J Clin
Invest 16: 124–132
Perondi R, Saino A, Tio RA, Pomidossi G, Gregorini L, Alessio P,
Morganti A, Zanchetti A, Manci G (1992) ACE inhibition attenuates
sympathetic coronary artery disease. Circulation 85: 2004–2013
15.
16.
17.
18.
Pfeffer MA, Braunwald E, Moye LA et al. (1992) Effect of captopril on
mortality and morbidity in patients with left ventricular dysfunction after
myocardial infarction. Results of the Survival and Ventricular
Enlargement Trial. N Engl J Med 327: 669–677
SOLVD Investigators (1992) Effect of enalapril on mortality and the
development of heart failure in asymptomatic patients with reduced left
ventricular fractions. N Engl J Med 327: 685–691
The CONSENSUS trial study group (1987) Effects of Enalapril on
mortality in severe congestive heart failure. Results of the Cooperative
North Scandinavian Survival Study (CONSENSUS). N Engl J Med 316:
1429–35
Tielemans C, Madhoun P, Lenears M, Schandene L, Goldman M,
Vanherweghem JL (1990) Anaphylactoid reactions during hemodialysis
on AN69 membranes in patients receiving ACE inhibitors. Kidney Intern
39: 982–984
19.
20.
Yeun JY (2001) Initial antihypertensive therapy. What are the current
drugs of choice? Postgrad Med 110 (5): 39–40
Yusuf S (2001) Angiotensin-converting enzyme inhibitors as a new
frontier in cardiovascular prevention: Results of the HOPE trial. IJCP
Suppl 117: 7–8
Literatur zu Kap. 33.11
1.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving
HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan
on renal and cardiovascular outcomes in patients with type 2 diabetes and
nephropathy. N Engl J Med 2001 Sep 20; 345 (12): 861–9
2.
Chung O, Hinder M, Sharma AM, Bönner G, Middeke M, Platon J, Unger
T. Comparison of the efficacy and safety of losartan (50–100 mg) with the
T-type calcium channel blocker mibefradil (50–100 mg) in mild to
moderate hypertension. Fundam Clin Pharmacol 2000 Jan-Feb; 14 (1): 31–
41
3.
Chung O, Unger T. Angiotensin II receptor blockade and end-organ
protection. Am J Hypertens 1999 Dec; 12 (12 Pt 1): 150S–156S
4.
Chung O, Unger T. Angiotensin II receptor blockade and end-organ
protection. Am J Hypertens 1999 Dec; 12 (12 Pt 2): 150S–156S
5.
6.
7.
8.
9.
10.
Chung O, Csikos T, Unger T. Angiotensin II receptor pharmacology and
AT1-receptor blockers. J Hum Hypertens 1999 Jan; 13 Suppl 1: S11–20;
discussion S33–4
Chung O, Unger T. Angiotensin II receptors in the kidney. Kidney Blood
Press Res 1998; 21 (2–4): 245–8
Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor
blocker valsartan in chronic heart failure. N Engl J Med 2001 Dec 6; 345
(23): 1667–75
Diabetic Nephropathy. Diabetes Care 2002 Jan; 25 (90001): S85–S89
Dickstein K, Kjekshus J. Comparison of baseline data, initial course, and
management: losartan versus captopril following acute myocardial
infarction (The OPTIMAAL Trial) OPTIMAAL
Trial Steering Committee and Investigators. Optimal Trial in Myocardial
Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 2001
Mar 15; 87 (6): 766–71, A7
11.
12.
13.
Hansson L, Lithell H, Skoog I, Baro F, Banki CM, Breteler M, Castaigne
A, Correia M, Degaute JP, Elmfeldt D, Engedal K, Farsang C, Ferro J,
Hachinski V, Hofman A, James OF, Krisin E, Leeman M, de Leeuw PW,
Leys D, Lobo A, Nordby G, Olofsson B, Opolski G, Prince M, Reischies
FM. Study on Cognition and Prognosis in the Elderly (SCOPE): baseline
characteristics. Blood Press 2000; 9 (2–3): 146–51
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E,
Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2
diabetes. N Engl J Med 2001 Sep 20; 345 (12): 851–60
Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlöf B. Baseline
characteristics in relation to electrocardiographic left ventricular
hypertrophy in hypertensive patients: the Losartan intervention for
endpoint reduction (LIFE) in hypertension study. The Life Study
Investigators. Hypertension 2000 Nov; 36 (5): 766–73
14.
15.
16.
17.
Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S,
Arner P. The effect of irbesartan on the development of diabetic
nephropathy in patients with type 2 diabetes. N Engl J Med 2001 Sep 20;
345 (12): 870–8
Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van
De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA,
Velazquez E, Califf R. Valsartan in acute myocardial infarction trial
(VALIANT): rationale and design. Am Heart J 2000 Nov; 140 (5): 727–50
Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ,
Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan
B. Effect of losartan compared with captopril on mortality in patients with
symptomatic heart failure: randomised trial-the Losartan Heart Failure
Survival Study ELITE II. Lancet 2000 May 6; 355 (9215): 1582–7
Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G,
Olofsson B, Ostergren J, Yusuf S. Candesartan in heart failure–assessment
18.
of reduction in mortality and morbidity (CHARM): rationale and design.
Charm-Programme Investigators. J Card Fail 1999 Sep; 5 (3): 276–82
Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Höhle S,
Meffert S, Stoll M, Stroth U, Zhu YZ. Angiotensin receptors. J Hypertens
Suppl 1996 Dec; 14 (5): S95–103
Literatur zu Kap. 33.12
1.
Dzau, VJ. Circulating versus local renin-angiotensin systems in
cardiovascular homeostasis. Circulation 1988; 77 (6 Pt 2): I4
2.
Wilkes, BM, Mento, PF, Pearl, AR et al.. Plasma angiotensins in anephric
humans: Evidence for an extrarenal angiotensin system. J Cardiovasc
Pharmacol 1991; 17: 419
3.
Seikaly, MG, Arant, BS, Jr, Seney, FD, Jr. Endogenous angiotensin
concentrations in specific intrarenal fluid compartments of the rat. J Clin
Invest 1990; 86: 1352
4.
Redgrave, J, Rabinowe, S, Hollenberg, NK, Williams, GH. Correction of
abnormal renal blood flow response to angiotensin II by converting
enzyme inhibition in essential hypertension. J Clin Invest 1985; 75: 1285
5.
Aus Dominiak P und Unger T. Angiotensin II-AT1-Rezeptorantagonisten.
2. Erweiterte und überarbeitete Aufl. Darmstadt: Steinkopff, 1999. S. 11–
13
6.
7.
8.
9.
Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ,
Lee RJ, Wexler RR, Saye JA, Smith RD. Angiotensin II receptors and
angiotensin II receptor antagonists. Pharmacol Rev 1993 Jun; 45 (2): 205–
51
Chen HH, Burnett JC Jr. C-type natriuretic peptide. The endothelial
component of the natriuretic peptide system. J Cardiovasc. Pharmacol
1998; 32 (Suppl 3): S22–S28
Schweitz H, Vigne P, Moinier D, Frelin jC, Lazdunski M. A new member
of the natriuretic peptide family ist present in the venom of the green
mamba (Dendroaspis angusticeps) J Biol Chem 1992; 267: 13928–13932
Lisy O, Lainchbury JG, Leskinen H, Burnett JC. Therapeutic actions of a
new vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in
experimental severe congestive heart failure. Hypertension 2001, 37,
1089–94
10.
11.
12.
13.
14.
15.
Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM,
McEnroe GA et al.Physiological role of silent receptors of atrial natriuretic
factor. Science 1987; 238: 675–678
Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med
1998 Jul 30; 339 (5): 321–8
Cao L, Gardener DG. Natriuretic peptides inhibit DNA sythesis in cardiac
fibroblasts. Hypertension 1995; 25: 227–234
Stein BC, Levin RI. Natriuretic peptides. Physilogy, therapeutic potential,
and risk stratification in ischemic heart disease. Am Heart J 1998; 135:
914 – 923
Robl J et al. Vasopeptidase Inhibitors: Incorporation of Geminal and
Spirocyclic Substituted Azepiones in Mercaptoacyl Dipeptides. J Med
Chem 1999, 42: 305 – 311
Asher JR, Naftilan A. Vasopeptidase inhibition: A new direction in
cardiovascular treatment. Current Hypertension Reports 2000, 2: 384–391
16.
17.
18.
19.
20.
Packer M. Drugs for heart failure that interfere with the renin-angiotensin
system. In: Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K,
Coats AJS: Heart Failure: Scientific Principles and Clinical Practice. New
York: Churchill Livingstone; 1997, pp 687–690
Kelly RA, Smith TW. Drugs used in the treatment of heart failure. In:
Braunwald E (editor): Heart Disease. A Textbook of Cardiovascular
Medicine, 5th edition. Philadelphia: WB Saunders Company; 1997, pp
471–491
Brunner HR. ACE inhibitors in renal disease. Kidney Int 1992; 42 (2):
463–479
Schmieder RE, Martus P, Klingbeil A. Reversal left ventricular
hypertrophy in essential hypertension. A meta-analysis of randomized
double-blind studies. JAMA 1996; 275 (19): 1507–1513
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in
severe heart failure. Results of the Cooperative North Scandinavian
21.
22.
23.
24.
Enalapril Survival Study (CONSENSUS) N Engl J Med 1987; 316: 1429–
1435
The SOLVED Investigators. Effect of enalapril on survival in patients
with reduced left ventricular ejection fractions and congestive herart
failure. N Engl J Med 1996; 325 (5): 293–302
Robl JA, Trippodo NC, Petrillo EW. Neutral endopeptidase inhibitors and
combined inhibitors of neutral endopeptidase and angiotensin-converting
enzyme. In: van Zwieten PA, Greenlee WJ: Antihypertensive Drugs.
Australia: Harwood Academic Publishers; 1997. pp 113–211
Trippodo et al. Effects of omapatrilat in low, normal and high renin
experimental hypertension. Am. J. Hypertens 1998; 11: 363–372
Hubner RA, Kubota E, Casley DJ, Johnston CI, Burrell LM. In-vitro and
in-vivo inhibition of rat neutral endopeptidase and angiotensin converting
enzyme with the vasopeptidase inhibitor gemopatrilat. Hypertension 2001;
19: 941–946
25.
26.
27.
Robl JA, Sun CQ, Stevenson J, Ryono DE, Simpkins LM, Cimarusti MP,
Dejneka T, Slusarchyk WA, Chao S, Stratton L, Misra RN, Bednarz MS,
Asaad MM, Cheung HS, Abboa-Offei BE, Smith PL, Mathers PD, Fox M,
Schaeffer TR, Seymour AA, Trippodo NC. Dual metalloprotease
inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as
inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J
Med Chem 1997 May 23; 40 (11): 1570–7
D´Uscio LV, Quaschning T, Burnett JC, Luscher TF. Vasopeptidase
ihibition prevents dysfunction of resistance arteries in salt-sensitive
hypertension in comparison with singel ACE-inhibition. Hypertension
2001; 37: 28–33
Quaschning T, D`Uscio LV, Shaw S, Luscher TF. Vasopeptidase
inhibition exhibits endothelial protection in salt-induced hypertension.
Hypertension 2001; 37: 1108–1113
28.
29.
30.
31.
Troughton RW, Rdemaker MT, Powell JD, Yandle TG, Espiner EA,
Frampton CM, Nicholls MG, Richards AM. Benefical renal and
hemodymic effects of omapatrilat in mild and severe heart failure.
Hypertesnion 2000; 36: 523–530
Blais C, Fortin D, Rouleau JL, Molinaro G, Adam A. Protective effect of
omapatrilat, a vasopetidase inhibitor, on the metabolism of bradykinin
innormal and failing hearts. J Pharmacol Exp Ther 2000; 295: 621 – 626
Chen Hh, Lainchbury JG,Matsuda Y, Harty GJ, Burnett JC. Endogenous
natriuretic peptides participate in renal and humoral actions of acute
vasopeptidase inhibition in experimental mild heart failure. Hypertension
2001; 38: 187–191
Vesterqvist O et al. Effects of BMS - 1867, a new dual metalloprotease
inhibitor, on pharmacodynamic makers of neutral endopeptidase. Clin
Pharmacol Ther 1997; 61: 230
32.
33.
34.
35.
Liao W. et al. Supine mean arterial blood presssure (MAP) lowering an
oral tolerance of BMS–186716, a new dual metalloprotease inhibitor of
angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) in
healthy male subjects abstract PIV–45]. Clin Pahrmacol Ther 1997; 61:
229
Ruddy M, Guthrie R, Papametriou V, Moulton K, Saini R. The safety and
24-hour antihypertensive effeciacy of the vasopeptidase inhibitor
omapatrilat: a pilot study abstract D059]. Am J Hypertens 1999; 12 (Pt2):
125A
Izzo JL, Herman TS, Nash S, McKenny J, Reeves RA: Omapatrilat in
hypertensive subjects over 65 years of age: a placebo controlled trial.
Abstr. P1.48]. J Hypertens 2000; 18 (Suppl.2): p. 27
Levine B, Maesaka JK, Smith MC, Levy EM. The safety and efficiacy of
omapatrilat in patients with hypertension and renal insufficiency. Abstr.
P2.27]. J Hypertens 2000; 18 (Suppl.2): p. 96
36.
37.
38.
39.
Larochelle P, Smith DHG, Simon H, Ledger GA, Reeves RA. Omapatrilat
in elderly patients with isolated systolic hypertension. J Hypertens 2000;
18 (Suppl.2): p. 96
Plouin PF, Mancia G, Cobbe SM, Brown M, Dahlhof B, Grossman E,
Ford I, Kolloch RE, Murphy M, Ruilope LM, Wolf R, Kostis JB.
Omapatrilat in persons with enhanced risk of atherosclerotic events: the
OPERA trial. Abstract P2.24]. J Hypertension 2000; 18 (Suppl.2): p. 95
Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM.
Vasopeptidase inhibition with omapatrilat improves cardiac geometry and
survival in cardiomyopathic hamsters more than does ACE inhibition with
captopril. J Cardiovasc Pharmacol 1999 Dec; 34 (6): 782–90
Kostis JB et al. Benefical effects of vasopeptidase inhibition on mortalitiy
and morbidity in heart failure: evidence from the omapatrilat heart failure
program. JACC 2000 (Suppl A, issue 2); 35: p. 240
40.
41.
Rouleau J, Pfeffer MA, Stewart DJ, Kerut EK, Porter CB, Parker JO,
Smith LK, Proulx G, Qian C, Block AJ. Vasopeptidaseinhibitor or
angiotensinconverting enzyme inhibitor in heart failure? Results of the
IMPRESS trial. Circulation 100, Suppl.1 (1999), I–782
Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut E, Porter
CB, Proulx G, Qian C, Block A for the IMPRESS investigators.
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on
exercise tolerance and morbidity in patients with heart failure: IMPRESS
randomised trial. Lancet 2000; 356: 615–620
Literatur zu Kap. 33.13
1.
ALLHAT Collaborative Research Group (2002) Major Outcomes in HighRisk Hypertensive Patients Randomized to Angiotensin-Converting
Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. JAMA 288:
2981–2997
2.
ALLHAT Collaborative Research Group (2002) Major Outcomes in
Moderately Hypercholesterolemic, Hypertensive Patients Randomized to
Pravastatin vs Usual Care. JAMA 288: 2998–3007
3.
Wing LMH, Reid CM, Ryan P et al. (2003) A comparison of outcomes
with angiotensin-converting-enzyme inhibitors and diuretics for
hypertension in the elderly. N Engl J Med 348: 583-592
4.
The Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (2003) The JNC 7 report. JAMA 289:
2560–2572
Literatur zu Kap. 33.14
1.
Ariens EJ (1984) Stereochemistry, a basis for sophisticated nonsense in
pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 26:
663–668
2.
Bakris GL, Barnhill BW et al. (1992) Treatment of arterial hypertension in
diabetic humans: importance of therapeutic selection. Kidney Int 41: 912–
919
3.
Fioretto P, Frigato F et al. (1992) Effects of angiotensin converting
enzyme inhibitors and calcium antagonists on atrial natriuretic peptide
release and action and on albumin excretion rate in hypertensive insulindependent diabetic patients. Am J Hypertens 5: 837–846
4.
Frishman WH, Bryzinski BS et al. (1994) A multifactorial trial design to
assess combination therapy in hypertension. Arch Intern Med 154: 1461–
1468
5.
6.
7.
8.
9.
10.
Gross F (1982) Stellung der Vasodilatatoren in der Therapie des
Hochdruckes. München, MMW Medizin Verlag
Guidelines Subcommittee (1999) 1999 World Health Organization –
International Society of Hypertension guidelines for the management of
hypertension. J Hypertens 17: 151–183
Holzgreve H (1980) Die Kooperation des Patienten bei der
Hochdrucktherapie. Münch med Wochenschr 122: 267–270
Holzgreve H, Distler A et al. (1989) Verapamil versus hydrochlorothiazide
in the treatment of hypertension: results of long term double blind
comparative trial. Brit med J 299: 881–886
Messerli FH and Nussberger J (2000) Vasopeptidase inhibition and angiooedema. Lancet 356: 608–609
Pool JL, Cushman WC et al. (1997) Use of the factorial design and
quadratic response surface models to evaluate the fosinopril and
11.
12.
13.
hydrochlorothiazide combination therapy in hypertension. Am J Hypertens
10: 117–123
Prisant LM, Weir MR et al. (1995) Low-dose drug combination therapy:
an alternative first-line approach to hypertension tretment. Am Heart J
130: 359–366
Robl JA, Sun C-Q et al. (1997) Dual metalloprotease inhibitors:
mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors
of angiotensin-converting enzyme and neutral endopeptidas. J Med Chem
40: 1570–1577
von Manteuffel GE, Rakette S et al. (1995) Wirksamkeit und
Verträglichkeit der Kombination Verapamil retard und
Hydrochlorothiazid. Fortschr Med 113: 374–378
Literatur zu Kap. 33.15
1.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative
Research Group (2000) Major cardiovascular events in hypertensive
patients randomised to doxazosin vs chlorthalidone. JAMA 13: 1967–1975
2.
Chalmers J (1999) 1999 World Health Organization–International Society
of Hypertension Guidelines for the Management of Hypertension:
Guidelines Subcommittee. J. Hypertension 17: 151–183
3.
Cohn JN (2001) Val-HeFT (Valsartan Heart Failure Trial) Clin Cardiol 24:
86
4.
Collins R, Peto R (1994) Antihypertensive drug therapy: effects on stroke
and coronary heart disease. In: Swales JD, ed. Textbook of hypertension.
Oxford: Blackwell Scientific Publication: 1156–1164
5.
Cowley AJ, Wiens BL, Segal R, Rich MW, Santanello NC, Dasbach EJ,
Pitt B (2000) Randomised comparison of losartan vs. captopril on quality
6.
7.
8.
9.
of life in elderly patients with symptomatic heart failure: the losartan heart
failure, ELITE quality of life substudy. Qual Life Res 9 (4): 377–84
Hansson L for the HOT Study Group (1993) The hypertension optimal
treatment study (the HOT study) Blood pressure 2: 62–68
Hansson L, Zanchetti A, Carruthers SG et al. for the HOT Study Group
(1998) Benefits of intensive blood pressure lowering and acetylsalicylic
acid in hypertensive patients. Lancet 351: 1755–1762
The IPPPSH Collaborative Group (1985) Cardiovascular risk factors in a
randomised trial of treatment based on the β-blocker oxprenolol: The
International Prospective Primary Prevention Study In Hypertensives
(IPPPSH) J Hypertension 37: 379–392
Isles CG, Walker LM, Beevers DG et al. (1986) Mortality in patients of
the Glasgow Blood Pressure Clinic. J Hypertension 4: 141–156
10.
11.
12.
13.
14.
15.
Lund-Johansen P (1994) Evolution of hypertension and haemodynamics.
In: Messerli FH, ed.: The ABCs of antihypertensive therapy. Raven, New
York: 5–15
Lund-Johansen P, Omvik P (1990) Hemodynamic patterns of untreated
hypertensive disease. In: Laragh JH, Brenner BM eds.: Hypertension:
Pathophysiology, diagnosis and management. Raven, New York: 305–327
Messerli FH, DeCarvalho JGR, Christie B et al. (1978) Systemic and
regional hemodynamics in low, normal and high cardiac output borderline
hypertension. Circulation 58: 441–448
Peart S (1987) Results of the MRC (UK) trial of drug therapy for mild
hypertension. Clin Invest Med 19: 616–620
Pitt B (1997) Evaluation of Losartan in the Elderly (ELITE) Trial: clinical
implications. Eur Heart J. 18: 1197–1199
Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ,
Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan
16.
17.
18.
19.
B (2000) Effect of losartan compared with captopril on mortality in
patients with ymptomatic heart failure: randomised trial-the Losartan
Heart Failure Survival Study ELITE II. Lancet 355: 1582–1587
Scholze J, Middeke M, Schrader J (2001) Deutsche Herzfrequenz-Studie.
Nieren- und Hochdruckkrankheiten 30: 235–238
Schwenger V, Ritz E (1998) Audit of antihypertensive treatment in
patients with renal failure. Nephrology, Dialysis & Transplantation 13:
3091–3095
Wiklund I, Halling K, Ryden-Bergsten T et al. (1997) Does lowering the
blood pressure improve the mood? Quality-of-life results from
hypertension optimal treatment (HOT) study. Blood Pressure 6: 357–364
Zanchetti A, Hansson L, Ménard J, Leonettia G, Rahn KH, Warnold J,
Wedel H, for the HOT Study Group (2001) Risk assessment and treatment
benefit in intensively treated hypertensive patients of the Hypertension
Optimal Treatment (HOT) study. J. Hypertension 19: 819–825
20.
21.
Lindholm LH, Ibsen H, Dahlöf B et al. (2002) Cardiovascular morbidity
and mortality in patients with diabetes in the Losartan intervention for
endpoint reduction in hypertension study (LIFE): a randomised trial
against atenolol. Lancet 359: 1004–1010
Wright JT for the ALLHAT Officers and Coordinators for the ALLHAT
Collaborative Research Group (2002) Major outcomes in high-risk
hypertensive patients randomized to angiotensin-converting enzyme
inhibitor or calcium channel blocker vs diuretic. JAMA 288: 2981–2997
Literatur zu Kap. 33.16
1.
ALLHAT Collabrative Research Group (2000) Major cardiovascular
events in hypertensive patients randomised to doxazosin vs chlorthalidone:
the antihypertensive and lipid-lowering treatment to prevent heart attack
trial (ALLHAT) JAMA 238: 1967–1975
2.
Assmann G, Schulte H (1998) The Prospective Cardiovascular Munster
(PROCAM) study. The prevalence of hyperlipidemia in persons with
hypertension, diabetes mellitus and the relationship to coronary heart
disease. Am Heart J 116: 1713–24
3.
Björck S, Mulec H, Johnsen SA, Norden G, Aurell M (1992) Renal
protective effect of enalapril in diabetic nephropathy. Brit Med J 304:
339–343
4.
Brenner BM et al. for the RENAAL Study Investigators (2001) Effects of
Losartan on renal and cardiovascular outcomes in patients with type 2
diabetes and nephropathy. N Engl J Med 345: 861–9
5.
6.
7.
8.
9.
10.
11.
Chae CU, Pfeffer MA, Glynn RJ et al. (1999) Increased pulse pressure and
risk of heart failure in elderly. JAMA 281: 634–639
Cohn JN (2001) Val-HeFT (Valsartan Heart Failure Trial) Clin Cardiol 24:
86
Coope J, Warrender TS (1986) Randomised trial of treatment of
hypertension in elderly patients in primary care. BMJ 293: 1145–1151
Dahlöf B, Lindholm LH, Eckborn T et al. (1991) Morbidity and mortality
in the Swedish Trial in Old Patients with Hypertension (STOPhypertension) Lancet 338: 1281–1285
Dahlöf B, Pennert K, Hansson I (1992) Regression of left ventricular
hypertrophy – a metaanalysis. Am J Hypertens 5: 110
Deutsche Liga zur Bekämpfung des hohen Blutdruckes Merkblatt:
Empfehlung zur Hochdruckbehandlung. 13. Auflage, Heidelberg (1999)
Domanski MJ, Davis BR, Pfeffer MA et al. (1999) Isolated Systolic
Hypertension. Hypertension 34: 375–380
12.
13.
14.
15.
Estacio RO, Jeffers BW, Hiatt WR et al. (1998) The effect of Nisoldipine
as compared with enalapril on cardiovascular outcomes in patients with
non-insulin-dependent-diabetes and hypertension. New Engl J Med 338:
645–681
Forslund L, Hjemdahl P, Held C, Bj]orkander I, Eriksson SV, Brodin U,
Rehnqvist N (2000) Prognostic implications of results from exercise
testing in patients with chronic stable angina pectoris treated with
metoprolol or verapamil. A report from the Angina Prognosis Study In
Stockholm (APSIS) Eur Heart J 21: 901–10
Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, Ghadirian P, LeLorier
J, Hamet P (1996) Shanghai trial of nifedipine in the elderly (STONE) J
Hypertension 14 (10): 1237–45
Grossmann E, Messerli FH, Golbourt U (1999) Does diuretic therapy
increase the risk of renal cell carcinoma in women? Am J Cardiol 83:
1090–1093
16.
17.
18.
19.
Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, Casiglia
E, Kerlikowske K, Coope J (1999) Antihypertensive drugs in very old
people: a subgroup meta-analysis of randomised controlled trials.
INDANA Group. Lancet 353 (9155): 793–6
Hallab M, Gallois Y, Chatellier G, Rohmer V, Fressinaud P, Marre M
(1993) Comparison of reduction in microalbuminuria by enalapril and
hydrochlorothiazide in normotensive patients with insulin-dependent
diabetes. Br Med J 306: 175–182
Hannson L, Lindholm LH, Niskanen L et al. (1999) Effect of angiotensinconverting enzyme inhibition compared with conventional therapy on
cardiovascular morbidity and mortality in hypertension. The Captopril
Prevention Project (CAPPP) randomised trial. Lancet 353: 611–616
Hansson L, Zanchetti A, Carruthers SG et al. for the HOT-Study Group:
Benefit of intensive blood pressure lowering and acetylsalicylic acid in
hypertensive patients. Lancet 351 (1998) 1755–1762
20.
21.
22.
23.
24.
Holzgreve H, Middeke M (1993) Treatment of hypertension in the elderly.
Drugs 46: 324–31
Joint National Committee on Prevention, Detection, Evaluation and
Treatment of High Blood Pressure (1997) The sixth Report of the JOINT
NATIONAL COMMITTEE on Prevention, Detection, Evaluation and
Treatment of High Blood Pressure. Arch Int Med 157: 2413–2446
Kailasam MT, Parmer RJ, Cervenka JH, Wu RA, Ziegler MG, Kennedy
BP, Adegbile IA, O´Connor DT (1995) Divergent effects of
dihydropyridine and phenylalkylamine calcium channel antagonist classes
on autonomic function in human hypertension. Hypertension 26: 143–149
Keil U (1993) Mortalität an Herzkreislauferkrankungen von 1985–1990.
Therapiewoche 43: 1658–1664
Klein R, Moss SE, Klein BE, DeMets DL (1989) Relation of ocular and
systemic factors to survival in diabetes. Arch Intern Med 149: 266–72
25.
26.
27.
28.
Kleber SX (1994) Socioeconomic aspects of ACE inhibition in the
secondary prevention in cardiovascular diseases. Am J Hyp 7: 112S–116S
Kober L, Torp-Pedersen C, Carlsen JR et al (1995) A clinical trial of the
angiotensin-converting enzyme inhibitor trandolapril in patients with left
ventricular dysfunction after myocardial infarction. New Engl J Med 333:
1670–1676
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of
angiotensin-converting-enzyme inhibition on diabetic nephropathy. N
Engl J Med 329: 1456–1462
Lindholm LH, Hansson L, Ekbom T, Dahlof B, Lanke J, Linjer E,
Schersten B, Wester PO, Hedner T, de Faire U (2000) Comparison of
antihypertensive treatments in preventing cardiovascular events in elderly
diabetic patients: results from the Swedish Trial in Old Patients with
Hypertension–2. STOP Hypertension–2 Study Group. J Hypertens 18:
1671–5
29.
30.
31.
32.
Maschio G, Alberti D, Danin G et al. and the Angiotensin-ConvertingEnzyme Inhibition in progressive renal insuffiziency study group (1996)
Effect of the angiotensin-converting-enzyme inhibitor benalapril on the
progression of chronic renal insufficiency. N Engl J Med 334: 939–945
Medical Research Council Working Party on mild to moderate
hypertension (1987) The MRC Mild Hypertension Trial: some subgroup
results. In: Strasser T, Gauren D, ed.: Mild hypertension: from drug trials
to practice. Raven Press, New York: 9–20
Messerli FH (1986) Osler´s maneuver, pseudohypertension and true
hypertension in the elderly. Am J Med 80: 906–910
Messerli FH, Grossmann E, Golbourt U (1998) Are beta-blockers
efficacious as first-line therapy for hypertension in the elderly? A
systematic review. JAMA 23: 1903–1907
33.
34.
35.
36.
37.
38.
Motro M, Shemesh J (2001) Calcium channel blocker nifedipine slows
down progression of coronary calcification in hypertensive patients
compared with diuretics. Hypertension 37 (6): 1410–3
MRC Working Party (1992) Medical Research Council trial of treatment
of hypertension in older adults: principal results. BMJ 304: 405–412
Muntoni S (1997) Cholesterol-Lowering Drugs for primary prevention?
The WOSCOP study. Pharm Research 33: 169–170
Packer M, Coats AJS, Fowler MB et al. (2001) Effect of carvedilol on
survival in severe chronic heart failure. N Engl J Med 344: 1651–8
Parving HH, Lehnert H et al. (2001) The effect of Irbesartan on the
development of diabetic nephropathy in patients with type 2 diabetes. N
Engl J Med 345: 870–8
Pfeffer MA, Lamas GA, Vaughan DE et al. (1988) Effect of captopril on
progressive ventricular dilation after anterior myocardial infarction. N
Engl J Med 319: 80–86
39.
40.
41.
42.
43.
Philipp T, Anlauf M, Distler A et al. (1997) Randomised, double blind,
multicenter comparison of hydrochlorothiazide, atenolol, nitrendipine and
enalapril in antihypertensive treatment: results of the HANE study. BMJ
315: 154–159
Pope JE, Anderson JJ, Felson DT (1993) A meta-analysis of the effects of
nonsteroidal inflammatory drugs on blood pressure. Arch Intern Med 153:
477–483
Randomised trial of cholesterol lowering in 4444 patients with coronary
heart disease. Lancet (1994) 344: 1383–1389
Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC (2001) Beta adrenergic
receptor blockers and weight gain: a systematic analysis. Hypertension 37:
250–4
SHEP Cooperative Research Group (1991) Prevention of stroke by
antihypertensive drug treatment in older persons with isolated systolic
44.
45.
46.
47.
hypertension. Final results of the Systolic Hypertension in the Elderly
Programm. JAMA 265: 3255–3264
Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary
Prevention Study Group (1995) Prevention of coronary heart disease with
pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301–7
SOLVD Investigators (1991) Effect of enalapril on survival in patients
with reduced left ventricular ejection fractions and congestive heart
failure. N Engl J Med 325: 293–302
Staessen JA, Fagard R, Thijs L et al.: for the Systolic Hypertension –
Europe (Syst-Eur) Trial Investigators (1997) Morbidity and mortality in
the placebo-controlled European Trial on Isolated Systolic Hypertension in
the Elderly. Lancet 360 757–764
Statement Deutsche Hochdruckliga (1999) Zum Einsatz von
Kalziumantagonisten und Diuretika. Synopsis 3: 38–39
48.
49.
50.
51.
52.
Tarif N, Bakris GL (1997) Preservation of renal function: the spectrum of
effects by calcium channel blockers. Nephrol Dial Transplant 12: 2244–
2250
Tatti P, Pahor M, Byington et al. (1998) Fosinopril versus Amlodipine
Cardiovascular Event Trial (FACET) Diab Care 21: 597–603
The LIPID Study Group (1998) Prevention of cardiovascular events and
death with pravastatin in patients with coronary heart disease and broad
range of initial cholesterol levels. N Engl J Med 339: 1349–1357
Trenkwalder P, Ruland D, Stender M, Gebhard J, Trenkwalder C, Lydtin
H, Hense HW (1994) Prevalence, awarness, treatment and control of
hypertension in a population over the age of 65. J Hypertension 12: 709–
716
United Kingdom Prospective Diabetes Study Group (1998) Tight blood
pressure control and risk of macrovascular and mikrovascular
complication in type 2 diabetes: UKPDS 38. Br Med J 389: 703–720
53.
54.
55.
56.
Whelton A, Fort JG, Puma L et al. (2001) Cyclooxygenase–2-specific
inhibitors and cardiorenal function: a randomised, controlled trial of
Celecoxib and Rofecoxib in older hypertensive osteoarthritis patients. Am
J Therapeutics 8: 85–95
Wiklund I, Halling K, Ryden-Bergsten T et al. (1997) Does lowering the
blood pressure improve the mood? Quality-of-life results from the
Hypertension Optimal Treatment (HOT) study. Blood Pressure 6: 357–364
Yusuf S, Sleight P, Pogue J et al. (2000) Effects of angiotensinconverting-enzyme inhibitor ramipril on cardiovascular events in high-risk
patients. The Heart Outcomes Prevention Evaluation Study Investigators.
N Engl J Med 342: 145–153
Zanchetti A, Chalmers JP, Arakava K et al. (1993) The 1993 guidelines
for the management of mild hypertension: memorandum from a
WHO/ISH meeting. Blood press: 86–100
57.
58.
59.
60.
Zanchetti A, Hansson L et al. (2001) Effects of individual risk factors on
the incidence of cardiovascular events in the treated hypertensive patients
of the Hypertension Optimal Treatment Study. HOT Study Group. J
Hypertens 19: 1149–59
Zucchelli P, Zuccala A, Borghi M Fuxaroli M, Sasdelli M, Stallone C,
Sanna G, Gaggi R (1992) Long-term comparision between captopril and
nifedipine in the progress of renal insufficiency. Kidney Int 42: 452–458
Lindholm LH, Ibsen H, Dahlöf B et al. (2002) Cardiovascular morbidity
and mortality in patients with diabetes in the Losartan intervention for
endpoint reduction in hypertension study (LIFE): a randomised trial
against atenolol. Lancet 359: 1004–1010
Wright JT for the ALLHAT Officers and Coordinators for the ALLHAT
Collaborative Research Group (2002) Major outcomes in high-risk
hypertensive patients randomized to angiotensin-converting enzyme
inhibitor or calcium channel blocker vs diuretic. JAMA 288: 2981–2997
61.
62.
Scholze F (2002) Adipositasbehandlung mit Sibutramin unter
Praxisbedingungen. Dtsch Med Wochenschr 127: 606–610
Lewis EJ, Hunsicker LG, Clarke WR et al. (2001) Renoprotective effect of
the angiotensin-receptor antagonist Irbesartan in patients with nephropathy
due to type 2 diabetes. N Engl J Med 345: 851–860
Literatur zu Kap. 33.17
1.
Wenzel RR, Bruck H, Noll G, Schäfers RF, Daul AE, Philipp T.
Antihypertensive Drugs and the Sympathetic Nervous System. J
Cardiovasc Pharmacol 2000; 35: 43–52
2.
Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Ishii M. Age-related
changes in muscle sympathetic nerve activity in essential hypertension.
Hypertension 1989; 13: 870–7
3.
Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS et al.
Plasma norepinephrine as a guide to prognosis in patients with chronic
congestive heart failure. N Engl J Med 1984; 311: 819–23
4.
Neri Serneri GG, Boddi M, Arata L, Rostagno C, Dabizzi P, Coppo M et
al. Silent ischemia in unstable angina is related to an altered cardiac
norepinephrine handling. Circulation 1993; 87: 1928–37
5.
6.
7.
8.
9.
Julius S, Gudbrandsson T. Early association of sympathetic overactivity,
hypertension, insulin resistance, and coronary risk. J Cardiovasc
Pharmacol 1992; 20 Suppl 8: S40–8
Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic
nerve activity in borderline hypertensive humans. Evidence from direct
intraneural recordings. Hypertension 1989; 14: 177–83
Noll G, Wenzel RR, Schneider M, Oesch V, Binggeli C, Shaw S et al.
Increased activation of sympathetic nervous system and endothelin by
mental stress in normotensive offspring of hypertensive parents.
Circulation 1996; 93: 866–869
Philipp T, Distler A, Cordes U. Sympathetic nervous system and bloodpressure control in essential hypertension. Lancet 1978; 2: 959–63
Wallin BG, Morlin C, Hjemdahl P. Muscle sympathetic activity and
venous plasma noradrenaline concentrations during static exercise in
10.
11.
12.
13.
normotensive and hypertensive subjects. Acta Physiol Scand 1987; 129:
489–97
Wenzel RR, Czyborra P, Lüscher TF, Philipp T. Endothelin in
Cardiovascular Control: The Role of Endothelin Antagonists. Curr
Hypertension Rep 1999; 1: 79–87
Bruck H, Gössl M, Spitthover R, Schäfers RF, Kohnle M, Philipp T et al.
The nitric oxide synthase inhibitor L-NMMA potentiates noradrenalineinduced vasoconstriction: effects of the alpha2-receptor antagonist
yohimbine. J Hypertens 2001; 19: 907–11
Davis JO, Freeman RH. Mechanisms regulating renin release. Physiol Rev
1976; 56: 1–56
Hilgers KF, Veelken R, Rupprecht G, Reeh PW, Luft FC, Mann JF.
Angiotensin II facilitates sympathetic transmission in rat hind limb
circulation. Hypertension 1993; 21: 322–8
14.
15.
16.
17.
18.
Kannan H, Nakamura T, Jin XJ, Hayashida Y, Yamashita H. Effects of
centrally administered angiotensin on sympathetic nerve activity and blood
flow to the kidney in conscious rats. J Auton Nerv Syst 1991; 34: 201–10
Weber F, Brodde OE, Anlauf M, Bock KD. Subclassification of human
beta-adrenergic receptors mediating renin release. Clin Exp Hypertens [A]
1983; 5: 225–38
Clozel M, Gray GA, Breu V, Löffler BM, Osterwalder R, Neidhart W et
al. The endothelin ETB receptor mediates both vasodilation and
vasoconstriction in vivo. Biochem Biophys Res Commun 1992; 186: 867–
73
Seo B, Oemar BS, Siebenmann R, von Segesser L, Lüscher TF. Both ETA
and ETB receptors mediate contraction to endothelin–1 in human blood
vessels. Circulation 1994; 89: 1203–8
Garcia-Villalon AL, Monge L, Fernandez N, Sanchez MA, Martinez MA,
Gomez B et al. Basal inhibitory action of endogenous endothelin on the
19.
20.
21.
22.
sympathetic contraction in the isolated rat tail artery. Eur J Pharmacol
1999; 384: 163–7
Mosqueda-Garcia R, Inagami T, Appalsamy M, Sugiura M, Robertson
RM. Endothelin as a neuropeptide. Cardiovascular effects in the brainstem
of normotensive rats. Circ Res 1993; 72: 20–35
Kawano Y, Yoshida K, Yoshimi H, Kuramochi M, Omae T. The
cardiovascular effect of intracerebroventricular endothelin in rats. J
Hypertens Suppl 1989; 7: S22–3
Goto K, Kasuya Y, Matsuki N, Takuwa Y, Kurihara H, Ishikawa T et al.
Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca
(2+) channel in vascular smooth muscle. Proc Natl Acad Sci USA 1989;
86: 3915–3918
Kiowski W, Lüscher TF, Linder L, Bühler FR. Endothelin–1-induced
vasoconstriction in humans. Reversal by calcium channel blockade but not
23.
24.
25.
26.
by nitrovasodilators or endothelium-derived relaxing factor. Circulation
1991; 83: 469–75
Wenzel RR, Duthiers N, Noll G, Bucher J, Kaufmann U, Lüscher TF.
Endothelin and calcium antagonists in the skin microcirculation of patients
with coronary artery disease. Circulation 1996; 94: 316–322
Noll G, Wenzel RR, de Marchi S, Shaw S, Lüscher TF. Differential effects
of captopril and nitrates on muscle sympathetic nerve activity in
volunteers. Circulation 1997; 95: 2286–92
Wenzel RR, Spieker L, Qui S, Shaw S, Lüscher TF, Noll G. I–1Imidazoline Agonist Moxonidine decreases Sympathetic Nerve Activity
and Blood Pressure in Hypertensives. Hypertension 1998; 32: 1022–1027
Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary
arteries by noradrenaline and serotonin. Nature 1983; 305: 627–30
27.
28.
29.
30.
31.
Hansen J, Jacobsen TN, Victor RG. Is nitric oxide involved in the tonic
inhibition of central sympathetic outflow in humans? Hypertension 1994;
24: 439–44
Sakuma I, Togashi H, Yoshioka M, Saito H, Yanagida M, Tamura M et al.
NG-methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide
synthesis, stimulates renal sympathetic nerve activity in vivo. A role for
nitric oxide in the central regulation of sympathetic tone? Circ Res 1992;
70: 607–11
Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM,
Loscalzo J et al. Impaired vasodilation of forearm resistance vessels in
hypercholesterolemic humans. J Clin Invest 1990; 86: 228–34
Li Q, Belz GG. Systolic time intervals in clinical pharmacology. Eur. J.
Clin. Pharmacol 1993; 44: 415–421
Schäfers RF, Nürnberger J, Wenzel RR, Philipp T, Michel MC.
Characterization of adrenoceptors mediating cardiovascular and metabolic
32.
33.
34.
35.
in vivo effects of α-methylnoradrenaline (AMN) in humans. NaunynSchmiedeberg's Arch. Pharmacol 1997; 356: R52
Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P et al.
Power spectral analysis of heart rate and arterial pressure variabilities as a
marker of sympathovagal interaction in man and conscious dog. Circ Res
1986; 59: 178–93
Esler M, Jennings G, Korner P, Blombery P, Sacharias N, Leonard P.
Measurement of total and organ-specific norepinephrine kinetics in
humans. Am J Physiol 1984; 247: E21–8
Saul JP, Rea RF, Eckberg DL, Berger RD, Cohen RJ. Heart rate and
muscle sympathetic nerve variability during reflex changes of autonomic
activity. Am J Physiol 1990; 258: H713–21
Delius W, Hagbarth KE, Hongell A, Wallin BG. General characteristics of
sympathetic activity in human muscle nerves. Acta Physiol Scand 1972;
84: 65–81
36.
37.
38.
39.
40.
Delius W, Hagbarth KE, Hongell A, Wallin BG. Manoeuvres affecting
sympathetic outflow in human skin nerves. Acta Physiol Scand 1972; 84:
177–86
Mark AL, Victor RG, Nerhed C, Wallin BG. Microneurographic studies of
the mechanisms of sympathetic nerve responses to static exercise in
humans. Circ Res 1985; 57: 461–9
Victor RG, Leimbach WJ, Seals DR, Wallin BG, Mark AL. Effects of the
cold pressor test on muscle sympathetic nerve activity in humans.
Hypertension 1987; 9: 429–36
Wallin BG. Intraneural recordings of normal and abnormal sympathetic
activity in man. In: Bannister SR, ed. Autonomic Failure. Oxford: Oxford
University Press; 1988: 177–195
Rupp H, Maisch B, Brilla CG. Drug withdrawal and rebound
hypertension: differential action of the central antihypertensive drugs
41.
42.
43.
44.
moxonidine and clonidine. Cardiovasc Drugs Ther 1996; 10 Suppl 1: 251–
62
Philipp T, Nast HP. [Hypertensive emergencies]. Internist (Berlin) 1974;
15: 165–9
Bohmann C, Schollmeyer P, Rump LC. Effects of imidazolines on
noradrenaline release in rat isolated kidney. Naunyn Schmiedebergs Arch
Pharmacol 1994; 349: 118–24
Ernsberger P, Damon TH, Graff LM, Schafer SG, Christen MO.
Moxonidine, a centrally acting antihypertensive agent, is a selective ligand
for I1-imidazoline sites. J Pharmacol Exp Ther 1993; 264: 172–82
Michel MC, Brodde OE, Schnepel B, Behrendt J, Tschada R, Motulsky HJ
et al. [3H]idazoxan and some other alpha 2-adrenergic drugs also bind
with high affinity to a nonadrenergic site. Mol Pharmacol 1989; 35: 324–
30
45.
46.
47.
48.
49.
Ernsberger P, Haxhiu MA, Graff LM, Collins LA, Dreshaj I, Grove DL et
al. A novel mechanism of action for hypertension control: moxonidine as a
selective I1-imidazoline agonist. Cardiovasc Drugs Ther 1994; 8 Suppl 1:
27–41
Wenzel RR, Allegranza G, Binggeli C, Shaw S, Weidmann P, T.F. L et al.
Differential activation of cardiac and peripheral sympathetic nervous
system by nifedipine: Role of pharmacokinetics. JACC 1997; 29: 1607–
1614
Burnier M, Brunner HR. Neurohormonal consequences of diuretics in
different cardiovascular syndromes. Eur Heart J 1992; 13 Suppl G: 28–33
Hjemdahl P. Sympatho-adrenal mechanisms and the antihypertensive
response to thiazide diuretics. Acta Pharmacol Toxicol (Copenh) 1984; 54
Suppl 1: 43–6
Waters J, Ashford J, Jäger B, Verboom CN. Use of moxonidine as initial
therapy in combination in the treatment of essential hypertension - results
50.
51.
52.
53.
of the TOPIC (Trial Of Physiotens In Combination) Study. Journal of
Clinical and Basic Cardiology 1999; 2: 219–24
Ferguson DW, Hayes DW. Nifedipine potentiates cardiopulmonary
baroreflex control of sympathetic nerve activity in healthy humans. Direct
evidence from microneurographic studies. Circulation 1989; 80: 285–98
Hoffman RP, Sinkey CA, Kienzle MG, Anderson EA. Muscle sympathetic
nerve activity is reduced in IDDM before overt autonomic neuropathy.
Diabetes 1993; 42: 375–80
Sanders JS, Ferguson DW. Diastolic pressure determines autonomic
responses to pressure perturbation in humans. J Appl Physiol 1989; 66:
800–7
Saxena PR. Interaction between the renin-angiotensin-aldosterone and
sympathetic nervous systems. J Cardiovasc Pharmacol 1992; 19: S80–8
54.
55.
56.
57.
58.
Matsukawa T, Gotoh E, Minamisawa K, Kihara M, Ueda S, Shionoiri H et
al. Effects of intravenous infusions of angiotensin II on muscle
sympathetic nerve activity in humans. Am J Physiol 1991
Distler A, Liebau H, Wolff HP. Action of angiotensin on sympathetic
nerve endings in isolated blood vessels. Nature 1965; 207: 764–5
Chalmers D, Dombey SL, Lawson DH. Post-marketing surveillance of
captopril (for hypertension): a preliminary report. Br J Clin Pharmacol
1987; 24: 343–49
Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int
1992; 42: 1020–29
Israili ZH, Hall WD. Cough and angioneurotic edema associated with
angiotensin-converting enzyme inhibitor therapy: a review of the literature
and pathophysiology. Ann Intern Med 1992; 117: 234–42
59.
60.
61.
62.
Lacourciere Y, Brunne H, Irwin R, al. e, Group atLcS. Effects of
modulators of the renin-angiotensin-aldosterone system on cough. J
Hypertension 1994; 12: 1387–93
Pitt B, Chang P, Timmermans P. Angiotensin II receptor antagonists in
heart failure: rationale and design of the Evaluation of Losartan in the
Elderly (ELITE) Study. Cardiovasc Drugs Ther 1995; 9: 693–700
Swedberg K, Eneroth P, Kjekshus J, Snapinn S. Effects of enalapril and
neuroendocrine activation on prognosis in severe congestive heart failure
(follw-up of the Consensus trial) Consensus Trial Study Group. Am J
Cardiol 1990; 66: 40D–44D
Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K
et al. A clinical trial of the angiotensin-converting-enzyme inhibitor
trandolapril in patients with left ventricular dysfunction after myocardial
infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N
Engl J Med 1995; 333: 1670–6
63.
64.
65.
66.
Ball SG, Hall AS, Murray GD. ACE inhibition, atherosclerosis and
myocardial infarction–the AIRE Study in practice.Acute Infarction
Ramipril Efficacy Study. Eur Heart J 1994; 15 Suppl B: 20–5; discussion
26–30
Pfeffer MA, Braunwald E, Moye LA, al. e. Effect of captopril on mortality
and morbidity in patients with left ventricular dysfunction after myocardial
infarction: results of the Survival and Ventricular Enlargement Trial. New
Engl J Med 1992; 327: 669–77
The SOLVD Investigators S. Effects of enalapril on mortality and the
development of heart failure in asymptomatic patients with reduced left
ventricular ejection fraction. New Engl. J. Med 1992; 327: 685–91
Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F et al. A
comparison of enalapril with hydralazine-isosorbide dinitrate in the
treatment of chronic congestive heart failure [see comments]. N Engl J
Med 1991; 325: 303–10
67.
68.
69.
70.
71.
72.
Miura S, Ideishi M, Sakai T, Motoyama M, Kinoshita A, Sasaguri M et al.
Angiotensin II formation by an alternative pathway during exercise in
humans. J Hypertens 1994; 12: 1177–81
Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification
of a highly specific chymase as the major angiotensin II- forming enzyme
in the human heart. J Biol Chem 1990; 265: 22348–57
Urata H, Strobel F, Ganten D. Widespread tissue distribution of human
chymase. J Hypertens Suppl 1994; 12: S17–22
van Zwieten PA, Julius S. The importance of the sympathetic nervous
system in hypertension. Introduction. J Hypertens 1999; 17: S1
Dominiak P. Modulation of sympathetic control by ACE inhibitors. Eur
Heart J 1993; 14 Suppl I: 169–72
Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT,
Boomsma F et al. Reduction of sympathetic hyperactivity by enalapril in
patients with chronic renal failure. N Engl J Med 1999; 340: 1321–8
73.
74.
75.
76.
77.
Brasch H, Sieroslawski L, Dominiak P. Angiotensin II increases
norepinephrine release from atria by acting on angiotensin subtype 1
receptors. Hypertension 1993; 22: 699–704
Timmermans P, Wong PC, Chin AT et al. Angiotensin II receptors and
angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205–51
Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I et al.
Randomised trial of losartan versus captopril in patients over 65 with heart
failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet 1997;
349: 747–52
Rump LC, Oberhauser V, Schwertfeger E, Schollmeyer P. Experimental
evidence to support ELITE [letter]. Lancet 1998; 351: 644–5
Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RR, Jr. Inhibition of
sympathetic outflow by the angiotensin II receptor antagonist, eprosartan,
but not by losartan, valsartan or irbesartan: relationship to differences in
78.
79.
80.
81.
prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55:
244–51
Wenzel RR, Wambach C, Schäfers RF, Daul AE, Michel MC, Siffert W et
al. Doxazosin, but not Losartan or Enalapril, Increases Exercise-induced
Sympathetic Activity. J Hypertension 1999; 17 (Suppl 3): S295
Schäfers RF, Adler S, Daul A, Zeitler G, Vogelsang M, Zerkowski H-R et
al. Positive inotropic effects of the beta2-adrenoceptor agonist terbutaline
in the human heart: effects of long-term beta1-adrenoceptor antagonist
treatment. J Am Coll Cardiol 1994; 23: 1224–1233
Schäfers RF, Löw-Kröger A, Philipp T. Wirksamkeit und Verträglichkeit
des neuen zentralwirksamen Antihypertensivums Moxonidin im Vergleich
zu Enalapril. Nieren- und Hochdruckkrankheiten 1994; 23: 221–224
Schäfers RF, Poller U, Pönicke K, Geissler M, Daul AE, Michel MC et al.
Influence of adrenoceptor and muscarinic receptor blockade on the
cardiovascular effects of exogenous noradrenaline and of endogenous
82.
83.
84.
85.
noradrenaline released by infused tyramine. Naunyn-Schmiedeberg's Arch.
Pharmacol 1997; 355: 239–249
Schäfers RF, Nürnberger J, Herrmann B, Wenzel RR, Philipp T, Michel
MC. Adrenoceptors mediating the cardiovascular and metabolic effects of
alpha-methylnoradrenaline in humans. J Pharmacol Exp Ther 1999; 289:
918–25
Erne P, Zuber M, Schüpfer G. Betablocker und koronare Herzkrankheit.
In: Lüscher TF, ed. Präventive Kardiologie in Klinik und Praxis. Bern:
Verlag Hans Huber; 1993: 231–244
ISIS–1. Randomised trial of intravenous atenolol among 16 027 cases of
suspected acute myocardial infarction: ISIS–1. First International Study of
Infarct Survival Collaborative Group. Lancet 1986; 2: 57–66
The IPPPSH Collaborative Group I. Cardiovascular risk and risk factors in
a randomized trial of treatment based on the beta-blocker oxprenolol: the
86.
87.
88.
89.
90.
International Prospective Primary Prevention Study in Hypertension
(IPPPSH) The IPPPSH Collaborative Group. J Hypertens 1985; 3: 379–92
Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G.
Primary prevention with metoprolol in patients with hypertension.
Mortality results from the MAPHY study. Jama 1988; 259: 1976–82
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL
Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
[see comments]. Lancet 1999; 353: 2001–7
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P et al.
Effect of carvedilol on survival in severe chronic heart failure. N Engl J
Med 2001; 344: 1651–8
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised
trial. Lancet 1999; 353: 9–13
Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler
MB. Increased beta-receptor density and improved hemodynamic response
91.
92.
93.
94.
to catecholamine stimulation during long-term metoprolol therapy in heart
failure from dilated cardiomyopathy. Circulation 1989; 79: 483–90
Sundlöf G, Wallin BG, Stromgren E, Nerhed C. Acute effects of
metoprolol on muscle sympathetic activity in hypertensive humans.
Hypertension 1983; 5: 749–56
Wallin BG, Sundlof G, Stromgren E, Aberg H. Sympathetic outflow to
muscles during treatment of hypertension with metoprolol. Hypertension
1984; 6: 557–62
Noll G, Wenzel RR, Shaw S, Lüscher TF. Calcium antagonists and
sympathetic nerve activation: are there differences between classes? J
Hypertens Suppl 1998; 16: S17–24
Sun N, Hong T, Zhang R, Yang X. The effects of verapamil SR and
bisoprolol on reducing the sympathetic nervous system's activity.
Hypertens Res 2000; 23: 537–40
95.
96.
97.
98.
Nayler WG, Szeto J. Effect of verapamil on contractility, oxygen
utilization, and calcium exchangeability in mammalian heart muscle.
Cardiovasc Res 1972; 6: 120–8
Behar S, Rabinowitz B, Zion M, Reicher-Reiss H, Kaplinsky E, Abinader
E et al. Immediate and long-term prognostic significance of a first anterior
versus first inferior wall Q-wave acute myocardial infarction. Secondary
Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Study Group.
Am J Cardiol 1993; 72: 1366–70
Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M,
Carr AA et al. Final outcome results of the Multicenter Isradipine Diuretic
Atherosclerosis Study (MIDAS) A randomized controlled trial. JAMA
1996; 276: 785–91
Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes:
implications of the appropriate blood pressure control in diabetes (ABCD)
trial. Am J Cardiol 1998; 82: 9R–14R
99.
100.
101.
102.
HINT. Early treatment of unstable angina in the coronary care unit: a
randomised, double blind, placebo controlled comparison of recurrent
ischaemia in patients treated with nifedipine or metoprolol or both. Report
of The Holland Interuniversity Nifedipine/Metoprolol Trial (HINT)
Research Group. Br Heart J 1986; 56: 400–13
Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE,
Weiss NS et al. The risk of Myocardial Infarction associated with
Antihypertensive Drug Therapies. JAMA 1995; 274: 620–625
SPRINT. Secondary prevention reinfarction Israeli nifedipine trial
(SPRINT) A randomized intervention trial of nifedipine in patients with
acute myocardial infarction. The Israeli Sprint Study Group. Eur Heart J
1988; 9: 354–64
Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G et al.
Outcome results of the Fosinopril Versus Amlodipine Cardiovascular
103.
104.
105.
Events Randomized Trial (FACET) in patients with hypertension and
NIDDM [see comments]. Diabetes Care 1998; 21: 597–603
The Multicenter Diltiazem Postinfarction Trial Research Group. The effect
of diltiazem on mortality and reinfarction after myocardial infarction. The
Multicenter Diltiazem Postinfarction Trial Research Group (MDPIT) N
Engl J Med 1988; 319: 385–92
Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH,
Syvertsen JO et al. Randomised trial of effects of calcium antagonists
compared with diuretics and ß-blockers on cardiovascular morbidity and
mortality in hypertension: the Nordic Diltiazem (NORDIL) study. The
Lancet 2000; 356: 359–364
Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et
al. Effects of intensive blood-pressure lowering and low-dose aspirin in
patients with hypertension: principal results of the Hypertension Optimal
106.
107.
108.
Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:
1755–62
Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH
et al. Randomised double-blind comparison of placebo and active
treatment for older patients with isolated systolic hypertension. The
Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet
1997; 350: 757–64
Lopez LM, Thorman AD, Mehta JL. Effects of amlodipine on blood
pressure, heart rate, catecholamines, lipids and response to adrenergic
stimulus. Am J Cardiol 1990; 66: 1269–71
Kailasam MT, Parmer RJ, Cervenka JH, Wu RA, Ziegler MG, Kennedy
BP et al. Divergent effects of dihydropyridine and phenylalkylamine
calcium channel antagonist classes on autonomic function in human
hypertension. Hypertension 1995; 26: 143–9
109.
110.
111.
112.
Packer M. Vasodilatator and inotropic drugs for treatment of chronic
congestive heart failure- distinguishing hype from hope. J Am Coll
Cardiol 1988; 12: 1299–1317
Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani
FE et al. Effect of vasodilatator therapy on mortality in chronic congestive
heart failure. Results of a Veterans Administration Cooperative Study. N
Engl J Med 1986; 314: 1547–52
ALLHAT. Major cardiovascular events in hypertensive patients
randomized to doxazosin vs chlorthalidone: the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT) ALLHAT
Collaborative Research Group. Jama 2000; 283: 1967–75
Messerli FH. Implications of discontinuation of doxazosin arm of
ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial. Lancet 2000; 355: 863–4
113.
Johansson M, Elam M, Rundqvist B, Eisenhofer G, Herlitz H, Jensen G et
al. Differentiated response of the sympathetic nervous system to
angiotensin-converting enzyme inhibition in hypertension. Hypertension
2000; 36: 543–8
Literatur zu Kap. 33.18
1.
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect
of ramipril on mortality and morbidity of survivors of acute myocardial
infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–
828
2.
Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial
Infarction Long-term Evaluation (SMILE) Study Investigators. The effect
of angiotensin-converting enzyme inhibitor zofenopril on mortality and
morbidity after anterior myocardial infarction. N Engl J Med 1995; 332:
80–85
3.
Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, Shi Y, Mallows
S. Valsartan, a new angiotensin II antagonist for the treatment of essential
hypertension: efficacy, tolerability and safety compared to an angiotensinconverting-enzyme inhibitor, lisinopril. J Hum Hypertens 1997; 11: 483–
490
4.
5.
6.
7.
Boer PH, Ruzicka M, Lear W, Harmsen E, Rosenthal J, Leenen FHH.
Stretch-mediated activation of cardiac renin gene. Am J Physiol 1994;
267: H1630-H1636
Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving
H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL
Study Investigators. Effects of losartan on renal and cardiovascular
outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med
2001; 345: 861–869
Cashin-Hemphill L, Holmvang G, Chan RC, Pitt B, Dinsmore RE, Lees
RS, for the QUIET Investigators. Angiotensin-converting enzyme
inhibition as antiatherosclerotic therapy: No answer yet. Am J Cardiol
1999; 83: 43–47
Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo
among 13.634 patients with suspected myocardial infarction: interim
8.
9.
10.
11.
report from the Chinese Cardiac Study (CCS–1) Lancet 1995; 345: 686–
687
Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A
randomized trial of the angiotensin-receptor blocker valsartan in chronic
heart failure. N Engl J Med 2001; 345: 1667–1675
Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, Bunt
AM. Angiotensin II antagonists for hypertension: are there differences in
efficacy. Am J Hypertens 2000; 13: 418–426
The Consensus Trial Study Group. Effects of enalapril on mortality in
severe congestive heart failure: results of the Cooperative North
Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429–
1435
Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M,
Mellenbrock S, Sullivan J, Bodin F. Valsartan, a new angiotensin I
antagonist for the treatment of essential hypertension: a comparative study
12.
13.
14.
15.
of the efficacy and safety against amlodipine. Clin Pharm Ther 1996; 60:
341–346
Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M,
Young J, Klinger G, Makris L, Rucinska E, for the Losartan
Haemodynamic Study Group. Losartan in heart failure: Hemodynamic
effects and tolerability. Circulation 1995; 91: 691–693
Dubey RK, Jackson EK, Lüscher TF. Nitric oxide inhibits angiotensin IIinduced migration of rat aortic smooth muscle cell: role of cyclic
nucleotides and angiotensin 1 receptors. J Clin Invest 1995; 96: 141–149
Dzau JV, Richard RE. Tissue angiotensin system in cardiovascular
medicine. A paradigm shift? Circulation 1994; 89: 493–498
Faxen DP, on behalf of the Multicenter American Research Trial with
Cilazapril after Angioplasty to Prevent Transluminal Coronary
Obstruction and Restenosis (MARCATOR) Study Group. Effect of high
dose angiotensin-converting enzyme inhibition on restenosis: Final results
16.
17.
18.
19.
of the MARCATOR study, a multicenter, double-blind, placebo-controlled
trial of cilazapril. J Am Coll Cardiol 1995; 2: 362–369
Fogari R, Zoppi A, Mugellini A, Preti P, Banderali A, Pesce RM, Vanasia
A. Comparative efficacy of losartan and valsartan in mild-to-moderate
hypertension: results of 24-hour ambulatory blood pressure monitoring.
Curr Ther Res 1999; 60: 195–206
Gillis JC, Markham A. Irbesartan: a review of its pharmakodynamic and
pharmakokinetic properties and therapeutic use in the management of
hypertension. Drugs 1997; 54: 885–902
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in
Nefrologia) Randomised placebo- controlled trial of effect of ramipril on
decline in glomerular filtration rate and risk of terminal renal failure in
proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857–1863
GISSI–3 (Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto
Miocardico) Effects of lisinopril and transdermal glyceryl trinitrate singly
20.
21.
22.
23.
and together on 6-week mortality and ventricular function after acute
myocardial infarction. Lancet 1994; 343: 1115–1122
Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology,
clinical efficacy and tolerability in the management of hypertension. Drugs
1996; 51: 820–845
Gohlke P, Lomberty V, Kuwer I, Bartenbach S, Schnell A, Linz W,
Schölkens BA, Wiemer G, Unger T. Long-term low-dose angiotensin
converting enzyme inhibitor treatment increases vascular cyclic guanosine
3'5'-monophosphate. Hypertension 1993; 22: 682–687
Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T,
Dekock M. Hemodynamic and neurohormonal effects of the angiotensin II
antagonist losartan in patients with congestive heart failure. Circulation
1993; 88: 1602–1609
Grodman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely
DB, Sweet CS. A randomized, placebo-controlled, double-blind, parallel
24.
25.
26.
study of various doses of losartan potassium compared with enalapril
maleate in patients with essential hypertension. Hypertens 1995; 25: 1345–
1350
Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly
allocated to ramipril or placebo for heart failure after acute myocardial
infarction: AIRE Extension (AIREX) study. Lancet 1997; 349: 1493–1497
Hall WD, Montoro R, LittleJohn T, Jain A, Feliciano N, Zheng H. Efficay
and tolerability of valsartan in combination with hydrochlorothizide in
essential hypertension. Clin Drug Invest 1998; 16: 203–210
Hansson L, Lindholm L-H, Ekbom T, Dahlöf B, Lanke J, Schersten B,
Wester P-O, Hedner T, de Faire U, for the STOP-Hypertension–2 study
group. Randomised trial of old and new antihypertensive drugs in elderly
patients: cardiovascular mortality and morbidity in the Swedish Trial in
Old Patients with Hypertension–2 study. Lancet 1999; 354: 1751–1756
27.
28.
29.
Hansson L, Lindholm L-H, Niskanen L, Lanke J, Hedner T, Niklasen A,
Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg E, Wester P-O,
Björck J-K, for the Captopril Prevention Project (CAPPP) study group.
Effect of angiotensin-enzyme inhibition compared with conventional
therapy on cardiovascular morbidity and mortality in hypertension: the
Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:
611–616
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.
Effects of an angiotensin converting-enzyme inhibitor, ramipril, on
cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–
153
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.
Effects of ramipril on cardiovascular and microvascular outcomes in
people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000; 355: 253–259
30.
31.
32.
33.
Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P, Sullivan
J, Oddou-Stock P. A comparison of the angiotensin II antagonists
valsartan and losartan in the treatment of essential hypertension. Am J
Hypertens 1999; 12: 414–417
Hovranek EP, Thomas I, Smith WB, Ponce GA, Bilsker M, Munger MA,
Wolf RA, for the Irbesartan Heart Failure Group. Dose related beneficial
long-term hemodynamic and clinical efficacy of irbesartan in heart failure.
J Am Coll Cardiol 1999; 33: 1174–1181
ISIS–4 Collaborative Group. Fourth International Study of Infant Survival:
A randomised factorial trial assessing early oral captopril, oral
mononitrate, and intravenous magnesium sulphate in 58.050 patients with
suspected acute myocardial infarction. Lancet 1995; 345: 669–685
Kassler-Taub K, LittleJohn T, Elliott W, Ruddy T, Adler E, for the
Irbesartan/Losartan Study Investigators. Comparative efficacy of two
34.
35.
36.
angiotensin II receptor antagonists, irbesartan and losartan, in mild-tomoderate hypertension. Am J Hypertens 1998; 11: 445–453
Kjøller-Hansen L, Steffensen R, Grande P. The angiotensin-converting
enzyme inhibition post revascularization study (APRES) J Am Coll
Cardiol 2000; 35: 881–888
Klinger G, Jaramillo N, Ikram H, Higginbotham M, Lang R, Kraus D,
Washington L, Sharma D, Grossman W. Effect of losartan on exercise
capacity, morbidity and mortality in patients with symptomatic heart
failure. J Am Coll Cardiol 1997; 29 (suppl): A752–755
Kober L, Torp-Pedersen C, Carlsen JE, Bagger J, Eliasen P, Lyngborg K,
Videbek J, Cole DS, Auclert L, Pauly NC, Aloit E, Persson S, Comm AJ.
A clinical trial of the angiotensin converting-enzyme inhibitor trandolapril
in patients with left ventricular dysfunction after myocardial infarction.
Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med
1995; 333: 1670–1676
37.
38.
39.
40.
Koenig W, on behalf of the multicentre study group. Ramipril vs. lisinopril
in the treatment of mild to moderate primary hypertension – A randomised
double-blind multicentre trial. Drug Invest 1992; 4: 450–457
Kromer EP. Angiotensin-II-Rezeptor-Antagonisten bei Herzinsuffizienz.
Internist 2000; 41: 917–924
Lacourcière Y, Asmar R, on behalf of the CHAMP study group.
Comparison of the effects of candesartan and losartan on ambulatory
blood pressure in patients with essential ambulatory hypertension: a forced
tritration study. Am J Hypertens 1999; 12: 41A (abstr)
Lang RM, Elkayam U, Yellen LG, Kraus D, McKelvie RS, Vaughan DE,
Ney DE, Makris L, Chang PI, on behalf of the losartan pilot exercise study
investigators. Comparative effects of losartan and enalapril on exercise
capacity and clinical status in patients with heart failure. J Am Coll
Cardiol 1997; 30: 983–991
41.
42.
43.
44.
45.
Leonetti G, Cuspidi C. Choosing the right ACE inhibitor: a guide to
selection. Drugs 1995; 49 (4): 516–535
Lewis EJ. Therapeutic intervention in the progression of diabetic
nephropathy. Am J Hypertens 1994; 7: 93S–95S
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the collaborative study
group. The effect of angiotensin-converting-enzyme inhibition on diabetic
nephropathy. N Engl J Med 1993; 329: 1456–1462
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E,
Atkins RC, Rohde R, Raz I, for the collaborative study group.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in
patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:
851–860
Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ, for the Collaborative
Study Group. Effect of intensive blood pressure control on the course of
type 1 diabetic nephropathy. Am J Kidney Dis 1999; 34: 809–817
46.
47.
48.
49.
Ling W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of
kinins to the cardiovascular actions of angiotensin-converting enzyme
inhibitors. Pharmacol Rev 1995; 47: 25–29
Lonn EM, Yusuf S, Dzavik V, Doris I, Yi O, Smith S, Moore-Cox A,
Bosch J, Riley WA, Teo KK, for the SECURE Investigators. Effects of
ramipril and vitamin E on atherosclerosis. The study to evaluate carotid
ultrasound changes in patients treated with ramipril and vitamin E
(SECURE) Circulation 2001; 103: 919–925
Lueders S, Schrader J, Schoel G, Ruschitzka F, Scheler F. 24-hour blood
pressure measurement for evaluation of first-dose response of captopril
and ramipril in patients with stimulated renin system. Z Kardiol 1992; 81
(Suppl 2): 41–44
MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan
and low-dose hydrochlorothiazide in patients with essential hypertension.
A double-blind, placebo-controlled trial of concomitant administration
50.
51.
52.
53.
compared with individual components. Arch Intern Med 1996; 156: 278–
279
Mallion JM, Siche JP, Lacourcière Y, and the Telmisartan Blood Pressure
Monitoring Group. ABPM comparison of the antihypertensive profiles of
the selective angiotensin II receptor antagonists telmisartan and losartan in
patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13:
657–664
Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency
as a predictor of cardiovascular outcomes and the impact of ramipril. The
HOPE randomized trial. Ann Intern Med 2001; 134: 629–636
Mann J, Oddou P. Ongoing clinical trials in systemic hypertension. Expert
Opin Investig Drugs 2001; 10 (11): 2031–2037
Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M,
Ponticelli C, Ritz E, Zuchelli P, and the angiotensin-converting-enzyme
inhibition in progressive renal insufficiency study group. Effect of the
54.
55.
56.
57.
angiotensin-converting-enzyme inhibitor benazepril on the progression of
chronic renal insufficiency. N Engl J Med 1996; 334: 939–945
McClellen KJ, Balfour JA. Eprosartan. Drugs 1998; 55: 713–718
McClellen KJ, Markham A. Telmisartan. Drugs 1998; 56: 1039–1044
McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J,
Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue
J. Comparison of candesartan, enalapril and their combination in
congestive heart failure: randomized evaluation of strategies for left
ventricular dysfunction. The RESOLVD Pilot Study Investigators.
Circulation 1999; 100: 1056–1064
The Multicenter European Research Trial with Cilazapril after
Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis
(MERCAPTOR) Study Group. Does the new angiotensin converting
enzyme inhibitor cilazapril prevent restenosis after percutaneous
transluminal coronary angioplasty? Circulation 1992; 86: 100–110
58.
59.
60.
61.
Nami R, Pavese G, Panza F, Caroti L, Gennari C. Comparative evaluation
of the antihypertensive effect and the tolerability of different ACE
inhibitors in the medium term treatment of essential hypertension. G Ital
Ric Clin Ter 1992; 13: 107–116
Oparil S, Guthrie R, Lewin AJ, Markury T, Reilly K, Triscari J, Witchar
JA, and Irbesartan/Losartan Study Investigators. An elective-titration
study of the comparative effectiveness of two angiotensin II-repector
blockers irbesartan and losartan. Clin Ther 1998; 20: 398–409
Packer M, Poole-Wilson P-A, Armstrong PW, Cleland JGF, Horrowitz JD,
Massie BM, Rydén L, Thygesen K, Uretsky BF, on behalf of the ATLAS
Study Group. Comparative effects of low and high doses of the
angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and
mortality in chronic heart failure. Circulation 1999; 100: 2312–2318
Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S,
Arner P, for the irbesartan in patients with type 2 diabetes and
62.
63.
microalbuminuria study group. The effect of irbesartan on the
development of diabetic nephropathy in patients with type 2 diabetes. N
Engl J Med 2001; 345: 870–878
Pfeffer MA, Braunwald E, Moya LA, Basta L, Brown EJ, Cuddy TE,
Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lomas GA,
Packar M, Rouleau L, Rutterford J, Wertheimer JH, Hawkins CM, on
behalf of the SAVE Investigators. Effect of captopril on mortality and
morbidity in patients with left ventricular dysfunction after myocardial
infarction: results of the Survival and Ventricular Enlargement Trial. N
Engl J Med 1992; 327: 669–677
Pitt B, Poole-Wilson, Segal R, Martinez F, Dickstein K, Camm AJ,
Konstam MA, Riegger G, Klinger GH, Neatan J, Sharma D, Thiyagarojan,
on behalf of the ELITE-II Investigators. Effect of losartan compared with
captopril on mortality in patients with symptomatic heart failure:
64.
65.
66.
67.
randomized trial – the Losartan Heart Failure Survival Study ELITE II.
Lancet 2000; 335: 1582–1587
Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I,
Deedwania PC, Ney DE, Snovely DB, Chong PI, on behalf of ELITE
Study Investigators. Randomised trial of losartan versus captopril in
patients over 65 with heart failure (Evaluation of Losartan in the Elderly
Study, ELITE) Lancet 1997; 349: 747–752
Plonin PF. Combination therapy with candesartan cilexetil plus
hydrochlorothiazide in patients unresponsive to low dose
hydrochlorothiazide. J Hum Hypertens 1997; 11 (Suppl 2): S65–S66
Randomised trial of a perindopril-based blood-pressure-lowering regimen
among 6105 individuals with previous stroke or transient ischaemic attack.
Progress Collaborative Group. Lancet 2001; 358: 1033–1041
Rangoonwala B, Rosenthal J. The ACE inhibitors: similarities and
differences. Hypertens Lipids Diabetes Commun 2000; 1: 11–20
68.
69.
70.
71.
Riegger GAJ, Bonza H, Petr P, Münz J, Spacek R, Pethig H, von Behren
V, George M, Arens H-J, for the symptom tolerability response to exercise
trial of candesartan cilexetil in heart failure (STRETCH) Improvement in
exercise tolerance and symptoms of congestive heart failure during
treatment with candesartan cilextil. Circulation 1999; 100: 2224–2230
Rosenthal J, Thurnreiter M, Plaschke M, Geyer M, Reiter W, Dahlheim H.
Reninlike enzymes in human vasculature. Hypertension 1990; 15: 848–
853
Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular
hypertrophy in essential hypertension: a meta-analysis of randomized
double-blind studies. JAMA 1996; 275: 1507–1513
Sever P. Candesartan cilexetil: a new long-acting, effective angiotensin II
type 1 receptor blocker. J Hum Hypertens 1997; 11 (Suppl 2): S91–S95
72.
73.
74.
75.
The SOLVD Investigators. Effect of enalapril on mortality and the
development of heart failure in asymptomatic patients with reduced left
ventricular ejection fractions. N Engl J Med 1992; 327: 685–691
The SOLVD Investigators. Effect of enalapril on survival of patients with
reduced left ventricular ejection fractions and congestive heart failure. N
Engl J Med 1991; 325: 293–302
Staessen JA, Fagard R, Lutgarde T, Celis H, Arabidze GG, Birkenhäger
WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F,
Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J,
Zanchetti A, for the systolic hypertension in Europe (Syst-Eur) Trial
Investigators. Randomised double-blind comparison of placebo and active
treatment for older patients with isolated systolic hypertension. Lancet
1999; 350: 757–764
Stumpe KO, Haworth D, Höglund C, Kerwin L, Martin A, Simon T,
Masson C, Kassler-Taub K, Osbakken M. Comparison of the angiotensin
76.
77.
78.
II receptor antagonist irbesartan with atenolol for treatment of
hypertension. Blood Press 1998; 7: 31–37
Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H, on
behalf of the CONSENSUS II study group. Effects of early administration
of enalapril on mortality in patients with acute myocardial infarction.
Results of the Cooperative New Scandinavian Enalapril Survival Study II
(CONSENSUS II) N Engl J Med 1992; 327: 678–684
Swedberg K, Pfeffer M, Granger C, Held P, Mc Murray J, Ohlin G,
Ölofson B, Ostergren J, Yusuf S. Candesartan in heart failure – assessment
of reduction in mortality and morbidity (CHARM): Rationale and design.
J Cardiac Failure 1999; 5: 276–282
Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G.
Outcome results of the Fosinopril versus Amplodipine Cardiovascular
Events Trial (FACET) in patients with hypertension and NIDDM.
Diabetes Care 1998; 21: 597–603
79.
80.
81.
82.
83.
Unger T. Significance of angiotensin type 1 receptor blockade: why are
angiotensin II receptor blockers different? Am J Cardiol 1999; 84: 9S–15S
Waßmann S, Nickenig G, Böhm M. Hypertonie und Herzinsuffizienz –
ACE-Hemmer oder AT1-Rezeptor- Antagonisten? Herz/Kreislauf 1999;
31: 208–215
Yaskey J, Verho M, Erasmus TP, Luus HG, Angela M, Grandin L, Akbary
MA, Rangoonwala, B. Efficacy of ramipril versus enalapril in patients
with mild to moderate essential hypertension. Br J Clin Pract 1996; 50 (6):
302–310
Dickstein K, Kjekshus J, and the OPTIMAAL Study Steering Committee
for the OPTIMAAL Study Group. Lancet 2002; 306: 752–760
Dahlöf B, Deverneux RB, Kjeldsen SE et al. for the LIFE Study Group.
Cardiovascular morbidity and mortality in the Losartan intervention for
end point reduction in hypertension study (LIFE): a randomised trial
against Atenolol. Lancet 2002; 359: 995–1003
Literatur zu Kap. 33.19
1.
Alderman MH, Budner N et al. (1988) Prevalence of drug resistant
hypertension. Hypertension 11 (Suppl II): II–71 - II–75
2.
Deutsche Liga zur Bekämpfung des hohen Blutdruckes e.V. (1995)
Empfehlungen zur Überwachung der Hochdruckbehandlung
3.
Report of Medical Research Council Working Party on Mild to Moderate
Hypertension (1981) Adverse reactions to bendrofluazide and propranolol
for the treatment of mild hypertension. Lancet II: 539–543
4.
Venning DR (1982) Validity of anecdotal reports of suspected adverse
drug reactions: the problem of false alarms. Brit Med J 284: 249–252
5.
Barsky AJ et al. (2002) Nocebo-Phänomen. JAMA 287: 622–627
Literatur zu Kap. 33.20
1.
Joint National Committee on Detection, Evaluation and Treatment of High
Blood pressure (JNC V) Arch Intern Med 1993; 153: 154–183
2.
Swales JD: Textbook of Hypertension. Refractory hypertension.
Blackwell, Oxford, 1197 (1994)
3.
Ebel H, Lübke H, Klaus D, Zehner J, Witzgall H:
Kombinationsbehandlung der arteriellen Hypertonie mit Propanolol,
Spironolacton-Thiabutazid und Dihydralazin. Dtsch Med Wochenschr
1978; 103: 1650–1655
4.
Yakovlevitch M, Black HR: Resistant hypertension in a tertiary care
clinic. Arch Intern Med 1991; 151: 1786–1792
5.
Edmonds D, Foerster E, Groth H, Greminger P, Siegenthaler W, Vetter W:
Does self-mesurement of blood pressure improve patient comliance in
hypertension. J Hypertens 1985; 3 (Suppl 1): 31–34
6.
7.
8.
9.
10.
Rademacher J, Chavan A, Bleck J, Vitzthum A, Stoess B, Gebel, MJ,
Galanski M, Koch KM, Haller H : Use of Dopplersonography to predict
the outcome therapy for renal-artery stenosis. New Engl J Med 2001; 344:
410–417
Ocon-Pujadas J, Mora-Macia J: White coat hypertension and related
phenomena. Drugs 1993; 46 (Suppl 2): 95 –102
Zweifler AJ, Shabab TS: Pseudohypertension. J Hypertension 1993; 11:
1–6
Klaus D, Wetchewald D, Saul F, Obermaier G, Lambers U: Vergleich von
direkter invasiver Blutdruckmessung mit indirekter Blutdruckmessung
mittels Oszillometrie und Sphygmomanometrie. Nieren-Hochdruckkrh
1991; 20: 160–169
Brown MJ, Dickerson JEC: Alpha-blockade and calcium antagonism: an
effective and well-tolerated combination for the treatment of resistant
hypertension. J Hypertens 1995; 13: 701–707
Literatur zu Kap. 33.21
1.
Urquhardt J. Role of patient compliance in clinical pharmacokinetics:
review of recent research. Clin Pharmacokinet 1994; 27: 202–215
2.
Haynes RB. Introduction. In: Haynes RB, Taylor DW, Sackett DL, Eds.,
Compliance in Health Care. Baltimore, The Johns Hopkins University
Press 1979; 1–7
3.
Kass MA, Zimmermann T, Yablonski M. Compliance to pilocarpine
therapy. Invest. Ophthalmol 1977; 108: (Abstract) 2
4.
Urquhardt J. The electronic medication event monitor. Lessons for
Pharmacotherapy. Clin Pharmacokinet 1997; 32: 345–356
5.
Métry, J-M. Measuring compliance in clinical trials and ambulatory care.
In: Métry J-M, Meyer UA, Eds., Drug Regimen Compliance. Issues in
Clinical Trials and Patient Management, John Wiley & Sons, New York
1999; 1–22
6.
7.
8.
9.
10.
Schneider M-P, Fallab Stubi C-L, Waeber B, Burnier M. The place of
microelectronic systems in measuring compliance. In: Métry J-M, Meyer
UA, Eds., Drug Regimen Compliance. Issues in Clinical Trials and Patient
Management, John Wiley & Sons, New York 1999; 85–96
Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost
and effectiveness of pharmaceuticals. Drug Inf J 1988; 22: 363–378
Feinstein A. On white-coat effects and the electronic monitoring of
compliance. Arch Int Med 1990; 150: 1377–1378
Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic
visits. Arch Intern Med 1990; 150: 1509–1510
Haynes RB. A critical review of the determinants of patient compliance
with therapeutic regimens. In: Sackett DL, Haynes RB, Eds., Compliance
with therapeutic regimens, Baltimore, USA, Johns Hopkins University
Press; 1976
11.
12.
13.
14.
15.
16.
Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance
challenge: recommendations for a call to action. A statement for healthcare
professionals. Circulation 1997; 95: 1085–1090
Düsing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive
therapy – the role of adverse effects and compliance. Blood Pressure 1998;
7: 313–315
Chesney MA, Ickovics J, Hecht FM, Sikipa G, Rabkin J. Adherence: a
necessity for successful HIV combination therapy. AIDS 1999; 13
(Suppl.): S271–278
Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy.
Soc Sci Med 2000; 50: 1599–1605
Laederach-Hofmann K, Bunzel B. Noncompliance in organ transplant
recipients: a literature review. Gen Hosp Psychiatry 2000; 22: 412–424
Monaco AP, Burke JF Jr., Ferguson RM, Halloran PF, Kahan BD, Light
JA, Matas AJ, Solez K. Current thinking on chronic renal allograft
rejection: issues, concerns, and recommendations from a 1997 roundtable
discussion. Am J Kidney Dis 1999; 33: 150–160
Literatur zu Kap. 34
Literatur zu Kap. 34.1
1.
Allenberg J-R, Hupp T (1995) Endovaskuläre und offene rekonstruktive
Chirurgie der Nierenarterien. Chirurg 66, 101–111
2.
Baert AL, Wilms G, Amery A, Vermylen J, Suy R (1990) Percutaneous
transluminal renal angioplasty: initial results and long-term follow-up in
202 patients. Cardiovasc Intervent Radiol 13, 22–28
3.
Baert AL (1994) Renal artery stent placement. Radiology 191, 619–621
4.
Bakker J, Gofette PP, Henry M, Mali WPTM, Melki J-P, Moss JG, Rabbia
C, Therasse E, Thomson KR, Thurnher S, Vignali C (1999) The ERASME
Study: a multicenter study on the safety and technical results of the Palmaz
stent used for the treatment of atherosclerotic ostial renal artery stenosis.
CVIR 22, 468–474
5.
6.
7.
8.
9.
Becker GJ, Pattynama PM, Brown J, Zemel G, Benenati JK, Katzen BT
(1993) Percutaneous renal angioplasty: effect on renal function in
azotemic patients (abstract) J Vasc Intervent Radiol 4, 48
Berger H, Habersetzer R, Jauch KW, Abendroth D (1987)
Katheterembolisation intrarenaler arterio-venöser Fistelbildungen. Chirurg
58, 675–677
Berglund G, Anderson O, Wilhelmsen L (1976) Prevalence of primary and
secondary hypertension: studies in a random population sample. Br Med J
2, 554–556
Billmann P, Hörl WH, Hohnloser S (1985) Lokale Lyse bei
Nierenarterienembolie. Fortschr Röntgenstr 142, 200–204
Blum U, Krumme B, Flügel P et al. (1997) Ostial renal artery stenoses:
treatment with vascular endoprostheses after unsuccessful balloon
angioplasty. N Engl J Med 336, 459–465
10.
11.
12.
13.
14.
Brawn LA, Ramsay LE (1987) Is "improvement" real with Percutaneous
transluminal angioplasty in the management of renovascular hypertension?
Lancet II, 1313–1316
Caps MT, Perissinotto C, Zierler E, Polissar NL, Bergelin RO, Tullis MJ,
Cantwell-Gab K, Davidson RC, Strandness DE Jr (1998) Prospective
study of atherosclerotic disease progression in the renal artery. Circulation
98, 2866–2872
Centenera LV, Hirsch JA, Choi IS et al. (1998) Wide-necked saccular
renal artery aneurysm: endovascular embolization with the Guglielmi
detachable coil and temporary balloon occlusion of the aneurysm neck.J
Vasc Intervent Radiol 9, 513
Chandrasoma P, Aberle AM (1986) Anastomotic line renal artery stenosis
after transplantation. J Urol 135, 1157–1162
Charron J, Belanger R, Vauclair R, Leger C, Razavi A (1975) Renal artery
aneurysm: polytraumal lesion of the kidney. Urology 5, 1
15.
16.
17.
18.
19.
20.
Cicuto KP, McLean GK, Oleaga JA, Freiman DB, Grossman RA, Ring EJ
(1981) Renal artery stenosis: anatomic classification for percutaneous
transluminal angioplasty. AJR 137, 599–601
Cluzel P, Alain R, Beyssen B, Pagny J-Y, Gauy J-C (1994) Stenosis of
renal branch arteries in fibromuscular dysplasia: results of percutaneous
transluminal angioplasty. Radiology 193, 227–232
Dean RH, Oskin TC (2000) Surgery of the renal arteries: indications,
technique, and results. Gefäßchirurgie 5, 6–13
Dong Q, Schoenberg SO, Carlos RC, Neimatallah M, Cho KJ, Williams
DM, Kazanjian SN, Prince MR (1999) Diagnosis of renal vascular disease
with MR angiography. RadioGraphics 19, 1535–1554
Fellows KE (1987) What is an arteriovenous malformation? Cardiovasc
Intervent Radiol 10, 53–54
Garber SJ, Raphael M (1992) Renal artery occlusion: to balloon or not to
balloon – that is the question. J Intervent Radiol 7, 111–113
21.
22.
23.
24.
25.
Gardiner GA, Meyerovitz MF, Stokes KR, Clouse ME, Harrington DP,
Bettmann MA (1986) Complications of transluminal angioplasty.
Radiology 159, 201–208
Gil Montero G, Bagley M (1975) Renal vascular hypertension secondary
to renal arterial aneurysm. Urology 6, 647
Greminger P, Steiner A, Schneider E et al.(1989) Cure and improvement
of renovascular hypertension after percutaneous angioplasty of renal artery
stenosis. Nephron 51, 326–366
Guglielmi G, Vinuela F, Dion J, Duckwiler G (1991) Electrothrombosis of
saccular aneurysms via endovascular approach. II. Preliminary clinical
experience. J Neurosurg 75, 8–14
Hageman JH, Smith RF, Szilagyi S, Elliott JP (1978) Aneurysms of the
renal artery: problems of prognosis and surgical management. Surgery 84,
563–572
26.
27.
28.
29.
30.
Hallett JW Jr, Fowl R, O'Brien PC et al. (1987) Renovascular options in
patients with chronic renal insufficiency: do the benefits justify the risk? J
Vasc Surg 5, 622–627
Hansen KJ, Starr SM, Sands E, Burkart JM, Plonk GW Jr, Dean RH
(1992) Contemporary surgical management of renovascular disease. J
Vasc Surg 16, 319–330
Harding MB, LR Smith, SI Himmelstein, K Harrison, HR Phillips, SJ
Schwab et al. (1992) Renal artery stenosis: prevalence and associated risk
factors in patients undergoing routine cardiac catheterization. J Am Soc
Nephrol 2, 1608–1616
Harrison EG, McCormack LJ (1971) Pathologic classification of renal
arterial disease in renovascular hypertension. Mayo Clin Proc 46, 161–167
Helenon O, Rody FE, Correas J-M, Melki P, Chauveau D, Chretien Y,
Moreau J-F (1995) Color Doppler US of renovascular disease in native
kidneys. RadioGraphics 15, 833–854
31.
32.
33.
34.
35.
Hennequin LM, Joffre FG, Rousseau HP, Aziza R, Tregant P, Bernadet P,
Salvador M, Chamontin B (1994) Renal artery stent placement: long-term
results with the Wallstent endoprosthesis. Radiology 191, 713–719
Hirning T, Gerlach A, Arlart IP (1993) PTA von 131
Nierenarterienstenosen: Hypertoniebehandlung und Organerhaltung.
Fortschr Röntgenstr 158, 115–120
Holley KE, Hunt JC, Brown AL, Kincaid OW, Sheps SG (1964) Renal
artery stenosis: a clinical pathologic study in normotensive and
hypertensive patients. Amer J Med 37, 14–22
Huppert PE, Duda SH, Erley CM, Roth M, Lauchart W, Dietz K, Claussen
CD (1993) Embolization of renal vascular lesions: clinical experience with
microcoils and tracker catheters. Cardiovasc Intervent Radiol 16, 361–367
Ingrisch H (1988) Perkutane Rekanalisation der Nierenarterie. In RW
Günther, M Thelen (Hrgb) Interventionelle Radiologie. Thieme, Stuttgart
New York
36.
37.
38.
39.
40.
Jaff MR, Olin JW (1998) Atherosclerotic stenosis of the renal arteries:
indications for intervention. Tex Heart Inst J 25, 34–39
Jensen G, Zachrisson BF, Delin K, Volkmann R, Aurell M (1995)
Treatment of renovascular hypertension: one year results of renal
angioplasty. Kidney Int 48, 1936–1945
Jette J, Tardif L, Beaudry C, Lassonde J (1992) Large renal arteriovenous
malformation: scintigraphic evaluation and therapeutic embolization. J
Can Ass Radiol 43, 381–384
Kaatee R, Beek FJA, de Lange EE, Leeuwen MS, Smits HFM, van der
Ven PJG, Beutler JJ, Mali WPTM (1997) Renal artery stenosis: detection
and quantification with spiral CT angiography versus optimized digital
subtraction angiography. Radiology 205, 121–127
Kadir S, Marshall FF, White RI Jr, Kaufmann SL, Barth KH (1983)
Therapeutic embolization of the kidney with detachable balloons. J Urol
129, 11–13
41.
42.
43.
44.
45.
Kadir S (1986) Diagnostic angiography. Saunders Co, Philadelphia
Kerber CW, Freeny PC, Cromwell L, Margoulis MT, Correa RJ (1977)
Cyanoacrylate occlusion of a renal arteriovenous malformation. AJR 128,
663–665
Klein GE, Szolar DH, Karaic R, Stein JK, Hausegger KA, Schreyer HH
(1996) Extracranial aneurysm and arteriovenous fistula: embolization with
Guglielmi detachable coil. Radiology 201, 489–494
Klinge J, Mali WPTM, Puijlaert CBAJ, Geyskes GG, Becking WB,
Feldberg MAM (1989) Percutaneous renal angioplasty: initial and longterm results. Radiology 171, 501–506
Kremer-Hovinga TK, deJong PE, deZeeuw D, Donker AJ, Schour KH,
VanDerHem GK (1986) Restenosis prevalence and long-term effects on
renal function after percutaneous transluminal renal angioplasty. Nephron
44 (Suppl 1), 64–67
46.
47.
48.
49.
50.
Kuhn FP, Kutkuhn B, Torsello G, Mödder U (1991) Renal artery stenosis:
preliminary results of treatment with the Strecker stent. Radiology 180,
367–372
Lacombe M, Hannoun L (1986) Les fistules artérioveneuses renales. Sem
Hop Paris 57, 126–132
Leertouwer TC, Gussenhoven EJ, Bosch JL, van Jaarsveld B, van Dijk
LC, Deinum J, Man in't Veld AJ (2000) Stent placement for renal arterial
stenosis: where do we stand? A meta-analysis. Radiology 216, 78–85
Martin LG, Mattern RF, Baer L, Fankuchen EI, Casarella WJ (1981)
Renal angioplasty for hypertension: predictive factor for long-term
success. AJR 137, 921–924
Martin LG, Casarella WJ, Alspaugh JP, Chuang VP (1986) Renal artery
angioplasty: increased technical success and decreased complications in
the second 100 patients. Radiology 159,631–634
51.
52.
53.
54.
55.
56.
Martin LG, Casarella WJ, Gaylord GM (1988) Azotemia caused by renal
artery stenosis: treatment by percutaneous angioplasty. AJR 150, 839–844
Martin LG, Cork RD, Kaufman SI (1992) Long-term results of angioplasty
in 110 patients with renal artery stenosis. J Vasc Intervent Radiol 3, 619–
626
McAlister DS, Johnsrude I, Miller MM, Clapp J, Thompson WM (1979)
Occlusion of acquired renal arteriovenous fistula with transcatheter
electrocoagulation. AJR 132, 998–1000
McLarron JP, Marshall VF, Whitsell JC (1975) Indications for surgery on
renal artery aneurysms. J Urol 114, 177
Milloy F, Fell EH, Dillon RF, Zayas AM (1958) Intrarenal arteriovenous
fistula with hypertensive cardiovascular disease. Am J Surg 96, 3–11
Nelson BD, Brosman SA, Goodwin WE (1973) Renal arteriovenous
fistulas. J Urol 109, 779–784
57.
58.
59.
60.
61.
62.
63.
Novick AC, Ziegelbaum M, Vidt DG, Gifford RW Jr, Pohl MA,
Goormastic M (1987) Trends in surgical revascularization for renal artery
disease: ten years' experience. JAMA 257, 498–501
Novick AC (1991) Management of renovascular disease: a surgical
perspective. Circulation 83 (Suppl I), 167–171
Novick AC (1994) Percutaneous transluminal angioplasty and surgery of
the renal artery. Eur J Vasc Surg 8, 1–9
Pattison JM, Reidy F, Rafferty MJ, Cameron JS, Sacks SH, Williams DG
(1992) Percutaneous transluminal renal angioplasty in patients with renal
failure. Q J Med 85, 883–888
Plouin PF, Darne B, Chatellier G et al. (1993) Restenosis after a first
percutaneous transluminal renal angioplasty. Hypertension 21, 89–96
Post K, Hupp T, Roeren T, Brambs HJ, Allenberg JR, Kauffmann GW
(1991) Nierenarterienaneurysmen. Radiologe 31, 56–61
Portasse EF (1975) Renal artery aneurysms. J Urol 113, 443
64.
65.
66.
67.
Poulias GE, Skoutas B, Doundoulakis N et al. (1991) Surgical treatment of
renovascular hypertension and respective late results: a twenty-years
experience. J Cardiovasc Surg 32, 69–75
Ramsay LE, Waller PC (1990) Blood pressure response to percutaneous
transluminal angioplasty for renovascular hypertension: an overview on
published series. Br Med J 300, 569–572
Rees CR, Palmaz JC, Becker GJ, Ehrman KO, Richter GM, Noeldge G,
Katzen BT, Dake MD, Schwarten DE (1991) Palamz stent in
atherosclerotic stenoses involving the ostia of the renal arteries:
preliminary report of a multicenter study. Radiology 181, 507–514
Roberts JP, Ascher NL, Fryd DS, Hunter DW, Dunn DL, Payne WD,
Sutherland DER, Castaneda-Zuniga W, Najarian JS (1989) Transplant
renal artery stenosis. Transplantation 48, 580–583
68.
69.
70.
71.
72.
Routh WD, Keller FS, Gross GM (1990) Transcatheter thrombosis of a
leaking saccular aneurysm of the main renal artery with preservation of
renal blood flow. AJR 154, 1097–1099
Rudnick KV, Sackett DL, Hirst S, Holmes C (1977) Hypertension in a
family practice. Can Med Assoc J 117, 492–497
Schoenberg SO, Bock M, Kallinowski F, Just A (2000) Correlation of
hemodynamic impact and morphologic degree of renal artery stenosis in a
canine model. J Am Soc Nephrol 11, 2190–2198
Schunk K, Schild H, Wandel E, Schinzel H, Weingärtner K (1990) Die
lokale Fibrinolyse bei Nierenarterienverschlüssen. Fortschr Röntgenstr
152, 147–150
Scoble J, Maher ER, Hamilton G, Dick R, Sweeney P, Moorhead JE
(1989) Atherosclerotic renovascular disease causing renal impairment: a
case for treatment. Clin Nephrol 31, 119–122
73.
74.
75.
76.
77.
Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JWK
(1987) Secondary hypertension in a blood pressure clinic. Arch Intern
Med 147, 1289–1293
Soussou ID, Starr DS, Lawrie GM, Norris GC, Jr (1979) Renal artery
aneurysm – long-term relief of renovascular hypertension by in site
operative correction. Arch Surg 114, 1410
Souza VJ, Glass TA, Velasquez G, Formanek AG (1984) Nonsurgical
treatment of childhood hypertension: embolization of an intrarenal
aneurysm. Cardiovasc Intervent Radiol 7, 229–231
Standards of Practice Comittee of the Society of Cardiovascular and
Interventional Radiology (1990) Guide-lines for percutaneous transluminal
angioplasty. Radiology 177, 619–626
Stansby G, Hamilton G, Scoble J (1993) Atherosclerotic renal artery
stenosis. Br J Hosp Med 49, 388–398
78.
79.
80.
81.
82.
83.
Steiner W, Ingrisch H, Stäbler A, Hillebrandt G, Illner W-D, Berger H
(1995) Perkutane transluminale Angioplastie arterieller Stenosen nach
Nierentransplantation. Akt Radiol 5, 91–96
Takaha M, Matsumoto A, Ochi K, Takeuchi M, Takemoto M, Sonoda T
(1980) Intrarenal arteriovenous malformation. J Urol 124, 315–318
Takebayashi S, Hosaka M, Kubota Y et al. (1998) Transarterial
embolization and ablation of renal arteriovenous malformations Efficacy
and damages in 30 patients with longterm follow-up. J Urol 159, 696–701
Tegtmeyer CI, Sos AJ (1986) Techniques of renal angioplasty. Radiology
161, 577–586
Thelen M, Weissbach L, Boldt I (1979) Transfemorale
Thrombusaspiration aus einer Nierenarterie mit Angiographiekathetern.
Fortschr Röntgenstr 130, 594–596
Tollefson DFJ, Ernst CB (1991) Natural history of atherosclerotic renal
artery stenosis associated with aortic disease. J Vasc Surg 14, 327–331
84.
85.
86.
87.
88.
Uflacker R (1986) Transcatheter embolization of arterial aneurysms. Br J
Radiol 59, 317–324
Van Jaarsveld BC, Krijnen P, Pieterman H, Derkx HM, Deinum J, Postma
CT, Dees A, Woittiez AJJ, Bartelink AKM, Man in t'Veld AJ, Schalekamp
MADH (2000) The effect of balloon angioplasty on hypertension in
atherosclerotic renal artery stenosis. New Engl J Med 342, 1007–1014
Vorwerk D, Günther RW, Keulers P, Jakse G (1993) Superselektive
Nierenarterienembolisation als Therapie der Wahl bei Blutungen benigner
Ursache. Dtsch Med Wochenschr 118, 325–329
Vorwerk D, Günther RW, Kaufmann G (1996) Embolisation der Niere. In:
RW Günther, M Thelen (Hrsg) Interventionelle Radiologie, 2. Aufl.
Thieme, Stuttgart New York
Wallace S, Gianturco C, Anderson JH, Goldstein HM, Davis LJ, Bree RL
(1976) Therapeutic vascular occlusion utilizing steel coil technique:
clinical applications. AJR 127, 381–387
89.
90.
Weibull H, Berquist D, Jendteg S et al. (1991) Clinical outcome and
healthcare cost in renal revascularization: percutaneous transluminal
angioplasty versus reconstructive surgery. Br J Surg 78: 620–624
Weibull H, Berqvist D, Bergentz SE, Jonsson K, Hulthen L, Manhen P
(1993) Percutaneous transluminal renal angioplasty versus surgical
reconstruction of atherosclerotic renal artery stenosis: a prospective
randomized study. J Vasc Surg 18, 841–852
Literatur zu Kap. 34.2
1.
Albanese CT, Wiener ES (1993) Routine total bilateral adrenalectomy is
not warranted in childhood familial pheochromocytoma. J Pediatr Surg 28:
1248
2.
Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull
R, Keiser HR (1988) Malignant pheochromocytoma: effective treatment
with a combination of cyclosphosphamide, vincristine, and dacarbazine.
Ann Intern Med 109: 268–273
3.
Bergland BE (1989) Pheochromocytoma presenting as shock. Am J Emerg
Med 7: 44–48
4.
Blake GM, Lewington VN, Fleming JS, Zivanovic MA, Ackery DM
(1988) Modification by nifedipine of 131I-metaiodobenzylguanidine
kinetics in malignant pheochromocytoma. Eur J Nuc Med 14: 435
5.
Boutros AR, Bravo EL, Zanettin G (1990) Perioperative management of
patients with pheochromocytoma. Cleve Clin J Med 57: 613–617
6.
7.
8.
9.
10.
Bravo EL (1994) Evolving concept in the pathophysiology, dieagnosis,
and treatment of pheochromocytoma. Endocrinol Rev 15: 356–368
Canale MP, Bravo EL (1993) Calcium channel entry blockers are effective
and safe in the preoperative management of pheochromocytoma.
Hypertension 21: 560–561
Cohen CD, Dent DM (1984) Phenochromocytoma and acute
cardiovascular death (with special reference to myocardial infarction)
Postgrad Med J 60: 111–115
Colson P, Ryckwaert F, Ribstein J, Mann C, Dareau S (1998)
Haemodynamic heterogeneity and treatment with the calcium channel
blocker nicardipine during pheochromocytoma surgery. 33: 9–14
Crout JR, Brown BB Jr 1969 Anesthetic management of
pheochromocytoma. The value of phenoxybenzamine and methoxyflurane.
Anesthesiology 30: 29–36
11.
12.
13.
14.
15.
16.
Cubbedu LX (1988) New alpha1-adrenergic receptor antagonists for the
treatment of hypertension: role of vascular alpha receptors in the control of
peripheral resistance. Am Heart J 116: 133–162
Dashwood MR (1982) Central and peripheral prazosin binding. Eur J
Pharmacol 86: 51–58
Dean RE (1958) Pheochromocytoma and pregnancy. Obstet Gynecol 11:
35–42
Desmonts JM, Marty J (1984) An anesthetic management of patients with
pheochromocytoma. Br J Anesth 56: 781–789
Dorero GA Jr, Stewart BH, Tarazi RC, Gifford RW Jr (1974) Preoperative
blood transfusion in the safe surgical management of pheochromocytoma.
A review of 46 cases. J Urol 111: 715–721
Dralle H, Scheumann GFW, Nashan B, Brabant G. (1994) Review: recent
developments in adrenal surgery. Acta Chir Belg 94: 137–140
17.
18.
19.
20.
21.
22.
Fries JG, Chamberlin JA (1968) Extra-adrenal pheochromocytoma:
Literature review and report of a cervikal pheochromocytoma. Surgery 63:
268–279
Gabita-Rosei E, Alicandri CI, Corea I (1977) Hypertensive crises in
patients with pheochromozytoma given metoclopramide. Lancet 1: 600
Gagner M, Branton G, Pharand D, Pomp A (1996) Is laparoscopic
adrenalectomy indicated for pheochromocytomas? Surgery 120: 1076–
1079
Gagner M, Lacroix A, Bolte E (1992) Laparoscopic adrenalectomy in
Cushing's syndrome and pheochromocytoma. N Engl J Med 327: 1033
Graham JB (1951) Pheochromocytoma and hypertension. An analysis of
207 cases. Int Abstr Surg 92: 105–121
Griffith MI, Felts JH, James FM, Meyers RT, Shealy GM, Woodruff LF Jr
1974 Successful control of pheochromocytoma in pregnancy
23.
24.
25.
26.
27.
28.
Hadden DR (1995) Adrenal disorders of pregnancy. Endocrinol Metab
Clin N Am 24: 139
Hoefnagel CA, Voute PA, de Kraker J, Marcuse HR (1987) Radionuclide
diagnosis and therapie of neural crest tumors usong iodine–131metaiodobenzylguanidine. J Nucl Med 28: 308–314
Hoefnagel CA, Schornagel J, Valdes Olmos RA (1991)
131 I metaiodobenzylguanidine therapy of malignant pheochromocytoma:
interference of medication. H Nucl Biol Med 35: 308
Hull CJ: Pheochromocytoma. Diagnosis, preoperative preparation and
anesthetic management. Br J Anaesth 58: 1453
Huston JR, Stewart WRC 1965 Hemorrhagic pheochromocytoma with
shock and abdominal pain. Am J Med 39: 502–504
Janetschek G, Finkenstedt G, Gasser R, Waibel UG, Peschel R, Bartsch G,
Neuman HPH (1998) Laparoscopic surgery for pheochromocytoma:
29.
30.
31.
32.
adrenalectomy, partial resection, excision of paragangliomas. J Urol 160:
330–334
Jones NF, Walker G, Tuthven CRJ, Sandler M 1968 α-Methyl-p-tyrosine
in the management of pheochromocytoma. Lancet 2: 1105–1109
Krane NK 1986 Clinically unsuspected pheochromcytoma: experience at
Henry Ford Hospital and a review of the literature. Arch Intern Med 146:
54–57
Lamberts SWL, Bakker WH, Reubi JC 1990 Somatostatin-receptor
imaging in the localization of endocrine tumors. N Engl J Med 323: 1246–
1249
Lee JE, Curley SA, Gagel RF, Evans DB, Hickey RC (1996) Corticalsparing adrenalectomy for patients with bilateral pheochromocytoma.
Surgery 120: 1064
33.
34.
35.
36.
37.
Lehnert H (1998) Phäochromozytom. In: Domschke W, Hohenberger W,
Meinertz T, Possinger K, Reinhardt D, Dölle R (Hrsg) Therapiehandbuch.
Urban & Schwarzenberg, München, K8 1–8
Loh KC, Fitzgerad PA, Matthay KK, Yeo RPB, Price DC (1997) The
treatment of malignant pheochromocytoma with lodine–131
metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116
reported patients. J Endocrinol Invest 20: 648–658
Manger WM, Gifford RW Jr 1977 Pheochromocytoma. In Laragh JH,
Brenner BM (eds) Hypertension: pathophysiology, diagnosis and
management. Raven, New York 1990
Mann C, Millat B, Boccara G, Atger J, Colson P (1996) Tolerance of
laparoscopy for resection of pheochromocytoma. Brit J Anesth 77: 795
Möbius E, Nies C, Rothmund M (1999) Surgical treatment of
pheochromocytomas. Surg Endosc 13: 35–39
38.
39.
40.
41.
Neumann HPH, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ,
Volk B, Kirste G (1993) Pheochromozytomas, multiple endocrine
neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med. 329:
1531–1538
Neumann HPH, Reincke M, Bender BU, Elsner R, Janetschek G (1999)
Preserved adrenocortical function after laparoscopic bilateral adrenal
sparing surgery for hereditary pheochromocytoma. J Endocrinol Metab 84:
2608–2610
Nicolson Jr JP, Vaughn Jr ED, Pickeruing TG, Resnick LM, Artusio K,
Kleiner HD, Lopez-Overjero JA, Laragh JH 1983 Pheochromocytoma and
prazosin. Ann Intern Med 99: 477–479
Nies C. Chirurgische Anatomie, konventionelle und minimalinvasive
Zugänge zur Nebenniere. In M. Rothmund (Hrsg) Endokrine Chirurgie
(2000) Springer Verlag, Heidelberg pp 349–361
42.
43.
44.
45.
46.
Page LB, Raker JW, Berberich FR 1969 Pheochromozytoma with
predominant epinephrine secretion. Am J Med 47: 648–652
Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G (2001) Factors
Associated with perioperative morbidity and mortality in Patients with
Pheochromocytoma: analysis of 165 operations at a single center, J
Endocrinol Metab 86: 1480–1486
Plouin PF, Chatelliert G, Fofol I, Corvol P (1997) Tumour recurrence and
hypertension persistence after successful pheochromocytoma operation.
Hypertension 29: 1133–1139
Prinz RA (1995) A comparison of laparascopic and open adrenalectomies.
Arch Surg 130: 489
Prys-Roberts C (2000) Pheochromocytoma – recent progress in its
management. Br J Anaesth 85: 44–57
47.
48.
49.
50.
51.
Quezado ZN, Keiser HR, Parker MM (1992) Reversible myocardial
depression after massive catecholamine release from a
pheochromocytoma. Crit Car Med 20: 549–551
Remine WH, Chong CC, van Heerden Ja, Sheps SG, Harrison Jr EG
(1974) Current management of pheochromocytoma. Ann Surg 179: 740–
748
Roizen MF (1994) Anesthetic implications of concurrent diseases. In:
Anesthesia. Edited by RD Miller, New York: Chruchill Livingstlóne, pp
903–1014
Rosenberg JC, Varco RL (1967) Physiologic and pharmacologic
considerations in the management of pheochromocytoma. Surg Clin North
Am 47: 1453–1460
Sakahara H, Endo K, Saga T, Hosono M, Kobayashi H, Konishi J (1994)
131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma.
Ann Nucl Med 8: 133
52.
53.
54.
55.
Shapiro B, Sisson JC, Wieland DM, Mangner TJ, Zempel SM, Mudgett E,
Gross MD, Carey JE, Zasadny KR, Beierwaltes WH (1991)
Radiopharmaceutical therapy of malignant pheochromzytoma with (131I)-metaiodobenzylguanidiine: results from ten years of experience. J Nucl
Biol Med 35: 269–276
Shapiro B, Sisson JS, Eyre P, Copp JE, Dmuchowski C, Beierwaltes WH
1985 131 I-MIBG – a new agent in diagnosis and treatment of
pheochromocytoma. Cardiology 72: 137–142
Sprung J, O'Hara JF Jr, Gills IS, Abdelmalak B, Sarnaik A, Bravo EL
(2000) Anesthetic aspects of laparoscopic and open adrenalectomy for
pheochromocytoma. Urology 55: 339–343
Strecker U. Lipp M (1997) Narkoseführung bei Phäochromozytom.
Zentralbl Chir 122: 460
56.
57.
58.
59.
Sutton MG, Sheps SG, Lie JT 1981 Prevalence of clinically unsuspected
pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc
56: 354–360
Ulchaker JC, Goldfarb DA, Bravo EL, Novick AC (1999) Successful
outcomes in pheochromocytoma surgery in the modern era. J. Urol 161:
764–767
Walz MK, Peitgen K, Hoermann R, Giebler RM et al. (1996) Posterior
retroperitoneoscopy as a new minimally invasive approach for
adrenalectomy: results of 30 adrenalectomies in 27 patients. World J Surg
20: 769–774
Young JB, Landsberg L ( (1998)) Catecholamines and the adrenal
medulla. In: Wilson JD, Forster DW, Kronenberg HM, Larsen R (eds)
Williams Testbook of Endcrinology, 9th edition, WB Saunders,
Philadelphia, pp 665–728
Literatur zu Kap. 34.3
1.
Ganguly A. Primary aldosteronism. N Engl J Med 1998; 339: 1828–1834
2.
Linos DA, Stylopoulos N, Boukis M, Souvatzoglou A, Raptis S,
Papadimitriou J. Anterior, posterior, or laparoscopic approach for the
management of adrenal diseases ? Am J Surg 1997; 173: 120–125
3.
Brown JJ, Davies DL, Ferris JB, Fraser R, Haywood E, Lever AF,
Robertson JIS. Comparison of surgery and prolonged spironolactone
therapy in patients with hypertension, aldosterone excess, and low plasma
renin. Br Med J 1972; 2: 729–734
4.
Celen O, O'Brien MJ, Melby JC, Beazley RM. Factors influencing
outcome of surgery for primary aldosteronism. Arch Surg 1996; 131: 646–
650
5.
Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas
SA, Muller FB, Acevedo R, Ulick S, Laragh JH. Diagnosis and treatment
of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877–885
6.
7.
8.
9.
10.
Orth DN. Medical Progress: Cushing's syndrome. N Engl J Med 1995;
332: 791–803
Swearingen B, Biller BM, Barker FG 2nd, Katznelson L, Grinspoon S,
Klibanski A, Zervas NT. Long-term mortality after transsphenoidal
surgery for Cushing's disease. Ann Intern Med 1999; 130: 821–824
Bakiri F, Tatai S, Aouali R, Semrouni M, Derome P, Chitour F,
Benmiloud M. Treatment of Cushing's disease by transsphenoidal,
pituitary microsurgery: Prognosis factors and long-term follow-up. J
Endocrinol Invest 1996; 19: 572–580
Hansen P, Bax T, Swanstrom L. Laparoscopic adrenalectomy: History,
indications, and current techniques for a minimally invasive approach to
adrenal pathology. Endoscopy 1997; 29: 309–314
Albergaria Pereira MA, Halpern A, Salgado LR, Mendonca BB, Nery M,
Liberman B, Streeten DH, Wajchenberg BL. A study of patients with
Nelson´s syndrome. Clin Endocrinol 1998; 49: 533–539
11.
12.
13.
14.
15.
Lamberts SW, de Jong FH, Birkenhager JC. Evaluation of a therapeutic
regimen in Cushing's disease. Acta Endocrinol (Copenh) 1977; 86: 146–
155
Jennings AS, Liddle GW, Orth DN. Results of treating childhood
Cushing's disease with pituitary irradiation. N Engl J Med 1977; 297: 957–
962
Välimäki M, Pelkonen R, Porkka L, Sivula A, Kahri A. Long-term results
of adrenal surgery in patients with Cushing's syndrome due to
adrenocortical adenome. Clin Endocrinol 1984; 20: 229–236
Hoffman DL, Mattox VR. Treatment of adrenal carcinoma with o,p'-DDD.
Med Clin North Am 1972; 56: 999
Child DF, Burke CW, Burley M, Rees LH, Fraser TR. Drug control of
Cushing's syndrome. Combined aminoglutethimide and metyrapone
therapy. Acta Endocrinol (Copenh) 1976; 82: 330–341
Literatur zu Kap. 34.4
1.
Agner T, Almdal T, Thorsteinzson B, Agner E (1984) A reevaluation of
atrial fibrillation in thyrotoxicosis. Dan med Bull 31: 157–159
2.
Bernini G, Moretti A, Lonzi S, Bendinelli C, Miccoli P, Salvetti A (1999)
Renin-angiotensin-aldosterone system in primary hyperparathyroidism
before and after surgery
3.
Bilezikian JP (1992) Managment of acute hypercalcemia. New Engl J Med
326: 1196–1203
4.
Consensus Development Conference Panel (1991) Diagnosis and
managment of asymtomatic primary hyperparathyroidism. Consensus
Development Conference Statement. Ann Intern Med 114: 593–597
5.
Crowley WF, Ridgway EC, Bough EW, Francis GS, Daniels GH,
Kourides IA, Myers GS, Maloof F (1977) Noninvasive evaluation of
cardiac function in hypothyroidism. Response to gradual thyroxine
replacement. N Engl J Med 296: 1–6
6.
7.
8.
9.
10.
11.
Doppman JL (1996) Preoperative localization of parathyroid tissue in
primary hyperparathyroidism. In: Favus JM (Hrsg) Primer on the
metabolic bone diseases and disorders of mineral metabolism. 3 rd edn,
Lippincott & Raven, Philadelphia, S 553–556
Ellyn FM, Kumar Y, Somberg JC (1992) Hypothyroidism complicated by
angina pectoris: therapeutic approaches. J Clin Pharmacol 32: 843–847
Fuller H, Spitell JA, McLonahey WM (1965) Myedema, a cause of
reversible hypertension. Circulation 31: 91–92
Gennari C, Nami R, Gonelli S (1995) Hypertension and primary
hyperparathyroidism: The role of adrenergic and renin-angiotensinaldosterone systes. Miner Electrolyte Metab 21: 77–81
Hellermann J, Treese N, Mohr-Kahaly S, Beyer J, Kahaly G (1994)
Kardiopulmonale Belastung bei Hyperthyreose. Z Kardiol 83: 38–43
Hellermann J, Kahaly G (1996) Kardiopulmonale Beteiligung bei
Schilddrüsenerkrankungen. Pneumologie 50: 375–380
12.
13.
14.
15.
16.
Hulter HN, Melby JC, Peterson JC (1986) Chronic continous PTH
infusion results in hypertension in normal subjects. J Clin Hypertens 2:
360–370
Jockenhövel F, Reinwein D (1994) Asymptomatischer primärer
Hyperparathyreoidismus: Behandeln oder beobachten ? Dtsch Med
Wochenschr 119: 967–973
Kahaly G, Mohr-Kahaly S, Beyer J, Meyer J (1995) Left ventricular
function analyzed by Doppler and echocardiographic methods in shortterm hypothyroidism. Am J Cardiol 75: 645–648
Kahaly G, Hellermann J, Mohr-Kahaly S, Treese N (1996) Impaired
cardiopulmonary exercise capacity in hyperthyroidism. Chest 109: 57–61
Kendrick AA, O´Reilly JF, Lazlo G (1988) Lung function and exercise
performance in hyperthyroidism before and after treatment. Q J Med 68:
615–627
17.
18.
19.
20.
21.
Klein I, Levey GS (1984) Unusual manifestation if hypothyroidism. Arch
Intern Med 144: 123–128
Klein I, Ojamaa K (1994) Editorial: Thyroid hormone and the
cardiovascular system: from theory to practice. J Clin Endocrinol Metabol
78: 1026–1027
Mitchell BK, Kinder BK, Cornelius E, Steward AF (1995) Primary
hyperparathyroidism: Preoperative localization using technetium sestamibi
scanning. J Clin Endocrinol Metab 80: 7–10
Mohr-Kahaly S, Kahaly G, Meyer J (1996) Kardiovaskuläre Wirkungen
von Schilddrüsenhormonen. Z Kardiol 85: 219–231
Nilsson I-L, Aberg J, Rastad J, Lind L (1999) Endothelial vasodilatory
dysfunction in primary hyperparathyroidism is reversed after
parathyroidectomy. Surgery 126: 1049–1055
22.
23.
24.
25.
26.
27.
Northcote RJ, McFarlane P, Kesson CM, Ballantyne D (1986) Continous
24-hour electrocardiographyin thyrotoxicosis before and after treatment.
Am Heart J 112: 339–344
Nussbaum SR (1993) Pathophysiology and managment of severe
hypercalcemia. Endocrinol Metab Clin North Am 22: 343–362
Reiners C (1990) Die Radiojodtherapie der funktionellen Autonomie:
Indikationen, Ergebnisse, Risiken. Acta Med Austriaca 17: 66–69
Reinwein D, Röher HD, Emrich D (1993) Therapie der Hyperthyreose –
aktueller Stand. Dtsch Med Wochenschr 118: 1036–1043
Roe SM, Burns RP, Graham LD, Brock WB, Russell WL (1994) Costeffectiveness of preoperative localization studies in primary
hyperparathyroid disease. Ann Surg 219: 582–586
Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P,
Wilson PWF, Benjamin EJ, D´Agostino RB (1994) Low serum
28.
29.
30.
31.
thyrotropin concentration as a factor for atrial fibrillation in older persons.
New Engl J Med 331: 1249–1251
Schiffl H, Sitter T, Lang SM (1997) Noradrenergic Blood pressure
dysregulation and cytosolic calcium in primary hyperparathyroidism.
Kidney Blood Press Res 20: 290–296
Shane E (1996) Hypercalcemia: Pathogenesis, clinical manifestation,
differential diagnosis and managment. In: Favus JM (ed) Primer on the
metabolic bone diseases and disorders of mineral metabolism. 3rd edn.
Lippincott & Raven, Philadelphia, pp 177–181
Streeten DH, Anderson GH, Howland T, Chiang R, Smulyan H (1988)
Effects of thyroid funhction on blood pressure. Recognition of
hypothyroid hypertension. Hypertension 11: 78–83
Umpierrez GE, Challapalli S, Patterson C (1995) Congestive heart failure
due to reversible cardiomyopathy in patients with hyperthyroidism. Am J
Med Sci 310: 99–102
32.
Ziegler R, Hesch RD, Kruse K, Raue F, Rothmund M (1997)
Nebenschilddrüsen und Calciumhomöostase (einschließlich Osteopathien)
In: Deutsche Gesellschaft für Endokrinologie (Hrsg) Rationelle Diagnostik
in der Endokrinologie. Thieme, Stuttgart, S 103–148
Literatur zu Kap. 34.5
1.
Akimura T, Furutani Y, Jimi Y, Saito K, Kashiwagi S, Kato S, Ito H
(1995) Essential hypertension and neurovascular compression at the
ventrolateral medulla oblongata: MR evaluation. Am J Neuroradiol 16:
401–405
2.
Anding K, Bloss HG, Krumme B, Schwabe M, Geiger H, Schollmeyer P,
Rump LC (1998) Neurovascular decompression of the left ventrolateral
medulla as a treatment of hypertension in a patient with renal artery
stenosis. NDT 13: 3253–3257
3.
Colon GP; Quint DJ, Dickinson LD, Brunberg JA, Jamerson KA, Hoff JT,
Ross DA (1998) Magnetic resonance evaluation of ventrolateral medullary
compression in essential hypertension. J Neurosurg. 88: 226–231
4.
Cushing H (1901) Concerning a definite regulatory mechanism of the
vasomotor center which controls blood pressure during cerebral
compression. Johns Hopkins Hosp Bull 12: 290–292
5.
6.
7.
8.
Dittmar C (1873) Ueber die Lage des sogenannten Gefaesscentrums in der
Medulla oblongata: Berichte ueber die Verhandlungen der koeniglich
saechsischen Gesellschaft der Wissenschaften zu Leipzig. Math Phys
Klasse 25: 449–469
Gajjar D, Egan B, Curé J, Rust P, VanTassel P, Patel SJ (2000) Vascular
Compression of the Rostral Ventrolateral Medulla in Sympathetic
Mediated Essential Hypertension. Hypertension 36: 78–82
Geiger H, Naraghi R, Crnac J, Engels G, Huk W, Fahlbuscb R, Luft FC
(1994) Neurovaskuläre Kompression im Hirnstammbereich bei Patienten
mit essentieller Hypertonie. Nieren- und Hochdruckkrankheiten 10: 519–
521
Geiger H, Naraghi R, Schobel HP, Frank H, Sterzel RB, Fahlbusch R
(1998) Decrease of blood pressure by ventrolateral medullary
decompression in essential hypertension. Lancet 352: 446–449
9.
10.
11.
12.
Hohenbleicher H, Schmitz SA, Koennecke HC, Offermann R, Offermann
J, Zeytountchian H, Wolf KJ, Distler A, Shama AM (2001) Neurovascular
Contact of Cranial Nerve IX and X Root-Entry Zone in Hypertensive
Patients. Hypertension 37: 176–181
Jannetta PJ, Segal R, Wolfson SK, Dujovny M, Semba A, Cock EE (1985)
Neurogenic hypertension: etiology and surgical treatment II, observations
in an experimental nonhuman primate model. Ann Surg 202: 253–261
Levy EI, Clyde B, McLaughlin MR, Jannetta PJ (1998) Microvascular
Decompression of the Left Lateral Medulla Oblongata for Severe
Refractory Neurogenic Hypertension. Neurosurgery 43: 1–6
Makino Y, Kawano Y, Okuda N, Horio T, Iwashima Y, Yamada N,
Takamiya M, Takishita S (1999) Autonomic function in hypertensive
patients with neurovascular compression of the ventrolateral medulla
oblongata. J Hypertension 17: 1257–1263
13.
14.
15.
16.
Morimoto S, Sasaki S, Miki S, Kawa T, Itoh H, Nakata T, Takeda K,
Nakagawa M, Kizu O, Furuya S, Naruse S, Maeda T (1997)
Neurovascular compression of the rostral ventrolateral medulla related to
essential hypertension. Hypertension 30: 77–82
Morimoto S, Sasaki S, Takeda K, Furuya S, Naruse S, Matsumoto K,
Higuchi T, Saito M, Nakagawa M (1999) Decreases in blood pressure and
sympathetic nerve activity by microvascular decompression of the rostral
ventrolateral medulla in essential hypertension. Stroke 30: 1707–1710
Naraghi R, Geiger H, Crnac J, Huk W, Fahlbusch R, Engels G, Luft FC
(1994) Posterior fossa neurovascular anomalies in essential hypertension.
Lancet 344: 1466–1470
Naraghi R, Schuster H, Toka HR, Baehring S, Toka O, Oztekin O,
Bilginturan N, Knoblauch H, Wienker TF, Busjahn A, Haller H,
Fahlbusch R, Luft FC (1997) Neurovascular Compression at the
17.
18.
19.
Ventrolateral Medulla in Autosomal Dominant Hypertension and
Brachydactyly. Stroke 28: 1749–1754
Palkovits M, Mezey E, Fodor M, Ganten D, Bahner U, Geiger H, Heidland
A (1995) Neurotransmitters and neuropeptides in the baroreceptor reflex
arc: connections between the nucleus of the solitary tract and the
ventrolateral medulla oblongata in the rat. Clin Exp Hypertens 17: 101–
113
Spitthoever R, Goessl M, Mitchell A, Bruck H, Wenzel TPRR (2000)
Malignant hypertension caused by neurovascular pulsatile compression of
the lateral medulla oblongata – a case report. DMW Suppl 3: S37
Watters MR, Burton DS, Turner GE, Cannard KR (1996) MR screening
for brain stem compression in hypertensioni. Am J Neuroradiol. 17: 217–
221
20.
Yamamoto I, Yamada S, Sato O (1991) Microvascular decompression for
hypertension: clinical and experimental study. Neurol Med Chir (Tokyo)
31: 1–6
Literatur zu Kap. 34.6
1.
Akiba M, Kodama T, Ito Y, Obara T, Fujimoto Y (1990) Hypoglycemia
induced by excessive rebound secretion of insulin after removal of
pheochromocytoma. World J Surg 14: 317–324
2.
Adams HA, Hempelmann G (1993) Anästhesie bei Patienten mit
Phäochromozytom. Anästhesiol Intensivmed Notfallmed Schmerzther 28:
500–509
3.
Behl P, Sante P, Blesovsky A (1987) Surgical treatment of isolated
coarctation of the aorta: 18 years' experience. Thorax 42: 309–314
4.
Frey L (1997) Gestose und HELLP-Syndrom. Anaesthesist 46: 732–47
5.
Grau T, Conradi R, Wacker J, Martin E (1999) Präeklampsie und
Anästhesie. Zentralbl Gynäkol 121: 603–636
6.
Hull CJ (1986) Phaeochomocytoma. Diagnosis, preoperative preparation
and anaesthetic management Br J Anaesth 58: 1453–1468
7.
8.
9.
10.
11.
Lo CY, Tam PC, Kung AWC, Lam KSL, Wong J (1996) Primary
Aldosteronism: Results of surgical treatment. Ann Surg 224: 125–130
Kinney MAO, Warner ME, van Heerden JA, Horlocker TT, Young WF,
Schroeder DR, Maxson PM, Warner MA (2000) Perianesthetic risks and
outcomes of pheochromocytoma and paraganglioma resection. Anesth
Analg 91: 1118–1123
Nagesser SK, Seters AP, Kievit J, Hermans, Krans HMJ, van de Velde
CJH (2000) Long-term results of total adrenalectomy for cushing's disease.
World J Surg 24: 108–113
Prys-Roberts C (2000) Phaeochomocytoma – recent progress in its
management. Br J Anaesth 85: 44–57
Schreiber R, Augustin D, Schumacher G, Peters D, Bühlmeyer K (1986)
Clonidin-Therapie der "paradoxen Hypertension" nach Operation der
isolierten Aortenisthmusstenose im Kindesalter. Klin Pädiat 198: 326–329
12.
13.
14.
Schüttler J, Westhofen P, Kania U, Kammerecker S, Hirner A (1995)
Quantitative Erfassung der Katecholaminsekretion als rationale Grundlage
des Anästhesiemanagements bei Phäochomozytomexstirpation.
Anästhesiol Intensivmed Notfallmed Schmerzther 30: 341–348
Winship SM, Winstanley JHR, Hunter JM (1999) Anaesthesia for Conn's
syndrome. Anaesthesia 54: 564–574
Witteles RM, Kaplan EL, Roizen MF (2000) Safe and cost-effective
preoperative preparation of patients with pheochromocytoma. Anesth
Analg 91: 302–304